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Abstract in English 
 
The bacterium Bacillus subtilis plays a major role as model 
for Gram-positive research, and is widely used as industrial 
workhorse for the production of high-value enzymes and 
metabolites. Successful development of commercially-attractive 
strains and of original products is the key of innovation in microbial 
industry. Evolving a natural B. subtilis strain into an overproducer 
involves genetic engineering. In spite of a wide range of genetic 
tools and techniques available for B. subtilis, engineering of the 
metabolic pathways, with the purpose to reach industrially 
significant amount of products, requires a deep and specific 
understanding of the metabolism. This thesis describes two aspects 
of genetic engineering applications in biotechnology research. On 
the one hand, metabolic engineering aiming to develop a direct 
“sugar to metabolite” microbial process is described. More 
precisely, both the exploration of thiamin (vitamin B1) biosynthesis, 
resulting in the elucidation of a new salvage pathway, and the 
identification and characterization of relevant mutations in thiamin-
regulated genes (thiN, yuaJ, and ykoD) are covered. On the other 
hand, this thesis gives a glimpse of how structural engineering of B. 
subtilis spores will allow to vehicle recombinant proteins of interest 
at their surface for putative probiotic applications. The spore display 
system presented is based on the original use of a coat-associated 
enzyme (oxalate decarboxylase) as original anchoring motif. Taken 
together, the described studies constitute a basis to draw 
perspectives in the future of B. subtilis research in biotechnology 
industry.  
Abstract in Portuguese 
 
Bacillus subtilis é um organismo modelo central no estudo 
de bactérias de Gram-positiva, além da sua importância na 
produção industrial de enzimas e de metabolitos de valor comercial. 
O desenvolvimento com sucesso de estirpes de valor comercial 
acrescido bem como de produtos originais é a chave para a 
inovação na indústria biotecnológica com base na utilização de 
microorganismos. O desenvolvimento de uma estirpe natural de B. 
subtlis num organismo super-produtor envolve engenharia 
genética. Apesar do vasto leque de ferramentas genéticas e outras, 
disponíveis para a manipulação de B. subtilis, a engenharia de uma 
via metabólica com a finalidade de se atingirem níveis 
industrialmente atractivos de produtos de interesse, requer em 
última análise um conhecimento profundo e específico do 
organismo.  Nesta Tese descrevemos duas aplicações da 
engenharia genética à investigação biotecnológica. Por um lado, 
são descritos dois exemplos  de engenharia metabólica com o 
objectivo de desenvolver processos de base microbiana de tipo 
“nutriente a metabolito”. Mais especificamente, cobrimos aqui a 
exploração da biosíntese de tiamina (vitamina B1), um trabalho que 
resultou na elucidação de uma via de recuperação, e na 
identificação e caracterização de mutações importantes em genes 
regulados pela tiamina (thiN, yuaJ, e ykoD). Por outro lado, esta 
tese ilustra de que modo a engenharia estrutural dos esporos de B. 
subtilis permite a sua utilização enquanto veículos para a 
apresentação funcional de proteínas recombinantes de interese, 
com vista a aplicações futuras em probiose. O sistema de 
apresentação de proteínas à superfície do esporo que 
descrevemos tem por base a utilização de uma descarboxilase do 
oxalato, normalmente um componente da estrutura superficial do 
esporo (ou manto), como um motivo de ancoramento original. Em 
conjunto, os estudos aqui descritos constituem uma base para 
perspectivar investigação e utilizações futuras de B. subtilis na 
indústria biotecnológica.  
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1. B. subtilis origins, ecology and genome features 
 
For more than a century, the rod-shaped endospore forming 
Bacillus subtilis has been a model of the Firmicutes, a major phylum 
of bacteria. It became a reference for Gram-positive 
microorganisms, due to its amenability to genetic manipulation 
(rapid growth, high natural competence for DNA uptake, stable 
integration of exogenous DNA into the chromosome, and safety for 
experimenters and environment). The accessibility to the well-
annotated genome sequence in addition to the wide availability of 
physiological and biochemical data make of B. subtilis a workhorse 
for both basic research and industrial purposes. Reflecting its 
central role in Research, about 25,000 articles in the PubMed 
reference library (National Center for Biotechnology Information, 
USA) and more than 1.1 million Google pages refer to B. subtilis 
biology. While sporulation, an archetypical form of cell 
differentiation, is one of the main topics of B. subtilis studies in 
academic groups, industrial research mainly focuses on the 
production of commercially attractive levels of small metabolites and 
enzymes. 
Most of the strains used in B. subtilis genetics derive from 
strain 168, a single tryptophan requiring auxotroph bacterium, which 
is highly competent. Developments of most of the genetic methods 
and studies of the physiology and sporulation of B. subtilis have 
been based on this strain. Important derivatives from strain 168 are 
centralized and maintained at the Bacillus Genetic Stock Center 
(BGSC), created in the seventies in the Ohio State University 
(USA).  Strain 168 was isolated in the late forties at the University of 
Yale (USA) after mutagenesis of Marburg B. subtilis with sublethal 
doses of X-rays, which resulted in a high frequency of auxotrophy 
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among the mutants [Burkholder and Giles, 1947]. Although most of 
those were subsequently lost, five auxotroph strains from this 
collection, requiring threonine (strain 23), nicotinic acid (strain 122), 
or tryptophan (strains 160, 166, and 168) are still available [Zeigler 
et al., 2008].  
B. subtilis was historically classified as a strict aerobe. 
However, subsequent research has demonstrated that it can also 
grow anaerobically, using nitrate or nitrite as alternative terminal 
electron acceptor [Nakano and Zuber, 1998]. Microbiology 
textbooks generally indicate soil as the main habitat of B. subtilis, 
like the other aerobic spore-formers. Recent research suggests that 
this may be an oversimplification. First, studies that examined soil 
using fluorescent antibodies failed to convincingly prove the 
existence of vegetative B. subtilis in the soil, except if associated 
with decaying plant matter. Interestingly, Bacillus endospores were 
found in the gut of various insects and animals. A reasonable 
explanation is that endospores introduced in the gastrointestinal 
tract by the way of food germinate and proliferate therein [Hong et 
al., 2009]. Studies performed with murine models demonstrated that 
B. subtilis (strain PY79) is rapidly cleared from mouse gut after only 
6 days [Hoa et al., 2001; Le Duc et al., 2004].  Although B. subtilis 
can not rigorously be considered as a gut commensal, the 
gastrointestinal tract represents an important part of its life cycle. 
Also supported by the finding of Bacillus endospores in diverse 
other surroundings including rocks, dust, and aquatic environments, 
the denomination of B. subtilis as a pure soil microorganism is not 
strictly correct anymore. 
With the emergence of Genomics in the nineties, many 
laboratories joined efforts to determine the complete genome 
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sequence of B. subtilis 168, a research model for gram-positive 
microorganisms. A consortium of 30 groups [Simpson, 2001] 
sequenced and annotated chromosomal segments covering the 
whole genome [Harwood and Wipat, 1996]. However, the main 
drawback of the consortium-generated results was the 
discrepancies in the sequences. In addition, the methods available 
at that time required the cloning of B. subtilis DNA into Escherichia 
coli, which could often result in the alteration of the original 
sequence. The regions containing putative errors were therefore re-
sequenced, leading to a more accurate genome sequence [Kunst et 
al. 1997]. With the development of fast and accurate sequencing 
techniques and of advanced annotation platforms, the sequence of 
B. subtilis 168 has been recently updated [Barbe, et al. 2009]. First, 
the Roche 454 technology was used. About 800 peer-reviewed 
publications reported the use of this high-throughput sequencing 
technology since its introduction in 2005 [Margulies et al., 2005]. To 
consolidate the data, the B. subtilis genome was then analyzed with 
the high density sequencing technology developed by 
Solexa/Illumina in 2006 [Bentley, 2006].  
The updated sequence results in more than 78% of identical 
genes compared to the first one. The 4,216 kb-genome of B. subtilis 
has an average G+C content of 43% and is made of 4,244 protein-
coding genes (89.7% of the total size), 30 rRNA and 86 tRNA. 
3,662 regions transcriptionally active during mid-exponential growth 
were reported, accounting for 77.3% of the genes as they are 
currently annotated [Rasmussen et al., 2009]. A systematic 
inactivation of B. subtilis genes revealed that 271 genes were 
essential for growth [Kobayashi et al., 2003]. A significant number 
(171) of new and mostly small genes was annotated in the new 
sequence. Also, 407 genes of unknown function (whose previous 
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name started with the letter “y”) were renamed on the basis of 
experimental evidence from the literature.  The coding loci were 
divided in two categories. The persistent genes encoding ubiquitous 
functions to survive and perpetuate life are called paleome, 
whereas the genes corresponding to the colonization of particular 
niches form the cenome [Barbe et al., 2009]. A common feature of 
Bacillus spp. is that the G+C content varies considerably throughout 
the chromosome. In addition, A+T islands are the marker of 
bacteriophages or transposons. It is therefore hypothesized that the 
chromosome results from horizontal transfer of DNA from 
organisms richer in A+T than B. subtilis [Tosato and Bruschi, 2004].  
The genome sequence of B. subtilis has a limited interest 
per se. More interesting are the genomic studies aiming at 
associating genomic items of the sequence with their functions, 
which are identified experimentally or predicted in silico. Elucidation 
of the complexity and dynamics of transcriptional activity in the 
whole-genome notably involves methods based on high-density 
oligonucleotide tiling array technology. This powerful technology 
relies on short fragments designed to cover the entire genome or 
contiguous regions of the genome and fixed onto a solid surface. 
Labelled target molecules (cDNA) are then hybridized to the 
unlabeled probes. Relevance of genome-wide investigations with 
tiling arrays were notably demonstrated with B. subtilis [Nicolas et 
al., 2009]. 
In the current post-genomic era, studies of DNA topology 
and secondary structures are also taken in account to understand 
storage and management of genetic superinformation. Analysis of 
DNA secondary structure aims to figure out whether the presence of 
hairpins and bends along the chromosome is correlated to 
phenomena that primary structure cannot explain, such as preferred 
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sites of integration in transposon mutagenesis, cellular shape and 
non-coding DNA. Investigation on DNA supercoiling also adds onto 
the knowledge of regulation of gene expression. DNA supercoiling 
is dependant on environmental factors, such as osmolarity, 
temperature, oxygen, and carbon sources, resulting in activation or 
repression of gene expression. Gene organization is considered as 
well, together with DNA secondary structure and supercoiling, 
because complex interactions exist among different regions of the 
chromosome [Tosato and Bruschi, 2004]. More specifically, the 
position of a gene within an operon can have a significant impact on 
the control of its expression. Exemplifying this, a study on the 
influence of the position of sigD, a gene encoding the sigma D 
factor of RNA polymerase in B. subtilis and driving expression of 
genes required for cell separation and flagella assembly, was 
recently published [Cozy and Kearns, 2010]. The part of motile cells 
reaches 70% when sigD is expressed at its original locus within the 
so-called motility operon, whereas it goes up to 100% when this 
gene is moved upstream. It is also documented that the position of 
a gene in the chromosome can have a strong impact on its function 
[Dworkin and Losick, 2001]. 
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2. Industrial biotechnology with B. subtilis 
  
2.1 Advantages/Drawbacks of B. subtilis as an industrial 
workhorse 
 
As a non-pathogenic bacterium (biological hazardous level 
1), B. subtilis is attractive for industrial purposes for various 
reasons. First, it enables the development of valuable industrial 
processes, thanks to its short fermentation cycle times (high growth 
rates), and relatively inexpensive and easy large-scale fermentation 
at high cell densities. The single membrane of B. subtilis cells 
enables direct transfer to the growth medium of proteins transported 
by secretion machineries, which greatly simplify downstream 
processes. High concentrations of extracellular proteins (up to 25 
g/l) can therefore be reached [Perkins et al., 2009], considering that 
secreted proteins concentrations in the gram per liter range are 
usually significant. Registration is also simplified, as B. subtilis 
profits of the GRAS (Generally Regarded As Safe) status with the 
US Food and Drug Administration (FDA). Importantly, the GRAS 
status is attached to products derived from B. subtilis but not the 
microorganism itself. The QPS (Qualified Presumption of Safety) 
status, the European equivalent of GRAS, was recently introduced 
by the EU authorities [EFSAa, 2007]. Furthermore, proteins 
produced in B. subtilis are free of endotoxin lipopolysaccharide 
(LPS), a molecule present in the outer membrane of Gram-negative 
bacteria that must be completely removed before using recombinant 
proteins for clinical purposes [Zweers et al., 2008].  
Despite these relevant advantages, production of 
heterologous proteins with B. subtilis raises some major limitations. 
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First, expression of at least height cell wall-associated and/or 
secreted proteases (AprE, Bpf, Epr, Mpr, NprB, NprE, Vpr and 
WprA; Wu et al., 2002) generates significant degradation of 
secreted heterologous proteins. Moreover, like many other 
prokaryotes, B. subtilis is not able to glycosylate proteins during 
their secretion. It is therefore not a producer of choice for 
pharmaceutical proteins, when total structural authenticity is 
required (mammalian proteins) [Westers et al. 2004].  
 
2.2 Market for industrial compounds produced with B. subtilis 
 
Industrial enzymes represent a major area of biotechnology, 
resulting in the development of a number of new products and 
improvements in the process and performance of several existing 
products. Worldwide, about 20 companies share the production of 
industrial enzymes. The European key players are AB Enzymes 
GmbH (Germany), BASF AG (Germany), Chr. Hansen AS 
(Denmark), Danisco AS (Denmark), Direvo Biotech AG (Germany), 
DSM Food Specialties (The Netherlands), Evonik Industries 
(Germany) and Novozymes AS (Denmark).  It is estimated that 
Bacillus spp. enzymes represent 50% of the total enzyme market. 
The global market for industrial enzymes is expected to be worth 2 
billion euros by 2012. Industrial enzymes produced with B. subtilis 
address various applications. The market is clustered in technical 
enzymes (i.e. enzymes used in textile, detergent, and pulp & paper 
industries) (50%), food (36%) and feed (14%) enzymes. Current 
growth of the animal feed enzymes segment is notably supported 
by the increased use of phytase to improve nutrient value of 
feedingstuffs and reduce phosphorous pollution in intensive farming 
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areas [Thakore, 2008]. The main compounds produced from 
industrial fermentations of B. subtilis are summarized in Table 1.  
 
Table 1: Main compounds produced by industrial fermentation of B. 
subtilis. Adapted from Schallmey et al., 2004 and Zeigler and Perkins, 
2008. 
 
Products      Industrial applications 
 
Enzymes: 
Alpha-Acetolactate decarboxylase  Beverage 
Alpha-Amylase    Food, Paper, Starch, Textile, Brewing 
Beta-Glucanase    Beverage 
Beta-Glucosidase    Brewing 
Cellulase     Detergents 
Cyclodextrin glucanotranssferase  Food, Pharma, Cosmetics 
Galactomannase    Feed, Beverage 
Glutaminase     Food, Flavor 
Lipases     Detergent 
Neutral (metallo-) Protease   Detergent, Food 
Alkaline (serine-) Protease   Detergent, Textile 
Penicillin Acylase    Pharma 
Pullulanase     Starch, Food, Beverage 
Poly-gamma-glutamic acid   Food, Pharma, Cosmetics 
Urease  Analysis, Beverage 
Xylanases     Baking, Feed, Beverage, Brewing, Food 
 
Fine chemicals: 
D-Ribose     Food, Feed, Cosmetics, Pharma 
Poly-gamma-glutamic acid   Food, Feed, Pharma 
Purine nucleosides (inosine, guanosine) Food 
Riboflavin     Food, Pharma 
Streptavidin     Microarrays  
Thaumatin     Food, Pharma 
Surfactins     Pharma, Bioremediation 
 
Others: 
Natto (fermented soy)    Food 
Animal Probiotics    Feed 
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Industrial enzymes produced with B. subtilis can have 
interesting properties, like a broad pH optimum and a good 
thermostability, such as the chimeric cellulase produced with strain 
KSM-635 [Ito et al., 1989]. In addition, high production titers can be 
reached, for instance for poly-gamma-glutamic acid produced with 
strain F-2-01 5 (up to 50 g/l) [Schallmey et al. 2004]. Although few 
vitamins are currently produced by fermentation, extensive strain 
engineering allows for production of commercially attractive levels 
of riboflavin (vitamin B2) in B. subtilis [Perkins et al., 1999]. 
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3. Genetic engineering in B. subtilis 
 
3.1 Targets of metabolic engineering 
 
Metabolic engineering of microorganisms consists in the 
genetic optimization of biosynthetic pathways toward the 
overproduction of commercially attractive metabolites. Reaching 
relevant titers generally involves significant modifications of 
biosynthetic pathways. This task may be difficult when knowledge is 
lacking on the exact biochemistry and/or genetics. In addition, 
severe imbalance in the central metabolism (e.g. metabolism of 
nucleotide bases, aminoacids etc.) can have detrimental 
consequences on the engineered strain. For example, metabolic 
engineering directed towards high vitamin B5 (pantothenate) 
production in B. subtilis requires manipulation of the genes involved 
in the synthesis of leucine, valine and isoleucine branched-chain 
aminoacids [Perkins et al., 2009]. Various strategies of metabolic 
engineering in B. subtilis address the following objectives: (i) 
overcoming limitations of carbon flux in the metabolic routes, (ii) 
reducing maintenance metabolism, (iii) improving protein secretion 
and protein folding. 
 
3.1.1 Carbon limitation in metabolic pathways 
  
On the one hand, rechanneling the carbon flux towards a 
metabolite of interest generally consists in interfering with specific 
enzymatic reactions in other metabolic pathways. A gene knockout 
causes the annihilation of these enzymatic reactions, while the 
 11
Chapter I             General Introduction 
  
selection of appropriate mutations only results in bottlenecks that 
slow down enzymatic turnover.  
On the other hand, carbon limitation in the metabolic 
pathway of interest is overcome by enhancing gene expression. 
More precisely, either the amount or the stability of messenger 
RNAs available for ribosomal translation can be increased, or the 
transcriptional regulation can be reduced. Transcriptional 
attenuation typically controls genes expression in metabolic 
pathways. It consists in the binding of regulatory protein or 
metabolites to a specific segment of the nascent mRNA, resulting in 
the formation of hairpin secondary structures [Henkin and Yanofsky, 
2002]. Premature termination of transcription through this 
mechanism is for instance involved in the complex regulation of 
tryptophan biosynthesis in B. subtilis [Gollnick et al., 2005]. 
Specifically, the riboswitch mechanism is a widely distributed way 
for negative regulation of gene expression in bacteria, 
independently of any protein cofactor. This sensor-regulatory 
system relies on genetic elements in the 5'-untranslated regions of 
mRNAs which are able to specifically bind small metabolites. This 
results in allosteric rearrangement of the mRNA with subsequent 
effects on transcription or translation. In Bacillus species, 
riboswitches control the expression of more than 2% of all genes, 
responding to various metabolites including amino acids, 
nucleotides and protein cofactors [Montange and Batey, 2006]. 
Seven riboswitches have been identified in bacteria, involving the 
following metabolites: coenzyme B12 [Nahvi et al., 2002], flavine 
mononucleotide [Mironov et al., 2002; Vitreschak et al. 2002; 
Winkler a et al., 2002], S-adenosylmethionine [Grundy and Henkin, 
1998; Montange and Batey, 2006], adenine and guanine [Mandal et 
al., 2003],  lysine [Blount et al., 2006; Sudarsan et al., 2003], and 
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thiamin pyrophosphate [Mironov et al., 2002; Rodionov et al. 2002; 
Sudarsan et al. 2003; Winklerb et al., 2002]. Riboswitches can serve 
as antimicrobial drug targets [Blount et al., 2006; Sudarsan et al., 
2005], but also support the understanding and engineering of high 
metabolites producing strains. Deregulated mutants of B. subtilis 
can be selected on the basis of their resistance to anti-metabolites 
which are analogues of the compound to be overproduced. For 
example, the B. subtilis strain currently used for industrial 
production of vitamin B2 (riboflavin) by DSM Nutritional Products 
Ltd. (Switzerland) is able to overcome a key transcriptional 
attenuation in the riboflavin biosynthetic pathway, promoted by a 
high intracellular concentration of flavine mononucleotide 
coenzyme. This deregulation is due to a mutation in ribC locus, 
selected after a screening of clones resistant to roseoflavin, a toxic 
riboflavin analogue [Perkins et al., 1999].  
 
3.1.2 Maintenance metabolism 
   
An important criterion for industrial production of metabolites 
by high-cell density microbial processes is a low maintenance 
energy metabolism to reduce non-productive consumption of 
substrate. Maintenance metabolism is inherent to a given 
microorganism and represents the energetic cost dedicated to 
survival, without biomass or product formation. In carbon-rich 
cultures of B. subtilis, the energetic growth efficiency is reduced 
mainly due to a massive overflow metabolism, the primary 
dissipating flux of ATP equivalents [Dauner et al., 2001]. 
Comparatively, carbon-limited fermentation processes, with a low 
growth rate and high biomass concentration, decrease the 
maintenance energy demand, which still remains quite high in B. 
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subtilis.  Once the specific biosynthetic pathways have been 
optimized for a given metabolite, reduction of the maintenance 
metabolism is a valid objective for improvement of commercial 
process performance. For this purpose, energy respiration can be 
improved by redirecting electron flow to more efficient proton 
pumping branches within respiratory chains. Depending on the 
respiratory chain branch, one to three protons can be translocated 
by transported electron. This impacts the resulting proton gradient 
crossing the cytoplasmic membrane in return to generate ATP. A 
successful example was reported for the production of riboflavin, for 
which energy metabolism engineering rate was reduced by 40%. 
The results from this study suggest that increasing respiratory 
energy generation is a general strategy to improve product yields in 
industrial bioprocesses with B. subtilis [Zamboni et al., 2003]. 
Another promising area for industrial bioprocesses is the 
development of bacterial cells with the lowest experimentally 
determined waste of energy and with industrially relevant 
phenotypes. Such a purpose is based on the concept of a minimal 
gene set, referring to the smallest possible group of genes that 
would be sufficient to sustain a functioning cellular life form under 
the most favourable conditions [Koonin, 2000]. For industrial 
biotechnology, the stake is the development of a minimal production 
host, deprived from the irrelevant or adverse traits and harboring a 
gene scaffold optimized for high metabolites production.  In 
academic research, studying such a minimal gene set aims to 
highlight for instance the biological functions which are essential in 
most, if not all, bacterial species. A major advance in Synthetic 
Biology was recently achieved by researchers at the J. Craig Venter 
Institute (USA). Their results constitute the first proof-of-principle 
that microbial genomes can be designed in silico, chemically made 
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in the laboratory and transplanted into a recipient cell to produce a 
new self-replicating cell controlled only by the synthetic genome 
[Gibson et al., 2010].  
The non-essential genes in B. subtilis may have been 
acquired during evolution through the perpetually changing 
ecological niches. Efforts to minimize the B. subtilis genome were 
motivated in the past years by the will to generate a less complex 
organism, easy to model and understand. Determination of a 
minimal set of genes combines both computational and 
experimental approaches. Experimental conditions, such as 
nutrients in culture media, are major factors of variability. A minimal 
cellular-function set rather than a minimal gene set was therefore 
recently explored by computational approaches [Azuma and Ota, 
2009]. Results of this study suggest that 41 pathway maps (of the 
KEGG database; Kyoto Encyclopedia of Genes and Genomes) are 
essential in B. subtilis, including 25 conserved pathway maps and 
16 organism-specific pathway maps. The conserved maps include 
many pathways classified as "genetic information processing", 
whereas the organism-specific maps mainly include pathways for 
catabolism, reflecting evolutionary aspects. The genome of B. 
subtilis was experimentally reduced by removing prophages and 
AT-rich islands, consisting in 332 genes (SP-beta, PBSX 
prophages, prophage-like regions, and the largest operon pks). This 
resulted in a genome reduction of 7.7% [Westers et al., 2003]. 
Further work on minimalization of the B. subtilis genome led to a 
collection of 157 interval strains, generated in maintaining 821 
genes (essential genes and genes necessary for knockout 
procedure, competence etc.) In total, 77.8% of the genome (3,281 
Mbp) was deleted in this collection of strains. These strains were 
phenotypically characterized and some of the mutants grew 
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interestingly much faster than the wild-type B. subtilis [Henry et al., 
2010]. 
 
3.1.3 Protein secretion and protein folding 
  
In B. subtilis, export of proteins requires dedicated transport 
machineries composed of channels and ATP-dependant or proton 
gradient-dependant proteins to drive active movements across the 
membrane (Figure I-1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I-1: Protein export pathways in B. subtilis. Adapted from 
Tjalsma et al., 2004. Proteins can be sorted to various destinations 
depending on the presence or absence of an amino-terminal signal 
peptide (+/-SP). Depending on the class of their signal peptide, proteins 
can be secreted into the medium via the Sec or Tat pathway, or by ABC 
transporters. Proteins that have to be retained at the extracytoplasmic side 
of the membrane can contain either a transmembrane segment (TM) or a 
lipid modification (lipobox). Proteins that need to be retained in the cell wall 
can be exported via either the Sec or Tat pathway. Proteins containing cell 
wall-binding repeats (CWB) are exported via the Com system in the cell 
wall interface.  
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Proteins to be secreted have a signal peptide that directs 
their transport. The majority of extracytoplasmic proteins are 
exported via the well characterized Sec translocation pathway, 
ubiquitously conserved in prokaryotes. Despite the high secretion 
capacity of the Sec pathway, secretion of heterologous proteins 
remains difficult. Overexpression of the components of the secretion 
machinery and of chaperones is therefore a strategy to improve the 
production of heterologous proteins [Vitikainen et al., 2005; Wu et 
al., 1998]. An alternative secretion route, the Tat pathway, is also of 
interest and has been explored by genomic and proteomics 
approaches [Tjalsma et al., 2004; Van Dijl et al., 2002]. In B. 
subtilis, Tat translocases are made of the two subunits TatA and 
TatC. Whereas the Sec pathway only transports unfolded proteins, 
the Tat machinery translocates folded proteins. Another specific 
feature is a twin-arginine (RR) motif in the signal peptide, essential 
for recognition by the Tat translocation machinery. To improve the 
production of recombinant enzymes in industrial bioprocesses (e.g. 
proteases, lipases, alpha-amylases), it is crucial to investigate 
whether a commercially relevant Sec dependent protein can be re-
routed into the Tat pathway. A successful example of engineering of 
the Tat pathway was recently reported, using the B. subtilis serine 
protease subtilisin as a case study [Kolkman et al., 2008]. To 
reduce the degradation rate of secreted proteins, it is important to 
countereffect the extracellular proteases produced by B. subtilis. 
The use of protease-deficient host strains (e.g. WB800; Wu et al., 
2002) have thus shown to improve the stability of secreted proteins 
[Murashima et al., 2002; Westers et al., 2004; Wu et al., 1991]. 
Correct formation of disulfide bounds, happening just after 
protein translocation, is another bottleneck in the production of 
heterologous proteins in B. subtilis. Disulfide bounds play a key role 
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in accurate protein folding, and therefore in protein activity and 
resistance to extracellular proteases. The demand in proteins with 
disulfide bonds for biopharmaceutical applications (e.g. human 
insulin and growth hormones) is strong, while the ability of B. 
subtilis to produce such molecules is very poor so far. Disulfide 
bonds consist of intra- or inter-molecular bridges formed through the 
enzyme-dependant oxidation of thiol groups of two cystein residues. 
Native B. subtilis thiol-disulfide oxidoreductases (BdbA to BdbD) 
catalyze the required oxidation. This system is however overloaded 
when recombinant proteins with disulfide bonds are overproduced. 
Proof-of-principle for the optimized production of disulfide bond 
proteins within B. subtilis was reported in a recent publication in 
which depletion of the major cytoplasmic disulfide bond reductase 
(TrxA), together with recombinant expression of an efficient 
staphylococcal thiol-oxidase (DsbA), results in a 3.5-fold increase in 
secretion in the growth medium of the disulfide-bond-containing 
alkaline-phosphatase from E. coli [Kouwen et al., 2008]. Exploring 
both engineering of protein translocation and folding would likely 
broaden the capacity of B. subtilis to secrete a novel class of 
pharmaceutically relevant proteins with high yields. 
 
3.2 Strategies and tools for directed genetic modifications in 
B.subtilis 
 
3.2.1 Integration or deletion of DNA in the chromosome 
 
Efficient gene insertion, deletion or modification involve 
techniques of genetic transfer, including bacteriophage-mediated 
transduction, protoplasts fusions, and transformation with various 
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concentrations of naked or protoplast-protected DNA [Harwood and 
Cutting, 1990]. Thanks to the natural competence of this organism, 
transformation in B. subtilis is an easy process, while 
electroporation and conjugation appear to be comparably inefficient.  
B. subtilis 168 does not have any endogenous plasmid. 
Mechanisms of plasmid replication involving a single-strand circular 
intermediate DNA are thus not available. Consequently, the 
significance of plasmid-based expression systems in B. subtilis is 
questionable. Stable chromosomal integration is therefore the 
preferred method for industrial production purposes. Various 
methods to insert exogenous DNA fragments into the unique 
chromosome have been developed for laboratory studies of B. 
subtilis model organism [for a review: Perkins et al., 2009].  
Molecular genetic engineering deals with the exchange of a 
chromosomal gene by a mutated allele or an inactivated copy. 
Integration of this exogenous DNA into the chromosome of the 
recipient strain relies on homologous recombination (Figure I-2, 
panel A). Several strategies have been developed to promote gene 
replacements in bacterial chromosomes. 
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FIGURE I-2: Schematic view of homologous DNA recombination in B. 
subtilis. Panels B and C adapted from D.R. Zeigler. 2002. Bacillus 
Genetic Stock Center (The Ohio State University). (A) Recombination by 
crossover; an exchange of genetic material between homologous DNA 
molecules. (B) Knockout mutation by Campbell-like mechanism (single 
crossover) using an integration vector in a hypothetical open reading frame 
orfA. (C) Ectopic integration by double crossover to insert a hypothetical 
open reading frame, orfA, into a target locus on the chromosome of the 
recipient strain. orfA is flanked by two non-contiguous DNA regions 
(orange color), where the homologous recombination takes place. Bla; 
encodes -lactamase for antibiotic selection in E. coli, abr; antibiotic 
resistance gene selectable in gram-positives, or;: origin of replication that 
functions in E. coli but not in gram-positives. The crossed lines indicate 
crossover events. 
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3.2.1.1 Methods using an antibiotic marker 
A first set of methods leads to a stable chromosomal 
modification ensured by an antibiotic marker maintained in the host 
strain. The most basic strategy deals with the use of recombinant 
integrative plasmids from E. coli harboring an antibiotic cassette 
next to the DNA fragment to be integrated. These plasmids bear a 
conditional replication, meaning that replication functions in E. coli 
but not in B. subtilis. As the recombinant vector has a single 
homologous sequence, antibiotic-resistant transformants result from 
a single crossover by homologous recombination into the target 
locus, so called “Campbell-type mechanism” (Figure I-2, panel B).  
This concept was improved with the development of the 
pMUTIN vectors collection for systematic gene inactivation. After 
integration, the gene to be disrupted is placed under the control of 
an IPTG (isopropyl β-d-1-thiogalactopyranoside)-inducible Pspac 
promoter [Vagner et al., 1998]. The main drawback of these two 
approaches is that antibiotic selection pressure needs to be 
constantly applied to maintain the vector into the chromosome 
through generations. This can be applied in laboratories studies but 
is inappropriate in large-scale fermentations.  
Another collection of plasmids enables stable integration in 
the recipient chromosome by ectopic integration [Guerout-Fleury et 
al., 1996]. The DNA fragment to be integrated in B. subtilis is 
inserted along a selectable antibiotic marker, between the 5’- and 
3’-regions of a B. subtilis non-essential gene. These two sequences 
being homologous to sequences in the recipient chromosome, a 
double crossover takes place, leading to the integration of the 
exogenous DNA into the now-disrupted chromosomal target (Figure 
I-2, panel C). The main loci targeted by the existing plasmids for 
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ectopic integration include amyE, bpr, dif, epr, gltA, lacA, pyrD, 
sacA, sacB, thrC, and vpr, all of which are non essential genes.  
A second set of genetic engineering methods has been 
recently developed. These new strategies are based on long 
flanking homology (LFH) PCR constructs in B. subtilis.  LFH-PCR 
was initially developed in yeast for gene disruption [Walch, 1996]. 
Instead of being cloned in an E. coli vector, a disruption cassette is 
generated in vitro by PCR, in such a way that both sides of the 
antibiotic marker it contains has LFH regions of several hundred 
base pairs. The LFH regions are homologous to the targeted DNA 
sequence in the chromosome. Integration is ensured by a double-
crossover event. 
The presence of antibiotic resistance genes into genetically 
engineered strains for the production of commercial products is 
currently possible with US and EU regulations as long as the final 
product is strictly deprived of genes encoding antibiotic resistances, 
harbored by the industrial microorganisms. Nevertheless, 
registration of the genetically engineered strain is facilitated and 
perception of consumers is improved in the case of marker-free 
microorganisms.  
 
3.2.1.2 Marker-free methods 
 
Marker-free engineering consists in a two-steps method: first 
the insertion of a counter-selectable marker that subsequently loops 
out of the chromosome target to be knocked out. This method is 
however quite labor intensive and has a limited efficiency. One 
example is the Cre/lox site-specific recombination system, in which 
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two flanking regions, homologous to the target to be deleted, and an 
antibiotic marker are combined by PCR. This cassette is flanked by 
two loxP mutants (lox71 and lox66). Cre recombinase catalyzes 
then a reciprocal site-specific recombination between the two loxP 
sites, promoting a loop-out of the DNA located in between. Cre 
recombinase is entered in the host via a plasmid (pTSC) to be 
constitutively expressed, or is directly inserted in the chromosome 
as an IPTG-inducible cre expression construct. The whole process 
can be accomplished in about 2-4 days [Yan et al. 2008]. A very 
similar approach uses two dif sites, recognized by the B. subtilis 
native RipX/CodV site-specific recombinases [Bloor and 
Cranenburgh, 2006]. Another strategy is based on PCR-
construction of a cassette with a counter-selection marker and an 
antibiotic resistance gene [Brans et al., 2004; Fabret et al., 2002; Yu 
et al., 2009]. This cassette is flanked by two homology regions 
targeting the chromosomal locus to be deleted. Two short directly 
repeated (DR) sequences are included in the design of the flanking 
homology regions. In a first step, the cassette is integrated in the 
chromosomal target by homologous recombination (antibiotic 
selection). The counter-selection pressure is then used to promote 
the loop-out of the cassette by a single-crossover event between 
the two short DR sequences. The target DNA in between is 
therefore also excised from the chromosome. Several systems 
using this strategy have been recently reported with various 
counter-selection markers: (i) the E. coli toxin gene mazF, placed 
under the control of a xylose-inducible promoter to promote its 
excision [Yu et al. 2009], (ii) the product of the blaI gene, which 
represses the lysA gene under the control of the Bacillus 
licheniformis PblaP promoter and therefore confers lysine auxotrophy 
(lysine prototroph mutants, resulting from a loop-out of the cassette, 
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are selected on minimal medium) [Brans et al., 2004], (iii) the upp 
gene, encoding uracil phosphoribosyl-transferase (eviction of upp-
cassette from the chromosome is promoted with 5-fluorouracil, a 
toxic analogue of pyrimidine) [Fabret et al., 2002].  
Another method to generate markerless in-frame deletion 
relies on the pEpUC1 E. coli – B. subtilis shuttle vector. This vector 
for conditional integration and excision is based on plasmid pE194 
[Weisblum et al., 1979]. The plasmid contains a selectable 
erythromycin-resistance cassette, a temperature-sensitive origin of 
replication inhibited over 51°C, and short sequences located 
upstream and downstream of the target gene to be deleted. 
Transformation and integration of the plasmid is performed at 51°C, 
selecting for erythromycin resistance. Excision is then forced at 
28°C for 72 hours, in the absence of antibiotic selection.  The target 
gene is excised along with the plasmid, which loops out of the 
chromosome to be replicated. 
 When the gene to be modified is involved in a biosynthetic 
or metabolic pathway, a more straightforward approach can be 
used. A LFH-PCR product containing an antibiotic marker is first 
constructed and integrated in the target chromosomal locus. This 
leads to an auxotrophic phenotype. Same LFH regions are then 
used to generate another LFH-PCR product, in which the antibiotic 
marker sequence has been replaced by the modified target locus. 
Selection for recovery of a prototrophic phenotype allows then to 
get the desired mutation at the native locus (partial or complete 
deletion of the ORF or its promoter region, insertion of point 
mutations).    
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3.2.2 Enhancement of gene expression 
 
The above-mentioned integrative plasmids can be used to 
add extra-copies of target genes into the bacterial chromosome. 
The same recombinant plasmid can be integrated at different loci of 
the engineered recipient strain. Alternatively, the copy number of 
the integrated plasmids (i.e. of the genes of interest it harbours) can 
be expanded by increasing concentrations of the selective 
antibiotics. B. subtilis clones containing amplified copies already 
exist in the bacterial population, and are simply selected with this 
method. Correct implementation of this strategy requires finding the 
optimal copy number. For large-scale fermentation, antibiotic 
selection pressure must be maintained at least during the inoculum 
fermentation runs in order to stabilize the integrated plasmid(s). 
This might be associated with important cost and safety issues in 
industrial processes. Another disadvantage is that the number of 
copies of these plasmids might vary, and unneeded foreign DNA 
may be introduced in addition to that of the desired gene.  
In a more straightforward strategy, the native promoter 
region of the target genes is replaced by a strong promoter. Efficient 
strong promoters result in constitutive expression and harbor 
binding sites recognized by sigma A RNA polymerase. Sigma A is 
the major B. subtilis sigma factor, so transcription has a high 
chance to be initiated in vegetative growth conditions, being 
however maximal during exponential growth. Examples of strong 
promoters used in B. subtilis are: (i) the promoter of B. subtilis veg 
gene (Pveg), which can be used in a form containing tandem 
binding sites (for high gene expression) or in a form lacking the 
upstream site (for medium gene expression) [Le Grice et al., 1982; 
Moran et al., 1982], (ii) the promoter of B. subtilis P43 protein, 
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active during exponential and lag phases of growth thanks to its 
recognition by both sigma factors A and B [Wang and Doi, 1984], 
(iii) other strong constitutive promoters, denominated SP01-15 and 
its derivative SP01-26 [Lee and Pero, 1981], originating from the 
bacteriophage SP01. 
Following gene overexpression with a strong promoter, 
messenger RNAs accumulate in the cytoplasm and might be 
“polluting” the cell compartment. Instead of increasing the amount of 
mRNA molecules, another strategy consists in extending the half-
life of the existing one. The translation rate is therefore improved. A 
general model in E. coli suggests that RNaseE, a 5’-end-dependent 
endoribonuclease, is responsible for the initiation of the decay of 
most mRNAs. RNase E binds to the accessible 5’-end and 
promotes successive cleavage events resulting in mRNA fragments 
with accessible 3’-ends, which are rapidly degraded by 3’-5’-
exoribonucleases [Régnier and Arraiano, 2000]. Although this 
enzyme is absent in B. subtilis,  ribonucleases J1 and J2 were 
recently found to have a dual 5'-3'- 
exoribonucleolytic/endoribonucleolytic activity, promoting the decay 
of many different mRNAs and small non-coding RNAs [Arraiano et 
al., 2010; Evens et al., 2005; Mathy et al., 2007]. The 5’-end is 
therefore a key determinant of mRNA stability. Stem–loop 
structures, present at the 5’-end of aprE, ermA, ermC, glpD, ompA, 
and papA mRNAs for example, interfere with the accessibility of the 
5’-untranslated region of mRNA, conferring stability to the 
messenger [Sharp and Bechhofer, 2005].  
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4. B. subtilis endospore and its applications 
 
4.1 Endospore formation  
 
Just like about 200 species among 25 genera of aerobic 
bacteria, B. subtilis vegetative cells have the ability to produce 
ovoid-shape dormant cells when confronted to nutrient deprivation 
and high population density. Sporulation in B. subtilis constitutes the 
best studied example of a prokaryotic differentiation process, and 
has been extensively studied during the past years.  
 Sporulation leads to a metabolically inactive and extremely 
resistant structure. Even after a very long period of dormancy, 
spores can sense when environmental conditions become 
favourable for growth, possibly thanks to enzymes present on their 
surface [Dricks, 2003], and convert to a regular vegetative cell cycle 
through germination. During the three last decades, large efforts 
focused on understanding the events leading to the induction of 
sporulation or the sequential events that lead to spore formation 
[Errington, 2010; Piggot and Hilbert, 2004].   
In all endospore forming organisms, sporulation follows a 
similar morphological sequence and spores have the same 
concentric architectural plan [Henriques and Moran, 2007]. An 
asymmetric cell division occurs, resulting in a large mother cell 
containing a smaller cell (prespore or forespore) that will develop 
into a mature endospore. The plasma membrane of the mother cell 
grows around the forespore, resulting in an engulfed core 
surrounded by two membranes and isolated from the external 
medium. The core contains chromosomal DNA, ribosomes and 
other enzymes, but is metabolically inactive. The inner and outer 
 27
Chapter I             General Introduction 
  
membranes locate the assembly of peptidoglycans. The inner thin 
layer is called primordial germ cell wall, and the outer thick layer is 
defined as cortex.  Formation of the spore cortex is accompanied by 
a dramatic decrease in water content, resulting in the dehydrated 
state of the core which contains the genetic material. This ensures 
dormancy and thermostability of the spore. The cortex also provides 
protection of the spore against extreme desiccation. Closely 
apposed to the cortex, the multilayer spore coat is then 
concentrically formed. The undercoat, an elastic layer of amorphous 
material and undefined composition, ensures the proper adhesion 
of cortex and coat. Spore coat is mainly composed of about 80 
proteins. Although most of these proteins are a part of the coat 
structure, at least 20 of them have an enzymatic function or show 
similarity to known enzymes. They can for instance play a role in 
the assembly process (by posttranslational modifications), modulate 
germination, or participate in spore protection. For example, the 
product of the oxdD gene, located in the inner coat layer, shows an 
oxalate decarboxylase activity which is suspected to confer 
protection to spores against a harmful compound produced by fungi 
in the soil [Costa et al., 2004]. The successive overlay of these 
proteins around the cortex takes place in the cytoplasm of the 
mother cell, covering a period of about 6 hours and resulting in the 
formation of a lamellar inner coat and an electron-dense outer coat. 
A collection of about 40 polypeptides from 6 to 70 kDa can be 
extracted from purified spores by treatment with alkali compounds 
or reducing agents in presence of detergents. This extraction 
solubilises proteins of the inner coat and most of the outer coat, but 
does not damage the cortex. The coat contributes to the resistance 
of the spore to extreme physical (e.g. high pressures, ultraviolet and 
gamma radiations) and chemical stresses (e.g. lysozyme, oxidizing 
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agents such as ozone, chlorine dioxide, hypochlorite, peroxide 
nitrite, hydrogen peroxide, and formaldehyde). Although the 
periphery of B. subtilis spores is not surrounded by a real 
exosporium (like in spores of Bacillus thuringiensis, Bacillus 
anthracis, Bacillus mycoides, Bacillus cereus or some Clostridia), a 
thin glycoprotein layer was recently brought to light and could 
represent a rudimentary exosporium of unknown function. After 
completion of this building process, the mother cell undergoes 
autolysis, resulting in the release of the mature endospore into the 
surrounding environment (Figure I-3). 
 
Cx 
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FIGURE I-3: Ultrastructure of B. subtilis spores. Adapted from 
Henriques and Moran, 2007. Sectioning electron micrograph of cross-
sections. The spore compartments or structures are recognized in the 
spore: core (Cr), cortex peptidoglycan layer (Cx), undercoat region (Uc), 
inner (Ic) and outer (Oc) coat layers. 
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The major morphological changes taking place in the course 
of endospore formation (Figure I-4) are the consequence of a 
complex metabolic cascade.  
 Ic 
Cx Oc  
 
 
 
 
 
FIGURE I-4: The main stages of coat assembly during B. subtilis 
sporulation. Courtesy of C. Serra and A.O. Henriques (ITQB-NL). Coat 
assembly covers a period of about 6 hours, starting with the asymmetric 
division which results in the mother cell (MC) and forespore (FS) 
compartments. Sporulation then proceeds with engulfment of the forespore 
by the mother cell. Gene expression in the mother cell is governed in large 
part by the action of two primary transcription factors, RNA polymerase 
factors sigma E (σE) and sigma K (σK). The following spore layers are 
represented: cortex peptidoglycan layer (Cx), inner (Ic) and outer (Oc) coat 
layers. 
 
Both external and internal stimuli, including the nutrient 
status of the cell, cell cycle and cell density signals, help the cell to 
decide if it should go on with vegetative growth, develop 
competence, or in the worse case, launch the irreversible process 
of sporulation. Initiation of sporulation (Figure I-5) involves the 
activation and expression of hundreds of genes and the expenditure 
of a large amount of energy. A multicomponent phosphorelay, 
leading to the phosphorylation of master regulator Spo0A, controls 
entry in the sporulation process. After sensing a still-unknown 
starvation factor, five sensor histidine kinases (KinA, KinB, KinC, 
KinD, KinE) autophosphorylate. They transfer their phosphoryl 
group to Spo0A through two proteins, Spo0F and Spo0B. The 
phosphorylated Spo0A activates or represses the transcription of 
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121 genes in the mother cell. Notably, Spo0A~P represses abrB 
encoding a transcriptional repressor that regulates expression of 
several sporulation genes and genes for competence, by binding 
DNA. Expression of the sporulation genes is mainly governed by 
the action of the two RNA polymerase factors sigma E (SigE) and 
sigma K (SigK), acting as primary transcription factors, and three 
accessory regulators SpoIIID, GerR and GerE, acting as DNA 
binding factors. Expression of the genes encoding structural coat 
proteins (so called cot genes) is governed by a cascade of these 
expression factors in the mother cell in the chronological sequence 
SigE>SpoIIID>SigK>GerE.  
The complex, and not fully understood network of 
interactions between spore coat proteins, is crucial for coat 
assembly and its protective functions. One of the key features of the 
network is the influence of a small subset of proteins that direct the 
assembly of most of the coat [Kim et al., 2006].  
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FIGURE I-5: Initiation of the sporulation process in B. subtilis.                                    
Adapted from Burbulys et al., 1991; Henriques and Moran, 2007; Piggot 
and Hilbert, 2004. Initiation of sporulation involves master regulator 
Spo0A, activated by a phosphorelay. Expression of specific sporulation 
genes is driven by the RNA polymerase factors SigmaE (SigE) and 
SigmaK (SigK). Sigma K is initially synthesized as a preprotein, whose 
proteolytic activation is conditioned by a signal from the forespore. SpoIIID, 
GerR and GerE are the main accessory regulators of the gene expression 
in the course of endospore formation.  
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FIGURE I-6. Simplified structure and interactions of B. subtilis spore 
coat. Adapted from Henriques and Moran, 2007. The multilayer coat of B. 
subtilis spores is assembled in a complex order from proteins 
accumulating in the cytoplasm of the mother cell (see text for more 
details). SafA, SpoIVA, SpoVID, CotE and CotH are morphogenetic 
proteins (i.e. proteins essential for the assembly but not for the production 
of other coat proteins). CotB, CotC and CotG are the most abundant 
structural coat proteins. OxdD is a coat-associated enzyme. SafA brigdes 
the cortex and the coat, and the CotE-shell locates at the inner/outer-coat 
interface. Expression of the represented proteins is sequentially driven by 
RNA polymerase sigmaE (for SpoIVA, SpoVID, SafA, CotE, CotH) and 
sigmaK (for OxdD, CotB, CotC, CotG) subunits. The subscript n or number 
indicates multimerization of the protein. Solid arrows represent 
dependencies for the gene expression and/or protein assembly. Broken 
arrows indicate protein interactions. 
 
Assembly of the coat layers (Figure I-6) involves interactions 
between the two essential proteins made under sigma E control: 
SpoIVA, produced at the early stage of sporulation, and CotE. 
SpoIVA localizes at the outer forespore membrane and directs the 
assembly of CotE which forms a shell-like structure surrounding the 
engulfed forespore. The region delimited by SpoIVA and CotE is 
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named the precoat. The precoat is then converted into an inner coat 
layer concomitantly with outer coat assembly outside the CotE ring, 
both processes depending of sigma K factor. CotE is essential for 
assembly of the outer coat layer and spore resistance to lysozyme. 
Several sigma K-controlled proteins are thus targeted to the inner 
coat layer, presumably including the OxdD oxalate decarboxylase. 
Three additional proteins play an important role in coat formation: 
SpoVID, SafA and CotH. The CotE ring is maintained around the 
forespore by SpoVID that also direct expression of SafA. Both 
SpoVID and SafA are produced under sigma E control. SpoVID-
SafA interaction is essential in lysozyme resistance of the spores. It 
should be noted that a poorly understood interaction is also 
postulated between SafA and the OxdD inner coat-associated 
enzyme. Finally, CotH is involved in the assembly of various outer 
coat components such as CotB, CotC, and CotG [Barak et al., 
2005; Henriques et al. 2004; Henriques and Moran, 2007; Wang et 
al., 2009]. 
 
4.2 Spore-display  
 
 Display at the surface of B. subtilis endospores consists in 
the fusion of genes encoding respectively an anchoring motif 
naturally occurring in the spore coat (carrier) and a molecule of 
interest to be exposed (passenger). Transcription of the fusion gene 
is driven by the promoter of the anchoring motif, to ensure that both 
carrier and passenger are expressed in a timely manner, and during 
endospore formation. Consequently, the fusion accumulates in the 
cytoplasm of the mother cell before it assembles around the spore 
cortex together with the other coat proteins (Figure I-7).  
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FIGURE I-7: Spore display concept in B. subtilis. Courtesy of C. Serra and 
A.O. Henriques (ITQB-NL). During the sporulation process, the coat 
protein used as carrier and the fusion protein (carrier-passenger of 
interest) are accumulated and assembled in the spore coat, in the mother 
cell. The mature spore is then released with the lysis of the mother cell. 
 
Besides the well-known advantages of B. subtilis spores 
(easy preparation at large scale, indefinite storage time and 
resistance to harsh environments often met in industrial processes), 
specific benefits are offered by spore display systems. The display 
of heterologous proteins on the cell-surface of microorganisms for 
various biotechnological applications has been reported for viruses 
[Arbabi-Ghahroudi et al., 2009; Azzazy et al., 2002], yeast [Kondo 
and Ueda, 2004;Tanaka et al., 2010; Tannino et al., 2009], and 
bacteria [Daugherty, 2007; Wernérus and Stahl, 2004]. The most 
recent examples of bacterial display deal with surface proteins of E. 
coli [Kenrick et al., 2010, Yim et al., 2010, Yim et al., 2006] or an 
exosporium protein of B. thuringiensis [Park et al., 2009]. When 
filamentous phages or bacterial cells are used for surface display, 
the protein of interest has first to cross the cytoplasmic membrane 
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before being exposed outside. Some of these proteins, which either 
fold fast in the cytoplasm or have a high hydrophobic composition, 
are often trapped in the cytoplasmic membrane and cannot be 
translocated. In addition, microbial display systems are limited in the 
size of the proteins (smaller than 80 kDa) that can be displayed 
[Samuelson et al., 2002; Yim et al., 2006]. These problems can be 
prevented by using endospores formed by B. subtilis, as synthesis 
of the carrier-passenger fusion occurs in the cytoplasm of the 
mother cell. Moreover, the full set of ATP-dependant molecular 
chaperones is present in the cytoplasm to assist in the correct 
folding of the passenger protein and the multimerization of the 
passenger protein is possible [Kim and Schumann, 2009; Kwon et 
al., 2007]. 
A broad range of potential applications of spore display 
arose, including the screening of novel binding partners, 
immobilization of active enzymes for many industrial processes 
(bioconversion), environmental bioremediation, biosensors, and the 
delivery of drugs and vaccines. B. subtilis spores as vehicles for 
heterologous antigenic molecules have surely been the most 
studied application for the past decade. Successful antigen-specific 
immune responses were observed following oral or nasal 
administration of recombinant B. subtilis spores in murine models 
[for a review: Barak et al., 2005; Cutting et al., 2009; Li et al., 2009; 
Ricca and Cutting, 2003]. 
A few structural proteins (CotG, CotB and CotC) of the 
outermost layer of the B. subtilis spore coat have been selected as 
anchor for their location and their relative abundance. These 
proteins are structural tyrosine-rich proteins present as multimers 
within the spore coat. They were successfully used to display 
proteins and enzymes. CotB was initially used to display the 
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carboxyl terminal fragment of the tetanus toxin (TTFC) [Isticato et 
al. 2001], and then the protective antigen (PA) of B. anthracis [Duc 
et al., 2007]. CotC has been used to display the B subunit of the 
heat-labile toxin (LTB) of E. coli [Mauriello et al., 2004], and the 
passenger antigens above-mentioned; the TTFC fragment 
[Mauriello et al., 2004] and the anthrax PA [Duc et al., 2007]. Two 
tegumental proteins of Clonorchis sinensis [Zhou et al., 2008] have 
as well been spore displayed with CotC as anchoring motif. CotG 
was used as anchoring partner to the bioactive -galactosidase of 
E. coli [Kwon et al., 2007]. This enzyme is a very large molecule 
(116 kDa for each monomer) which is only active as a tetramer. 
This successful example demonstrates that the multimeric nature 
and the size of the passenger enzyme are not major concerns for 
spore-based display. It was also reported that streptavidin, a 60 
kDa-protein of Streptomyces avidinii was displayed at the surface of 
B. subtilis spores fused to CotG. Active streptavidin is formed of 
four monomers (15 kDa each) and has strong affinity for biotin. 
Various biotin-coupled biomolecules (e.g. proteins, nucleic acids, 
carbohydrates can therefore be detected by spores displaying 
streptavidin [Kim et al., 2005]. A variant of the green fluorescent 
protein (GPuv) was also surface-exposed on B. subtilis spores with 
CotG, offering interesting perspectives for the study of interactions 
with this coat protein [Kim et al., 2007]. Finally,  recent work towards 
the development of a spore vaccine application describes the use of 
the three coat proteins CotB, CotC and CotG to display an antigen, 
the urease subunit (UreA) of Helicobacter acinonychis, a major 
animal pathogen, also recognized as a useful model to study the 
virulence of Helicobacter pylori [Hinc et al., 2010]. 
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5. Probiotics 
 
5.1 Microbial Probiotics 
 
The use of food derived from microbial activity goes back to 
the foundation of human civilizations with fermented milk, which 
was probably the first food to contain active microorganisms. The 
word “probiotic” means “for life”, and indicates microorganisms 
associated with beneficial effects for humans and animals. The 
current definition adopted by FAO (Food and Agriculture 
Organization of the United Nations) and the WHO (World Health 
Organization) for probiotics is “live microorganisms which, when 
administered in adequate amounts, confer a health benefit on the 
host” [FAO/WHO, 2001]. Two main mechanisms for probiotic action 
have been suggested [Anadon et al., 2006]: (i) nutritional effect: 
stimulation of indigenous enzymes, and production of vitamins or 
antimicrobial substances, (ii) health or sanitary effect: increase in 
colonization resistance, competition for gut surface adhesion, and 
stimulation of immune response. Bacterial and yeast species used 
in animal feed can be normal resident of the gastrointestinal tract, or 
not. A probiotic dose of 106 to 107 CFU/g of administrated feed is 
considered as optimal to obtain a balance between probiotic 
microorganisms and resident bacteria. [Guillot, 2009].  
 
5.2 European regulation 
 
In the EU, the European Food Safety Authority (EFSA) is the 
keystone for independent scientific risk assessment of food and 
feed. The European regulation (EC) No 1831/2003 establishes the 
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rules governing the authorisation of additives in animal nutrition 
[EFSAb, 2003]. The assessment of microbial feed additives 
(enzymes and microorganisms) in feedingstuffs is based on their: (i) 
identity, characterization, conditions of use and methods of control, 
(ii) efficacy, (iii) safety under the conditions of use for target species 
and consumer, including toxicity evaluation, antibiotic resistance 
profile and transferability, (iv) worker safety assessment, (v) 
environmental risk assessment.  
Commercialisation of genetically modified (GM) probiotics 
for food/feed applications is not a priori excluded in the EU. An 
authorisation may be granted for food/feed products which consist 
of, contain or are produced from GM organisms. These products 
must not promote adverse effects on human/animal health or on the 
environment, not mislead the consumer (e.g. not be nutritionally 
disadvantageous). The strict approval by EFSA relies on a rigorous 
safety assessment described in the regulation (EC) No 1829/2003 
[EFSAc, 2003]  
 
5.3 B. subtilis as Probiotic 
 
For over a thousand years, B. subtilis fermented soybean 
has been used in human food (traditional Japanese Natto), 
underlining harmlessness of this bacterium as probiotic.  In vitro and 
in vivo studies have been performed to support the safety of using 
B. subtilis PY79 (1A747, Bacillus Genetic Stock Center, USA; 
Youngmann et al., 1984], a prototrophic strain derived from the 
Marburg 168 type strain, as a potential microbial supplement. An 
important aspect of safety for the potential microbial supplements is 
to ensure that no enterotoxin is produced by the bacterium. Neither 
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genes known to encode enterotoxins in B. cereus nor haemolytic 
activity were detected. In addition, B. subtilis PY79 laboratory strain 
has no antibiotic resistance. No indication of pathogenicity, infection 
or toxicity can therefore be related to the consumption of B. subtilis 
strains [Hong et al., 2008]. 
An in vitro study held with human intestinal-like cells (Caco-
2) showed that B. subtilis can also provide health benefits through 
the production of competence and sporulation factor (CSF), a 
bioactive pentapeptide involved in quorum-sensing, known to confer 
to bacteria the ability to communicate and change behaviour of the 
same or other species in response to conditions and perturbations 
of the environment (nutrient availability, competition with other 
potentially pathogenic microorganisms). Once taken up by intestinal 
epithelial cells, CSF notably induces cytoprotective heat shock 
proteins (Hsps), which prevent oxidant-induced intestinal epithelial 
cell injury and loss of barrier function [Fujiya, 2007]. 
Since the prohibition by the European Union (EU) of 
antibiotics use in feed as promoter for growth in 2006, a market for 
innovative growth-promoting or prophylactic products in modern 
farming has arisen. Table 2 presents a list of the probiotics products 
based on spores of B. subtilis strains. Some of them were 
authorized by the EFSA and are qualified for QPS status. 
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Table 2: Commercial probiotics containing spores of B. subtilis.  
Adapted from Hong et al. 2005. 
 
Products Target  Manufacturer Comments/References 
Baozyme-Aqua Schrimps Sino-Aqua Corp., 
Taiwan 
B. subtilis strains Wu-S and Wu-T  
Badisubtilis Humans Bidiphar Pharma, 
Vietnam 
 
BioGrow® Poultry, 
Calves, 
Swine 
Provita Eurotech 
Ltd., Ireland 
Mixture of B. licheniformis and B. 
subtilis strains 
BioPlus 2B® (a) Piglets, 
Turkeys (b) 
Chr. Hansen AS, 
Denmark 
Mixture of B. licheniformis (DSM   
5749) and B. subtilis (DSM 5750) in 
a 1:1 ratio. Dose of 1.6 x 109 
CFU/kg feedingstuff [EFSAd, 2006] 
Biosporin® Humans Biofarm, Ukraine Mixture of B. subtilis 2335 and B. 
licheniformis 2336 strains (ratio 3:1) 
Biostart® Aquaculture Microbial 
Solutions, South 
Africa 
Mixture of two strains of B. subtilis 
and strains of B. licheniformis, B. 
megaterium, and Paenibacillus 
polymyxa 
B. subtilis 035® (a) Chickens Chr. Hansen AS, 
Denmark 
Same B. subtilis strain than BioPlus 
2B® (DSM 5750). Dose range of 1.6
x 109 CFU/kg feedingstuff (EFSA, 
2006e) 
Biosubtyl DL Humans IVAC, Vietnam Mixture of B. subtilis and 
Lactobacillus acidophilus 
Calsporin® (a) Chickens Calpis Co. Ltd., 
Japan, 
represented in 
the EU by Orffa 
Inter. Holding  
 
Dose of 1 x 10
9 
CFU/kg feedingstuff
[EFSAf, 2007] 
CloSTAT® (a) Chickens Kemin Industries, 
Inc., USA 
B. subtilis PB6. Dose range of 1 x 
107 - 5 x 107 CFU/kg feedingstuff 
[EFSA, 2009] 
Lactipan Plus (a) Humans Istituto 
Biochimico 
Italiano, Italy 
 
Medilac Humans Hanmi Pharma 
Ltd., China 
Mixture of B. subtilis RO179 and 
Enterococcus faecium 
Nature’s First Food Humans Nature’s First 
Law, USA 
Mixture of 42 species, including B. 
subtilis 
Neolactoflorene (a) Humans New Pharma, 
Italy 
Mixture of 3 lactic acid bacteria 
strains and B. subtilis 
Pastylbio Humans Pasteur Institute, 
Vietnam 
 
Primal DefenseTM Humans Garden of Life, 
USA 
Mixture of 14 bacterial species,  
including B. subtilis 
Promarine® Schrimps Sino-Aqua Corp., 
Taiwan 
Mixture of 4 strains of B. subtilis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) Authorized in EU by EFSA 
(b) Undergoing assessment by EFSA for permanent authorisation in EU 
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As microoganisms have to be in a viable state to be efficient 
probiotics, spore-based products are interesting because of their 
robustness and their long shelf life. B. subtilis laboratory strain 
(PY79) was shown to be able to grow under aerobic and anaerobic 
conditions. Spores of PY79 are completely resistant to SGF 
(simulated gastric fluid) and SIF (simulated intestinal fluid). This 
may ensure that an oral dose of spores can reach and have a 
potential effect in the gastrointestinal tract [Hong et al., 2008].  
Recent in vivo studies in murine and poultry models show 
that ingested B. subtilis spores are able to proliferate in the small 
intestine. Data generated from these studies show evidence that 
spores of B. subtilis administrated as oral dose can survive the 
harsh acid environment of the stomach and are then able to 
germinate in the intestines, where the pH of gastric juices is 
sufficiently reduced. After a safe transit across the stomach, spore 
germination followed by vegetative growth takes place in the upper 
part of the small intestine, subsequently ending by sporulation in the 
lower part of the intestine. Although spore probiotics are 
metabolically dormant upon administration, they are able to display 
metabolic activity after germinating in the gastrointestinal tract. A 
first in vivo study performed with a mouse model used a molecular 
approach based on the detection of mRNA of a chimeric gene 
fusion in different sections of the intestine by RT-PCR after oral 
administration of a single dose of B. subtilis spores. The chimeric 
gene was obtained from the fusion of the ftsH gene of B. subtilis 
and lacZ of E. coli. The ftsH gene being only expressed during 
vegetative cell growth, an ftsH-lacZ fusion can only be expressed 
after germination of the administrated spores harbouring the fusion. 
Negative control experiments were conducted on wild-type strains 
(without the fusion) and on spores of B. subtilis harbouring the 
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fusion, proving that the RNA detection is specific of the vegetative 
state. Germination of administrated spores could be observed in the 
jejunum and ileum, but not in the duodenum of mice [Casula and 
Cutting, 2002]. Using either rrnO or cotB genes of B. subtilis, which 
expression is respectively specific of the vegetative state or the 
sporulation, fused to tetC as a reporter gene (encoding a fragment 
of the tetanus toxin of Clostridium tetani), Tam et al., 2006 gave the 
first indications (immunological and molecular evidence) that B. 
subtilis spores not only germinate in the mouse gut but are also 
able to grow and resporulate The B. subtilis rrnO gene fused to lacZ 
of E. coli also demonstrated on a poultry model that spore 
germination is induced either prior to or upon entry into the small 
intestine [Cartman et al., 2008]. 
Persistence experiments with the B. subtilis PY79 laboratory 
strain resulted in the detection of spores released from the mouse 
gut not more than 12 days after oral administration, suggesting that 
B. subtilis is a transient member of the gut microflora. This can likely 
be explained by the fact that laboratory B. subtilis strains can not 
form biofilms. Adherence and invasion in various cell culture lines 
were tested in vitro and showed a limited ability to bind for the 
domesticated B. subtilis strains [Hong et al., 2008].  Although B. 
subtilis  does not appear to permanently colonize the host 
microflora, natural gut isolates of B. subtilis recovered from human 
faeces persist in the murine gut for almost twice as long as the 
laboratory strain PY79, with shedding still detectable up to 27 days 
after administration. These isolates were shown to form biofilms and 
were able to adhere to Caco-2 cells [Tam et al., 2006].   
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6. Scope of the thesis 
  
Besides the interest in its study as a model organism for 
fundamental research, B. subtilis has been a major workhorse for 
industrial microbial processes. The work presented in this thesis 
describes various aspects of the development of new commercial 
applications of B. subtilis based on genetic engineering. On the one 
hand, it aims to show how metabolic engineering, supported by 
random mutagenesis and environmental chemistry, helps to better 
understand metabolic pathways and to generate a vitamin 
overproducer organism.  On the other hand, this thesis describes an 
example of structural engineering applied to the design of 
innovative applications for B. subtilis spores.  
Chapter I provides a bibliographic introduction summarizing 
the origin of B. subtilis laboratory strains and associated key 
features. Due to its intrinsic properties, this microorganism is widely 
used in the industrial production of enzymes and of metabolites of 
high commercial value, as well as in the preparation of probiotic 
mixtures for animals and humans. Use of B. subtilis for efficient 
biotechnological applications often requires genetic modifications in 
order to optimize the metabolic pathways or some structural 
elements.  
Chapter II illustrates how environmental chemistry and 
metabolic engineering can impact development of a B. subtilis 
overproducing strain for vitamin B1 (thiamin). More precisely, this 
chapter reports on the elucidation of an unknown thiamin salvage 
pathway from thiamin-degraded residues, therefore supplying new 
building blocks for the biosynthetic pathway independently of the de 
novo synthesis of thiamin. The new salvage pathway highlights in 
particular the microbial adaptation to the environment and gives 
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new insights to reconsider the physiological significance of 
thiaminase II.  
Chapter III describes mutagenesis studies performed with 
B. subtilis which result in better understanding the thiamin salvage 
pathways, and generating a thiamin overproducing strain. Thiamin-
deregulated mutations were generated. In our study, they map to 
yloS, yuaJ, and ykoD loci, and are in agreement with the known 
riboswitch mechanism of thiamin regulation. When combined in the 
same B. subtilis host, these new mutations result in the significant 
increase of thiamin production in fermentation, on the way to 
industrially relevant overproducing strains.  
The work reported in Chapter IV is an example of genetic 
engineering of B. subtilis spore coat applied to a new concept of 
spore display. While spore display was mainly oriented in the last 
decade toward vaccinology applications, using structural proteins of 
the spore coat as anchoring motif, the use of spore-coat associated 
enzyme of the inner coat layer was never explored. The results of 
our feasibility study suggest that oxalate decarboxylase (OxdD) has 
potential as carrier protein to vehicle bioactive molecules at the 
spore surface. As a proof-of-concept, spore display of endogenous 
monomeric (B. subtilis phytase) and heterologous oligomeric (E. coli 
-glucuronidase) passengers was successfully performed. 
Finally, Chapter V summarizes the topics of this thesis, and 
puts them in perspective with the future of B. subtilis industrial 
biotechnology. 
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Contribution: 
Sébastien Potot constructed all the B. subtilis mutant strains and 
conducted the in vivo confirmation of the newly identified thiamin salvage 
pathway in B. subtilis. 
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Abstract 
 
The physiological function for thiaminase II, a thiamin-
degrading enzyme, has eluded investigators for more than 50 
years. Here, we demonstrate that this enzyme is involved in the 
regeneration of the thiamin pyrimidine rather than in thiamin 
degradation, and we identify a new pathway involved in the salvage 
of base-degraded forms of thiamin. This pathway is widely 
distributed among bacteria, archaea and eukaryotes. In this 
pathway, thiamin hydrolysis products such as N-formyl-4-amino-5-
aminomethyl-2-methylpyrimidine (formylaminopyrimidine; 15) are 
transported into the cell using the ThiXYZ transport system, 
deformylated by the ylmB-encoded amidohydrolase and hydrolyzed 
to 4-amino-5-hydroxymethyl-2-methylpyrimidine (HMP; 6) - an 
intermediate on the de novo thiamin biosynthetic pathway. To our 
knowledge this is the first example of a thiamin salvage pathway 
involving thiamin analogs generated by degradation of one of the 
heterocyclic rings of the cofactor.  
 
 
 
Notes:  
 
Numbers in bold in the text body refer to the compounds (including those 
represented in the schemes and figures). 
 
The denomination thiA/ThiA in the thiamin biosynthetic pathway, used by 
the authors in this chapter is a synonym of thiC/ThiC, used in both 
chapters III and V of this thesis (as defined in Subtilist 
[http://genolist.pasteur.fr/SubtiList] and SubtiWiki [www.subtiwiki.uni-
goettingen.de]). 
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Introduction 
 
Thiamin is an essential cofactor in all living systems. It is 
biosynthesized de novo in microorganisms and plants via a complex 
pathway, but it is not synthesized in humans and is therefore an 
essential nutrient. The biosynthesis of thiamin by microorganisms 
has been studied extensively and most of the genes involved have 
been characterized (Scheme 1) [Begley, 2006; Begley and Ealick, 
2004].  
In Bacillus subtilis, HMP-PP (7) is produced by 
rearrangement of aminoimidazole ribonucleotide (AIR; 5) [Lawhorn 
et al., 2004] followed by phosphorylation [Park et al., 2004], and the 
thiazole phosphate (4) is formed by an oxidative condensation of 
glycine (1), 1-deoxy-D-xylulose-5-phosphate (DXP; 2) and cysteine 
(3) [Dorrestein et al., 2004]. Thiamin phosphate (8) is then formed 
by the coupling of the pyrimidine and the thiazole heterocycles 
[Hanes et al., 2007]. A final phosphorylation gives thiamin 
pyrophosphate (9) [Webb and Downs, 1997], the biologically active 
form of the cofactor. TenA was recently identified as a bacterial 
thiaminase II, an enzyme that catalyzes the hydrolysis of thiamin 
(10) to give HMP and hydroxyethylthiazole (11) (Scheme 2) [Toms 
et al., 2005].  
In many bacteria, the tenA gene clusters on the 
chromosome with or is fused to other thiamin biosynthetic genes 
(Supplementary Fig. 1) [Haas et al., 2005]. This chromosomal 
clustering is not consistent with a degradative function for this 
enzyme; therefore, though the structure and previously identified 
activity of TenA strongly suggested that it catalyzes a pyrimidine 
substitution reaction [Toms et al., 2005], thiamin is unlikely to be the 
physiological substrate for this enzyme.  
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Scheme 1: The main pathway for thiamin pyrophosphate 
biosynthesis in bacteria. 
 
 
 
 
 
 
Scheme 2: The previously identified TenA-catalyzed thiamin 
degradation 
 
Analysis of the genes that cluster on the chromosome with 
tenA in sequenced bacteria provided important clues as to the 
identity of the TenA substrate (Supplementary Fig. 1). In B. subtilis, 
tenA is clustered on the chromosome with a set of genes involved in 
the biosynthesis of the thiazole moiety of thiamin (thiO, thiS, thiG, 
thiF) and HMP pyrophosphorylation (thiD), whereas in Bacillus 
halodurans tenA clusters with a putative amidohydrolase (ylmB) and 
an ABC transporter (thiX, thiY, thiZ) [Rodinov et al., 2002]. In 
Bacillus cereus, tenA clusters with thiX, thiY and thiZ and thiE, thiO, 
thiS, thiG, thiF and thiD. Each of these clusters also contains an 
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upstream TPP riboswitch, which suggests thiamin regulation 
[Miranda-Rios, 2007; Winkler, 2002]. The sequence similarity of 
ThiY to the HMP synthase (Thi5) in Saccharomyces cerevisiae 
suggests that ThiXYZ is involved in the transport of HMP analogs 
[Rodinov et al., 2002]. Given that B. halodurans grows in basic soil 
(pH>10) [Horikoshi and Alkaliphiles, 1999; Takami and Horikoshi, 
1999], it seemed likely that these pyrimidine analogs could be 
generated by base-catalyzed degradation of the thiamin thiazole in 
soil (Fig. 1a) [Chahine and Dubois, 1983; Maier and Metzler, 1957]. 
We therefore proposed that YlmB, TenA and ThiXYZ are involved in 
the salvage of HMP from base-degraded forms of thiamin formed in 
soil.  
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Figure 1: Formation of formylaminopyrimidine and its identification in 
a mixture of thiamin degraded in the presence of soil. (a) Mechanistic 
proposal for the formation of formylaminopyrimidine (15) by thiamin 
hydrolysis. (b) HPLC analysis of partially purified X15 (pink trace) and its 
conversion to HMP (6) catalyzed by YlmB and TenA (light blue trace). (c) 
HPLC chromatogram of the reactions of YlmB and TenA with synthesized 
formylaminopyrimidine and aminopyrimidine. Dark blue trace: reaction of 
YlmB (20 M) with formylaminopyrimidine (2 mM, 30 min) showing its 
conversion to aminopyrimidine. Green trace: reaction of TenA (1 M) with 
aminopyrimidine (5 mM, 30 min) showing its conversion to HMP. 
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Results 
 
This paper describes the experimental validation of this 
hypothesis and the identification of the first example of a thiamin 
salvage pathway involving a heterocycle-degraded form of the 
cofactor.  
Though the high soil pH at which B. halodurans grows was 
an important clue to the function of TenA, the proposed thiamin 
degradation chemistry must also occur under neutral conditions 
because B. subtilis and B. cereus both grow in neutral soil. We 
therefore focused our attention on thiamin degradation under the 
milder reaction conditions in neutral soil to simplify the 
decomposition reactions mixtures. Even under these conditions, 
HPLC analysis of a reaction mixture generated by treating thiamin 
with sterilized soil (pH 7, 15 d, 25 °C) revealed the presence of a 
large number of thiamin degradation products relative to a soil-free 
control that showed only low levels of decomposition after 6 months 
(Supplementary Fig. 2). This thiamin decomposition reaction is 
presumably catalyzed by metal-ion-bound hydroxide on the clay 
surface, as has been described previously for other clay-catalyzed 
hydrolysis reactions [Xu et al., 2001].  
A solution of soil-degraded thiamin was treated with the 
recombinant purified proteins YlmB and TenA at room temperature 
for 3 h. HPLC analysis of the resulting reaction mixture 
demonstrated that in addition to the expected TenA-catalyzed 
thiamin hydrolysis, a component eluting at 15 min (X15) disappeared 
from the reaction mixture (Supplementary Fig. 3). In the absence of 
YlmB, this compound was unaltered under these reaction 
conditions.  
 74
Chapter II             A new thiamin salvage pathway 
  
To determine whether any additional YlmB or TenA 
substrates were buried in the complex mixture of compounds 
eluting between 18 and 25 min, HPLC fractions containing these 
compounds were collected, treated with a mixture of TenA and 
YlmB and reanalyzed by HPLC (Supplementary Fig. 4). None of the 
components of this mixture were converted to HMP, which 
demonstrates that these compounds are not relevant to the 
proposed HMP salvage pathway.  
The crude thiamin decomposition mixture was greatly 
enriched in the YlmB substrate (X15) by chromatography on silica 
gel to remove the positively charged unreacted thiamin from the 
neutral degradation products. The resulting mixture was again 
treated with YlmB and TenA. HPLC analysis of this reaction mixture 
demonstrated that a combination of YlmB and TenA catalyzes the 
conversion of X15 to HMP (Fig. 1b).  
X15 was further purified by HPLC. Its structure was 
determined to be N-formyl-4-amino-5-aminomethyl-2-
methylpyrimidine (15, Fig. 1a) by mass spectrometry and NMR 
analysis. A mechanistic proposal for the formation of this product is 
outlined in Figure 1a [Chahine and Dubois, 1983]. In this 
mechanism, water addition to the thiazolium heterocycle of 10 gives 
12, which then undergoes ring opening to give 13. Tautomerization 
to 14 followed by hydrolysis gives the formylaminopyrimidine (15).  
Formylaminopyrimidine (15) was synthesized by formylation 
of aminopyrimidine (17) and demonstrated to be identical to X15 by 
NMR, mass spectrometry and HPLC analysis (Supplementary Fig. 
5). YlmB catalyzed the deformylation of 15 to give aminopyrimidine, 
and TenA catalyzed the hydrolysis of this aminopyrimidine to give 
hydroxypyrimidine (6) (Fig. 1c). The hydroxypyrimidine formed by 
TenA can then be phosphorylated by ThiD and incorporated into the 
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thiamin biosynthetic pathway (Scheme 1). Formylaminopyrimidine is 
not a substrate for TenA and is stable under the reaction conditions. 
We have also demonstrated that ThiY (the putative substrate-
binding component of the ABC transporter ThiXYZ) binds 
formylaminopyrimidine and probably delivers it to the ThiXYZ 
transport system. These identified functions suggest the HMP 
salvage pathway shown in scheme 3.  
 
 
 
 
 
 
 
 
 
Scheme 3: The identified functions for ThiY, YlmB, and TenA, which 
suggest a new salvage pathway for the thiamin pyrimidine (6). 
 
The kinetic parameters for the YlmB-catalyzed reaction are 
kcat = 14.0 ± 0.7 min–1, Km = 5 ± 1.6 M and kcat/Km = 2.8 ± 0.97 min–
1 M–1, and the kinetic parameters for the TenA-catalyzed reaction 
are kcat = 22.0 ± 0.48 min–1, Km = 11.8 ± 1.6 M and kcat/Km = 1.9 ± 
0.26 min–1 M–1. The YlmB assay was based on formate detection 
using formate dehydrogenase and monitoring NADH production 
[Quayle, 1966], whereas the TenA assay was based on ammonia 
detection using -ketoglutarate/glutamate dehydrogenase and 
monitoring NADPH consumption [Day and Keillor, 1999]. The 
equilibrium binding constant for the formylaminopyrimidine binding 
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to ThiY was determined to be 200 nM by measuring the change in 
protein fluorescence upon binding. Thiamin does not bind to ThiY.  
To evaluate the in vivo relevance of this HMP salvage 
pathway, we examined the ability of TenA and ThiA (HMP-requiring) 
mutants in B. subtilis to grow on formylaminopyrimidine, 
aminopyrimidine, and thiamin that was completely base degraded. 
The results of these experiments are shown in Table 1 and 
Supplementary Figure 6. The ThiA (also known as ThiC) mutant is 
HMP-requiring, as expected, and grows on all of the 
hydroxypyrimidine sources. The TenA mutant does not require a 
hydroxypyrimidine source as it is able to biosynthesize it using ThiA. 
The TenA/ThiA double mutant, however, is 
hydroxypyrimidinerequiring and is unable to salvage the pyrimidine 
from formylaminopyrimidine, aminopyrimidine, or base-degraded 
thiamin. 
 
Table 1: Complementation studies on ThiA and TenA mutants 
in B. subtilis. 
  B. subtilis strain/mutant 
 ThiA (1) TenA ThiA (1) TenA WT 
Thiamin + + + 
 
 + 
HMP + + + 
Aminopyrimidine + + - 
Formylaminopyrimidine + + - 
Base-degraded thiamin + + - 
Nothing - + - 
 + 
+ 
+ 
+ 
+ 
 
 
 
 
(1) ThiA is synonym to ThiC (used in Chapter III and V of this thesis). 
 
Although we have not carried out a comprehensive study on 
the substrate tolerance of TenA or YlmB, it is highly likely that other 
analogs of thiazole-degraded thiamin are also substrates for this 
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salvage pathway. In our identification of formylaminopyrimidine as a 
substrate for YlmB, we deliberately chose mild thiamin degradation 
conditions (soil, pH = 7) to simplify the degradation reaction 
mixtures and to mimic biological conditions. Under harsher reaction 
conditions, a larger set of reaction products is generated and it is 
likely that several additional substrates for YlmB and TenA exist in 
such mixtures. We have demonstrated that degradation product 16 
[Kurata et al., 1968] (Fig. 1a) is not a substrate for YlmB or TenA, 
whereas an analog of 15 with a hydroxyethyl substituent (19) on the 
amide nitrogen is a good substrate (data not shown). This 
demonstrates that some degree of degradation of the C5 chain of 
the thiazole is required to generate YlmB substrates.  
The previously reported thiaminase II activity of TenA is 
unlikely to be physiologically relevant because TenA can be 
overexpressed in Escherichia coli at a high level without inducing 
toxicity or a thiamin requirement. This is most likely due to the 
substrate selectivity of TenA, which catalyzes the hydrolysis of 
thiamin but not thiaminphosphate or pyrophosphate, the only forms 
of biosynthesized thiamin in the cell. In addition, though the TenA 
catalyzed thiamin hydrolysis does not follow Michaelis-Menten 
kinetics, it was possible to determine, using a competition assay 
that TenA catalyzes the hydrolysis of aminopyrimidine 100 times 
faster than it catalyzes the hydrolysis of thiamin, thereby further 
adding to the selectivity of TenA for thiamin degradation products.  
The three previously identified pathways for thiamin salvage 
involve phosphorylation of the biosynthetic intermediates HMP, 
thiamin and hydroxyethylthiazole [Imamura and Nakayama, 1981; 
Imamura and Nakayama, 1982; Melnick et al., 2004; Mizote and 
Nakayama, 1989]. These pathways were relatively easy to find as 
an extension of the biosynthetic studies. The identification of a 
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salvage pathway involving products resulting from the degradation 
of one of the thiamin heterocyclic rings suggests that additional 
salvage pathways involving other thiamin decomposition products 
are likely to exist.  
The identification of the physiological function of thiaminase I 
and II has been a long-standing unsolved problem. Although we do 
not yet clearly understand the physiological function of thiaminase I, 
the experiments described in this paper suggest that pyrimidine 
salvage rather than thiamin degradation is the physiological function 
of thiaminase II. The wide distribution of TenA in bacteria, archaea 
and eukaryotes suggests the presence of this salvage pathway in 
all three kingdoms of life. YlmB is less widely distributed and 
frequently not present in organisms containing TenA, which 
suggests that the deformylation of 15 can be catalyzed by a variety 
of amidohydrolases. The wide distribution of TenA also suggests 
that destruction of the thiamin thiazole is a commonly occurring 
thiamin degradation reaction and that this new salvage pathway is 
widespread and not restricted to soil-growing bacteria.  
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Materials and Methods 
 
Soil-catalyzed thiamin degradation.  
A solution of thiamin (100 ml, 100 mM, pH 7 phosphate 
buffer) containing 10 g of soil was vigorously stirred at room 
temperature for 15 d and filtered. The resulting solution was used 
as a substrate for YlmB and TenA. The soil was obtained from the 
lawn behind S.T. Olin laboratory at Cornell University in Ithaca, New 
York, USA and sterilized by autoclaving at 120 °C for 20 min before 
use. Purification of X15 was carried out by slowly pouring 4 ml of this 
reaction mixture onto a one-inch layer of silica previously 
equilibrated in 90% chloroform, 10% methanol in a sintered glass 
funnel. The silica was then washed with 1.5 l of 90% chloroform, 
10% methanol, the solvent was removed and the resulting sample 
of crude X15 was dissolved in 3 ml of water. A 250 ml aliquot of this 
sample was further purified by HPLC as described below. The 
fractions containing X15 in phosphate buffer were collected, the 
solvent was removed and the sample was dissolved in D2O. An 
NMR spectrum was obtained on a Bruker 300 MHz instrument,  
2.33 (s, 3H), 4.21 (s, 2H), 7.91 (s, 1H), 8.12 (s, 1H). The dried 
sample was extracted from the phosphate salts with methanol and 
analyzed by ESI mass spectrometry (Esquire mass spectrometer 
from Bruker with an ion-trap mass analyzer) to give a single ion with 
an m/z [M+] ratio of 167. 
 
Synthesis of formylaminopyrimidine (15).  
A suspension of aminopyrimidine (17) (276 mg, 2.0 mmol) 
and 1H-benzotriazole-1-carboxyaldehyde (18) (Sigma) (294 mg, 2.0 
mmol) in acetonitrile (30 ml) was stirred at room temperature for 1 
h. Filtration and washing with acetonitrile (15 ml) gave pure product 
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as a white solid (240 mg, 72%). 1H NMR (300 MHz, D2O):  2.33 (s, 
3H, CH3), 4.21 (s, 2H, CH2), 7.92 (s, 1H, CH), 8.12 (s, 1H, NCHO). 
13C NMR (300 MHz, D2O):  23.71, 35.55, 110.68, 153.85, 161.62, 
164.74,166.59. ESI mass spectrometry (Esquire mass spectrometer 
from Bruker with an ion-trap mass analyzer) gave a single ion with 
(m/z): [M]+ calcd. for formylaminopyrimidine, 167.2; found, 167.4. 
 
Synthesis of N-((4-amino-2-methylpyrimidin-5-yl)methyl)-N-(2-
hydroxyethyl)formamide (19).  
Ethanolamine (20) (940 mg, 15.4 mol) was added to a 
solution of 5-(chloromethyl)-2-methylpyrimidin-4-amine (21) (1.54 
mmol) [Dornow and Petsch, 1953] in chloroform (30 ml). The 
reaction was stirred at room temperature for 12 h. Solvent was 
removed and chromatography (silica gel, chloroform/methanol 5:1) 
afforded 2-((4-amino-2-methylpyrimidin-5-yl)methylamino)ethanol 
(22) as a white solid (180 mg, 62%). 1H NMR (300 MHz, CD3OD):  
2.38 (s, 3H, CH3),  2.69 (t, J = 5.4 Hz, 2H, CH2N),  3.65 (t, J = 5.4 
Hz, 2H, CH2O),  3.69 (s, 2H, CH2N),  7.90 (s, 1H, CH). 13C NMR 
(500 MHz, DMSO-d6):  25.16, 47.28, 50.61, 60.19, 111.87, 
153.56, 162.47, 165.14. ESI mass spectrometry (Esquire mass 
spectrometer from Bruker with an ion-trap mass analyzer) gave a 
single ion with (m/z): [M]+ calcd. for 22, 183.2; found, 183.4.  
A solution of 22 (100 mg, 0.53 mmol) and 18 (100 mg, 0.69 
mmol) in acetonitrile (20 ml) was stirred at room temperature for 1 
h. Chromatography (silica gel, acetonitrile/methanol 2:1) afforded 19 
as a white solid. 1H NMR (300 MHz, CD3OD):  2.38 (s, 3H, CH3) d 
3.33 (t, J = 5.1Hz, 2H, CH2),  3.65 (t, J = 5.1 Hz, 2H, CH2),  4.43 
(s, 2H, CH2),  7.99 (s, 1H, CH),  8.15 (s, 1H, NCHO). 13C NMR 
(500 MHz, DMSO-d6):  24.90, 40.92, 50.10, 59.82, 110.30, 
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156.24, 163.61, 166.64, 168.26. ESI mass spectrometry (Esquire 
mass spectrometer from Bruker with an ion-trap mass analyzer) 
gave a single ion with (m/z): [M]+ calcd. for 19, 211.2; found, 211.4.  
 
Analysis of the thiamin degradation and the TenA/YlmB 
reaction mixtures. 
All HPLC analysis was performed on a C18 column (Supelco, 
Supelcosil LC-18-T 15 cm_ 4.6 cm, 3 m) equilibrated in 100 mM 
phosphate buffer at pH 6.6 using a flow rate of 1 ml min–1. The 
elution method used a gradient defined as follows: 0–3 min 100% 
phosphate buffer (100 mM, pH 6.6); 3–4 min 90% phosphate buffer, 
10% water; 4–10 min 60% phosphate buffer, 33% water, 7% 
methanol; 10–15 min 60% phosphate buffer, 33% water, 7% 
methanol; 15–20 min 10% phosphate buffer, 30% water, 60% 
methanol; 20–30 min 60% phosphate buffer, 33% water, 7% 
methanol; 30–35 min 100% phosphate buffer. Reaction products 
were detected by measuring absorbance at 254 nm. 
 
Bioinformatics tools.  
Chromosomal clustering of tenA was analyzed using The 
SEED database (http://theseed.uchicago.edu/FIG/index.cgi). 
 
Overexpression and purification of YlmB.  
PCR amplification of the ylmB gene (GenBank ID 15615241) 
from B. halodurans genomic DNA was performed in the standard 
way using Pfx Platinum polymerase from Invitrogen. The ylmB gene 
was then cloned into a pET16b vector using Nde1 and Xho1 
restriction sites. After cloning, the ylmB plasmid was transformed 
into the BL21 (DE3) expression strain of E. coli. YlmB was obtained 
by inoculating a 1-l culture of LB medium, containing 100 mg l–1 
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ampicillin, with a 10-ml starter culture. The cells were grown to an 
optical density at 600 nm (OD600) of 0.6 at 37 °C, at which point 
expression was induced with 1 mM IPTG. After induction, the cells 
were grown for 8 h, pelleted, resuspended in lysis buffer (50 mM 
NaH2PO4, pH 8, 300 mM NaCl, 10 mM imidazole), lysed by 
sonication, and then clarified by centrifugation at 39,000g. The 
resulting cell-free extract was passed through a Ni-NTA column 
(Qiagen), which was then washed with 5 column volumes of lysis 
buffer followed by 300 ml of wash buffer (50 mM NaH2PO4, pH 8, 
300 mM NaCl, 20 mM imidazole). The pure protein was eluted with 
elution buffer (50 mM NaH2PO4, pH 8, 300 mM NaCl, 250 mM 
imidazole) and buffer exchanged by gel filtration into 100 mM 
phosphate buffer pH 7 containing 100 mM NaCl to prevent protein 
precipitation.  
 
Overexpression and purification of TenA.  
tenA (from B. subtilis, GenBank ID 16078230) was cloned 
into a pDESTF1 plasmid (a Gateway-adapted vector based on the 
pETsystem from Novagen containing a His6 tag) and transformed 
into the BL21 Star (DE3) pRare2 expression strain of E. coli. TenA 
was obtained by inoculating a 1-l culture of LB medium, containing 
100 mg l–1 ampicillin, with a 10-ml starter culture. The cells were 
grown to an OD600 of 0.6 at 37 °C, at which point expression was 
induced with 1 mM IPTG. After induction, the cells were grown for 8 
h, pelleted, resuspended in lysis buffer (50 mM NaH2PO4, pH 8, 300 
mM NaCl, 10 mM imidazole) and lysed by sonication. The resulting 
extract was clarified by centrifugation at 39,000g and passed over a 
Ni-NTA column (Qiagen), which was then washed with 5 column 
volumes of lysis buffer followed by 300 ml of wash buffer (50 mM 
NaH2PO4 pH 8, 300 mM NaCl, 20 mM imidazole). The pure protein 
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was eluted with elution buffer (50 mM NaH2PO4, pH 8, 300 mM 
NaCl, 250 mM imidazole) and buffer exchanged by dialysis against 
100 mM phosphate buffer pH 7. The extinction coefficient of TenA 
was determined to be 74,280 M–1cm–1 using a previously described 
method [Pace et al., 1995]. 
 
Overexpression and purification of ThiY.  
PCR amplification of the thiY gene (GenBank ID 15615245) 
from B. halodurans genomic DNA was performed in the standard 
way using Pfx Platinum polymerase from Invitrogen. To increase 
the solubility of ThiY the N-terminal 20 amino acids were truncated 
to remove a hydrophobic membrane anchor. The truncated thiY 
gene was then cloned into a pET16b plasmid using Nde1 and Xho1 
restriction sites. After cloning, the thiY plasmid was transformed into 
the BL21 (DE3) expression strain of E. coli. ThiY was obtained by 
inoculating a 1-l culture of LB medium, containing 100 mg l–1 
ampicillin, with a 10-ml starter culture. The cells were grown to an 
OD600 of 0.6 at 37 °C, at which point expression was induced with 1 
mM IPTG. After induction, the cells were grown for 8 h, pelleted, 
resuspended in lysis buffer (50 mM NaH2PO4, pH 8, 300 mM NaCl, 
10 mM imidazole) and lysed by sonication. The resulting extract 
was clarified by centrifugation at 39,000g and passed over a Ni-
NTA column (Qiagen), which was then washed with 5 column 
volumes of lysis buffer followed by 300 ml of wash buffer (50 mM 
NaH2PO4, pH 8, 300 mM NaCl, 20 mM imidazole). The pure protein 
was eluted with elution buffer (50 mM NaH2PO4, pH 8, 300 mM 
NaCl, 250 mM imidazole) and buffer exchanged by gel filtration into 
100 mM phosphate buffer pH 7.  
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Assay for YlmB-catalyzed hydrolysis of formylaminopyrimidine 
(15).  
The well-characterized formate dehydrogenase assay 
[Quayle, 1996] was used to measure the YlmB-catalyzed production 
of formate from formylaminopyrimidine. Before kinetic analysis, 500 
mM EDTA was added to YlmB (1 M) to remove any metal that may 
have bound during purification, such as Ni+2 from the Ni-NTA resin. 
After incubation, EDTA was removed by gel filtration. In each assay 
the concentrations of formate dehydrogenase, NAD+ and YlmB 
were held constant and the substrate concentration was varied. The 
oxidation of formate was not rate limiting in any of the assays. Each 
reaction contained 1 unit of formate dehydrogenase (a unit is 
defined as the amount that will oxidize 1.0 mol of formate to CO2 
per min in the presence of NAD at pH 7.6 at 37 °C), 1 mM NAD+, 1 
M YlmB, 5 M Co+2. The reactions were started by the addition of 
formylaminopyrimidine with the final concentrations varying from 5 
M to 400 M. The YlmB concentration was determined using the 
Bradford assay, and NADH production was monitored by measuring 
the increase in absorbance at 340 nm. Kinetic parameters were 
obtained by fitting the initial rate values (less than 10% conversion) 
to the Michaelis-Menten equation at varying substrate 
concentrations using the fitting program GraFit (Erithacus Software 
Ltd.). The parameters are: kcat = 14.0 ± 0.7 min-1, Km = 5 ± 1.6 M 
and kcat/Km = 2.8 ± 0.97 min-1 M-1. 
 
Assay for TenA-catalyzed hydrolysis of aminopyrimidine (17).  
The well-characterized glutamate dehydrogenase–based 
assay [Day and Keillor, 1999] was used to measure the production 
of ammonia from aminopyrimidine catalyzed by TenA. In the kinetic 
assays the concentrations of NADPH, -ketoglutarate, glutamate 
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dehydrogenase and EDTA were kept constant, while the 
aminopyrimidine concentration was varied from 10 M to 500 M. 
Each reaction contained 5 units of glutamate dehydrogenase (unit is 
defined as the amount of glutamate dehydrogenase that will reduce 
1 mol of -ketoglutarate to glutamate per min at pH 8.3 at 30 °C), 
5 mM -ketoglutarate, 0.1 mM EDTA, and 250 M NADPH. The 
reduction of -ketoglutarate to glutamate was not rate limiting in any 
of the assays. All reactions were performed by adding each reaction 
component to a solution of aminopyrimidine. The reaction was then 
started by adding TenA (0.5 M). The TenA concentration was 
determined from its extinction coefficient, and NADPH consumption 
was monitored by measuring the decrease in absorbance at 340 
nm. Kinetic parameters were obtained by fitting the initial rate 
values (less than 10% conversion) to the Michaelis-Menten 
equation at varying substrate concentrations using GraFit. The 
parameters are: kcat = 22.0 ± 0.48 min-1, Km = 11.8 ± 1.6 M and 
kcat/Km = 1.9 ± 0.26 min-1 M-1. 
 
Determination of the selectivity of TenA for aminopyrimidine 
versus thiamin.  
TenA (10 M) was incubated with equimolar amounts (5 
mM) of thiamin (10) and aminopyrimidine. The reaction was 
quenched after 2 min by filtration through a membrane with a 
molecular weight cutoff of 10 kDa to remove the TenA protein. After 
the quench, 100 l of the filtrate was analyzed by HPLC. The molar 
ratio of the products of the hydrolysis of thiamin and 
aminopyrimidine were determined using standard curves (peak area 
as a function of moles of compound). The molar ratio of these 
products was used as a measurement of relative rate. The extent of 
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thiamin hydrolysis was determined from the moles of thiazole (11) 
produced. The product of the aminopyrimidine hydrolysis was 
determined by subtracting the moles of thiazole produced from the 
total moles of hydroxypyrimidine (6) produced (thiamin hydrolysis 
results in a 1:1 ratio of thiazole to hydroxypyrimidine, Scheme 2), to 
provide the moles of hydroxypyrimidine that were produced 
exclusively from aminopyrimidine. Hydrolysis of thiamin resulted in 
0.0002 ± 0.000008 mol of product; hydrolysis of aminopyrimidine 
resulted in 0.02 ± 0.004 mol of product. From this data, we 
calculate a relative rate of aminopyrimidine hydrolysis to thiamin 
hydrolysis of 99 ± 4.  
 
Bacterial sources of YlmB, TenA and ThiY.  
The characterization of the pyrimidine salvage pathway was 
performed using YlmB and ThiY cloned from B. halodurans and 
TenA cloned from B. subtilis because these enzymes were the ones 
that overexpressed and purified to give the most soluble protein. 
The YlmB from B. subtilis has been overexpressed and catalyzes 
the same reaction as YlmB from B. halodurans, and the TenA from 
B. halodurans has also been overexpressed and catalyzes the 
same reaction as TenA from B. subtilis. Therefore, the pyrimidine 
salvage pathway has been experimentally characterized in both B. 
subtilis (in which TenA is not clustered with YlmB) and B. 
halodurans (in which TenA is clustered with YlmB).  
 
Determination of the formylaminopyrimidine/ThiY binding 
constant. 
The dissociation constant (Kd) for the binding of 
formylaminopyrimidine (15) to ThiY was determined by fluorescence 
titration, in which the decrease in protein fluorescence was 
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measured as a function of substrate concentration. Small aliquots 
(0.75 l, 186 M) of substrate were added to a ThiY solution (3 M) 
and the protein fluorescence was measured using a Cary Eclipse 
fluorescence spectrophotometer (Varian). The protein was excited 
at a wavelength of 280 nm and emission was detected at 340 nm, 
with slit widths of 5 mm for both excitation and emission. The Kd 
value was obtained by fitting the fluorescence data by nonlinear 
regression to the following quadratic equation:  
  
 
 
where Fo is the y intercept, F is the overall change in fluorescence, 
Po is the protein concentration and Lo is the ligand concentration 
added [Anderson et al., 1988]. All non-linear regression was 
performed in the program GraFit 5. The Kd for the binding of 
formylaminopyrimidine to ThiY is 200 nM.  
 
Construction of B. subtilis mutants.  
The thiA auxotroph TH2 strain was constructed by 
transforming wild-type strain 1A747 (Bacillus Genetic Stock Center) 
with a low non-congressional concentration of strain 1A603 
(containing the thiA::Tn917 mutation) chromosomal DNA, with 
selection on rich medium containing erythromycin (50 mg ml-1) 
[Schyns et al., 2005]. Strain TH140, which contains a deletion of the 
tenA gene, was constructed as follows: long flanking homology 
PCR [Wach, 1996] was used to generate a deletion mutation in the 
coding region of the tenA open reading frame, in which a 530-base-
pair-long nucleotide region of tenA was replaced with the 
chloramphenicol acetyltransferase (encoded by cat4) resistance 
cassette [Schyns et al., 2005]. To do this, two PCR fragment ‘arms’ 
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were first created: 0.2 ml of a 100 M solution of primers P1tenA 
and P2tenA-cat or primers P3tenA-cat and P4tenA (Supplementary 
Table 1) were added to 0.1 g 1A747 chromosomal DNA in a 50-l 
reaction volume containing 1 l of 40 mM dNTPs, 5 l of 10x buffer 
and 0.75 l of PCR enzyme (Taq and Tgo), as described by the 
manufacturer (Expand high-fidelity PCR system, Roche Applied 
Science). The PCR reaction was performed for 30 cycles using an 
annealing temperature of 55.7 °C and an elongation time of 45 s. 
The resulting fragments, called F1 and F2, respectively, were 
purified and next used as primers in a second round of PCR. F1 
and F2 fragments were diluted 50-fold and 1 l of each was added 
to 0.1 g of chromosomal DNA from strain TH12 in a 50-l reaction 
volume to amplify the cat4 cassette. In the first 10 cycles, an 
annealing temperature of 63 °C and an elongation time of 3 min 
were used. In the next 20 cycles, the elongation time was extended 
by 20 s after each cycle. The resulting products were then used in a 
third round of PCR as a template. The PCR products were diluted 
50-fold and 1 l was combined with 0.2 l of a 100 M solution of 
primer P1ten A and P4tenA in a 50-l reaction volume containing 
dNTPs, buffer and enzyme as described above. The PCR reaction 
parameters were identical to those used in the second-round PCR. 
The finished PCR fragments were next transformed into the wild-
type strain 1A747, selecting for 5 mg ml-1 chloramphenicol 
resistance on TBAB (Difco) medium (Cmr). A single Cmr colony 
deleted for tenA was isolated and named TH140 (tenA::cat). The 
presence of the cat cassette was confirmed by diagnostic PCR 
using P1tenA and P4tenA, using standard reaction conditions. 
Finally, both thiA and tenA mutations were combined by moving the 
tenA::cat deletion into the TH2 background at non-congressional 
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DNA concentrations. The resulting recombinant strain was named 
TH141.  
 
Complementation growth conditions.  
Complementation studies were performed using minimal 
medium (Spizizen salts, 0.04% tryptophan, 0.04% sodium 
glutamate and 1% glucose) supplemented with chloramphenicol (5 
g ml–1), erythromycin (1 g ml–1) or both depending on the 
antibiotic resistance of the B. subtilis mutant. Thiamin and related 
supplements (Table 1) were at a final concentration of 5 mM. Base-
degraded thiamin was prepared by reacting thiamin (1 M) with 5 M 
NaOH for 9 d followed by neutralization with HCl and 
chromatography on a plug of silica equilibrated with 90% 
chloroform, 10% methanol as described above. This sample was 
thiamin-free by HPLC analysis. 
 
Accession codes.  
GenBank: the following sequences were deposited as part 
of previous studies: the ylmB gene from B. halodurans genomic 
DNA (GenBank ID 15615241), tenA from B. subtilis (GenBank ID 
16078230), and the thiY gene from B. halodurans genomic DNA 
(GenBank ID 15615245). 
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Supplemental Material 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 1: Chromosomal clustering of tenA in B. 
cereus, B. halodurans and B. subtilis. The reactions catalyzed by 
ThiO, ThiS, ThiG, ThiF and ThiD are shown in Scheme 1. The 
functions of TenA, ThiY, and YlmB are identified in this paper and 
the function of TenI is still unknown. 
 
 
 
 
 
 
 
 
 
Supplementary Figure 2:  
HPLC chromatogram of the thiamin degradation reaction in 
soil at pH 7. Thiamin in soil undergoes extensive degradation after 
15 days (pink trace) while the thiamin that is not exposed to soil 
does not undergo the same degradation after 3 months (blue trace). 
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Supplementary Figure 3:  
HPLC chromatogram of the reaction of soil-degraded thiamin 
with TenA and YlmB. Pink Trace: Soil-degraded thiamin. Blue 
trace: Soil-degraded thiamin treated with YlmB and TenA. 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 4:  
HPLC chromatogram indicating the absence of any substrates 
for TenA/YlmB in the complex mixture eluting between 18 and 
25 minutes. Blue trace is the mixture in the absence of YlmB/TenA, 
pink trace is the mixture treated with YlmB and TenA 
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Supplemental Figure 5: 
(a) 1H-NMR of synthetic formyl-aminopyrimidine (15) and (b) the 
formyl-aminopyrimidine (15, X15) obtained from thiamin degraded in 
soil. 
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Supplementary Figure 6: 
Complementation studies using formylaminopyrimidine (15), top left: 
WT, top right : ThiA-, bottom left: TenA-, bottom left: ThiA-TenA-. 
Growth is seen on the WT, ThiA- and TenA- strains, while there is 
no growth on the ThiA-TenA- mutant. 
 
Supplementary Table 1: 
Strains and primers used in this work 
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Abstract 
 
In bacteria, thiamin pyrophosphate (TPP) is an essential 
cofactor that is synthesized de novo. Thiamin, however, is not an 
intermediate in the biosynthetic pathway but is salvaged from the 
environment and phosphorylated to TPP. We have isolated and 
characterized new mutants of Bacillus subtilis that deregulate 
thiamin biosynthesis and affect export of thiamin products from the 
cell. Deletion of the ydiA gene, which shows significant similarity to 
the thiamin monophosphate kinase gene of E. coli (thiL), did not 
generate the expected thiamin auxotroph, but instead generated a 
thiamin bradytroph that grew to nearly wild-type levels on minimal 
medium. From this thiL deletion mutant, two additional EMS-
induced mutants were isolated that de-repressed expression of a 
thiC-lacZ transcriptional reporter. One mutant, Tx1, contained a 
nonsense mutation within the B. subtilis yloS (thiN) gene that 
encodes a thiamin pyrophosphokinase, a result which confirmed 
that B. subtilis contains a single-step, yeast-like thiamin-to-TPP 
pathway in addition to the bacterial TPP de novo pathway. A 
second mutant was shown to contain two lesions, tx26-1 and tx26-
2. Genetic mapping and DNA sequencing indicated that the tx26-1 
mutation is an allele of yuaJ, which encodes a thiamin permease. 
The second mutation, tx26-2, was located within the ykoD cistron of 
the ykoFEDC operon, which putatively encodes the ATPase 
component of a unique thiamin-related ABC transporter. Genetic 
and microarray studies indicated that both mutant yuaJ and ykoD 
genes were required for derepression of thiamin-regulated genes. 
Moreover combination of the four mutations (thiL, thiN, yuaJ, and 
ykoD) into a single strain significantly increased production and 
excretion of thiamin products into the culture medium. These results 
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are consistent with the proposed “Riboswitch” mechanism of 
thiamin gene regulation (Winkler et al., 2002, Nature 419:952-956). 
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Introduction 
 
Vitamin B1 (thiamin pyrophosphate) is a cofactor of a 
number of important enzymes in carbohydrate and amino acid 
metabolisms, which can be synthesized by microorganisms, plants 
and fungi but not by mammals [Schowen, 1998]. Unlike other 
vitamin biosynthetic pathways in bacteria (e.g. riboflavin and biotin), 
thiamin is not part of the de novo pathway, but is actually part of the 
salvage pathway. In B. subtilis, thiamin pyrophosphate biosynthesis 
occurs by a complex multistep pathway [Begley et al., 1999]. The 
pyrimidine moiety, 4-amino-2-methyl-5-hydroxymethylpyrimidine 
pyrophosphate (HMP-PP), is derived from an intermediate in the de 
novo purine biosynthetic pathway, 5-aminoimidazole ribotide (AIR), 
in a conversion catalyzed by the thiC gene product [Begley et al., 
1999]. HMP-P is then phosphorylated to HMP-PP by the product of 
the thiD (yjbV) gene prior to coupling with the thiazole unit [Park et 
al., 2004]. The thiazole moiety, 5-(2-hydroxyethyl)-4-methylthiazole 
phosphate (HET-P), is derived from 1-deoxy-D-xylulose 5-phophate 
(DXP), glycine and cysteine in a complex oxidative condensation 
reaction requiring the products of at least five different genes, thiF, 
thiS, ,thiO, thiG and a nifS-like gene [Park et al., 2003]. Coupling of 
HMP-PP and HET-P is catalyzed by thiamin phosphate 
pyrophophorylase encoded by thiE, resulting in thiamin 
monophophate (TMP) [Begley et al., 1999]. TMP is then 
phosphorylated to form thiamin pyrophosphate (TPP) by the action 
of thiamin monophosphate kinase, encoded by thiL. B. subtilis 
contains another potential way to produce TPP, through a thiamin 
one-step salvage pathway formerly discovered in Saccharomyces 
cerevisiae [Nygaard and Saxild, 2005]. This pathway, initially 
thought to exist only in lower eukaryotes, is catalyzed by the 
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product of the thiN (yloS) gene [Melnick et al., 2004]. Two other 
salvage kinases, one specific for hydroxyethylthiazole and the other 
with a broad range of substrates specificity including vitamin B6 
compounds and HMP, have been identified in B. subtilis and are 
encoded by the genes thiM and pdxK (ywdB), respectively [Park et 
al., 2004]. However an ortholog to the E. coli gene thiK (ycfN) 
encoding thiamin kinase, a salvage enzyme that converts thiamin to 
TMP, has not been identified in B. subtilis [Melnick et al., 2004]. The 
B. subtilis thiamin biosynthetic pathway showing all known and 
proposed genes and intermediates is diagramed in Figure 1 (by 
recent convention, B. subtilis thi gene nomenclature has been 
changed to the E. coli nomenclature; some literature cited here may 
contain the original B. subtilis thi gene designations). 
Interestingly, a thiamin regulatory gene has not been 
identified so far in bacteria [Downs and Petersen, 1994; Lawhorna et 
al., 2004; Webb et al., 1996]. Instead, it has been proposed that 
thiamin pyrophosphate directly regulates expression of the thiamin 
biosynthetic genes by a novel mechanism called Riboswitch, in 
which TPP interacts with the nascent mRNA message at a cis-
acting site within the 5’-leader region (call the thi-box) to form a 
secondary structure that allow formation of a transcription 
terminator [Mandal et al., 2003; Miranda-Rios et al., 2001; Mironov 
et al., 2002; Winkler et al., 2002]. In addition to TPP, which was 
shown by transcription profiling to regulate expression of the thiC 
gene and the tenA-tenI-thiOSGFD operon [Lee et al., 2001], 
thiazole (HET) was also described to repress the ywbI-thiME 
operon in B. subtilis [Zhang and Begley, 1997; Zhang et al., 1997 ]. 
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Figure 1: Thiamin biosynthesis and salvage pathway of Bacillus 
subtilis. B. subtilis thi genes were previously identified by genetic, 
biochemical, and/or in silico evidence [Begley et al., 1999; Melnick et al., 
2004; Park et al., 2003; Park et al., 2004; Rodinov et al., 2002]; in some 
cases, their original y gene designation is listed. E. coli intermediates or 
genes not present in B. subtilis but with similar functions are given in 
parentheses [Begley et al., 1999]. Abbreviations are in brackets. The 
thiamin-TMP-TPP salvage pathway is shown in a shaded box. See the text 
for details. Question marks indicate possible unknown genes involved in 
the thiamin biosynthesis and salvage pathway [Lawhorna et al., 2004; 
Lawhornb et al., 2004; Melnick et al., 2004]. The organization of Bacillus 
thiamin biosynthesis genes is shown on the right. 
 
In silico screening of the B. subtilis genome with the thi-box 
sequence has resulted in the identification of several new putative 
thiamin-regulated genes [Rodinov et al., 2002]: the yuaJ gene and 
the ykoFykoE-ykoD-ykoC operon. yuaJ could encode an ATP-
independent thiamin transporter containing multiple trans-
membrane segments. YkoE and YkoC are likely two trans-
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membrane components while YkoD is an ATPase component and 
YkoF acts as a novel HMP/ thiamin-binding protein [Devedjiev et al., 
2004]. However, no genetic experiments have confirmed the role of 
these genes in thiamin transport, and their products show no 
similarity to the known thiamin ABC transporter genes of Salmonella 
typhimurium (thiBPQ) [Webb et al., 1998].  
In this study, we used mutagenesis and transcriptomics to 
identify and characterize mutants of B. subtilis that deregulate 
thiamin gene expression. As predicted by the Riboswitch model of 
gene regulation, none of these mutations were located in genes 
predicted to encode a regulatory protein. Instead, these mutations 
mapped to several genes previously identified as encoding a 
thiamin pyrophosphokinase activity (thiN), or encoding thiamin-
related transport proteins (ykoD and yuaJ). Moreover, we also show 
that these mutations must be combined to deregulate thiamin gene 
expression, resulting in bacterial strains that are altered in the 
production and export of thiamin. These results provide genetic 
support that intracellular TPP levels control thiamin biosynthetic 
gene expression. 
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Materials and Methods 
 
Bacterial strains, plasmids, and growth conditions.  
Plasmids and strains used in this study are listed in Table 1. 
Antibiotic resistance genes that confer resistance to neomycin 
(neo), tetracycline (tet), and chloramphenicol (cat), were obtained 
from plasmid pBEST501, pDG1514, and pC194, respectively (The 
Bacillus Genetic Stock Center, The Ohio State University [BGSC]). 
B. subtilis was grown in minimal medium (MM: 1X Spizizen salts, 
0.04% sodium glutamate, and 0.5% glucose) or Veal Infusion-Yeast 
Extract complete medium (VY), or grown on agar plates consisting 
of Tryptose Blood Agar Base (TBAB, Difco, Maryland, USA) or MM 
medium. E. coli was grown on MM or Luria-Bertani medium without 
glucose. The compositions of these media are described elsewhere 
[Harwood and Archibald, 1990]. For testing thiamin production in 
liquid test tubes cultures, a thiamin-free medium was used [Difco, 
1998]. Thiamin supplements (thiamin, TMP, or TPP) required for 
auxotrophy were added at 1 μM. Resistance to the thiamin anti-
metabolite pyrithiamin was tested at 0.1 or 10 μM.  
 
Thiamin biological assays.  
Total thiamin compounds were assayed using indicator 
strains derived from Salmonella typhimurium using known methods 
[Difco, 1998]. Strain DM456 (thiD906::mudJ) responds to thiamin, 
TMP and TPP in minimal medium, whereas strain DM1856 
(thiL934::Tn10d) responds to only TPP [Petersen and Downs, 
1997; Webb et al., 1998].  
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Table 1: List of plasmids and strains. 
 
 
 
 
 
 
 
 
Plasmids Relevant characteristic or genotype Reference 
pBR322 E. coli plasmid cloning vector Bolivar et al., 1977 
pMUTIN2 B. subtilis integration plasmid for gene inactivation Vagner et al., 1998 
pDG1728 B. subtilis plasmid for ectopic integration of lacZ transcriptional fusions at amyE Guérout-Fleury et al., 
1996 
pEpUC1 E. coli-B. subtilis shuttle vector to generate in-frame mutations S. Seror (pers.commu) 
pTH1 Internal 348-bp fragment of thiL (ydiA) cloned into pMUTIN2 This work 
pTH12 712-bp thiC promoter fragment cloned into pDG1728 This work 
pTH30 In-frame thiL (ydiA) deletion (G79-G202) cloned into pEpUC1 This work 
pTH31 Internal 353-bp yuaJ fragment cloned into pMUTIN2 This work 
  
Strains  
   B. subtilis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
PY79 SPc (cured) prototroph BGSC (1A747) 
TH12 SPc thiL::cat4 This work 
TH21 SPc amyE::thiC-lacZ This work 
TH22 SPc thiL::cat4 amyE::thiC-lacZ This work 
TH48 thiL::cat4  yuaJ (the 1st lesion in Tx26) ykoD (the 2d lesion in Tx26) This work 
TH76 yuaJ::pMUTIN2 This work 
TH83 thiL yuaJ ykoD This work 
TH95 thiL thiN (tx1) yuaJ ykoD yloA::Tn917 This work 
TH105 thiL::cat4 This work 
TH106 thiL::cat4  thiL::pMUTIN2 This work 
TH112 thiL::cat4 amyE::thiC-lacZ ykoD yufR::Tn917 This work 
TH128 ispA::neo This work 
TH137 yuaJ::pMUTIN2 ykoD::cat4 This work 
TH138 ykoD::cat4 This work 
1A603 (SPc2) trpC2 thiC84::Tn917 
1A631 (SPc2) trpC2 motA::Tn917 
1A633 (SPc2) trpC2 yloA::Tn917 
1A642 (SPc2) trpC2 yufR::Tn917 
Vandeyar and Zahler, 
1986 
Tx1 thiL::cat4  amyE::thiC-lacZ  thiN (tx1) This work 
Tx26 thiL::cat4  amyE::thiC-lacZ yuaJ ykoD This work 
RL2066 spoVM::spec Chiu et al., 1998 
   E. coli   
PT-R1 thiO-35 E. coli Genetic Stock 
Center 
K12 Wild type E. coli Genetic Stock 
Center 
   S.enterica serovar Typhimurium  
DM456 thiD906::MudJ(Km) Webb and Downs, 
1997 
DM1856 thiL934::Tn10d(Tc) Peterson and Downs, 
1997 
 
The response of DM456 to known amounts of thiamin, TMP, 
and TPP ranging from 0.0256 to 100 μg/ liter, was similar. In 
addition, DM456 was found to be more sensitive to TPP than 
DM1856. To assay B. subtilis cultures, supernatants were filter-
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sterilized before preparation of dilutions. Intracellular thiamin levels 
were measured from dilutions of 1 ml, filter-sterilized cellular 
extracts that were obtained by French press-breaking of the cells 
and centrifugation at 10,000g for 10 min. Indicator strains were 
grown overnight at 37°C in thiamin assay medium (TAM). Turbidity 
readings were made at 600 nm and compared to a range of 
standard solutions.  
 
Thiamin thiochrome/ HPLC assay.  
Individual thiamin compounds, thiamin, TMP, and TPP were 
measured using a modified thiochrome-HPLC assay procedure 
described previously [Chiu et al., 1999]. Briefly, 10 μl of culture 
supernatant or intracellular extracts are added to 200 μl of 4M 
potassium acetate. The sample is then oxidized by the addition of 
100 μl fresh 3.8 mM potassium ferricyanide in 7 M NaOH. The 
mixture is vigorously mixed and then quenched by addition of 100 μl 
fresh 0.06% H2O2 in saturated KH2PO4. Samples are transferred to 
HPLC vials and injected onto a Supelcosil LC-18-T column (15cm X 
4.6 mm, 3 μm) (Supelco – Ref. No 58970- U). Elution is made by a 
10% - 35% methanol (H2O 50% - 25%) gradient in the presence of 
40% 0.1 M K2HPO4 (pH 6.6) and 4 mM tetrabutyl ammonium 
hydrogen sulfate. Fluorescence is measured at 444 nm after 
excitation at 365 nm. The chronological order of elution from the 
column is thiamin, TMP, and TPP. This procedure was utilized to 
monitor both internal and external thiamin production during 
fermentation. In our HPLC/DAD assay used to directly measure 
thiamin and the intermediates HMP and HET in the fermentation 
broth, chromatography of samples was performed on a 
Phenomenex LUNA C18 column, using an Agilent 1100 HPLC 
system equipped with a thermo-stated auto-sampler and a diode 
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array detector (DAD). The column dimensions are 150 x 4.6 mm, 
particle size 5 micron. The column temperature was kept constant 
at 20°C. The mobile phase is a mixture of 0.4 g pentane sulfonate in 
water, pH 2 (A) and methanol (B). Gradient elution is applied, 
ranging from 2% A (3 min) to 20% A in 20 minutes. The flow rate is 
1 ml/min. The detection method is UV absorption at 254 nm. The 
selectivity of the method was verified by injecting 10 μl standard 
solutions of the relevant reference compounds, thiamin, HMP, and 
HET, each at 100 μg/ml. The target compounds were completely 
separated without special sample preparation.  
 
Molecular and genetic techniques.  
Standard genetic and molecular biology techniques used in 
this study have been previously described by Maniatis et al., 1982. 
DNA transformation, PBS1 generalized transduction, and other 
standard B. subtilis genetic techniques have been described 
previously [Cutting and Vander Horn, 1990]. 
 
Construction of thiL (ydiA) mutant.  
Comparison of the E. coli ThiL protein sequence to the 
protein database of Subtilist database detected significant similarity 
to only one protein sequence, YdiA (P(N)= 8.1e-15). The gene 
encoding this protein, ydiA, is 975 base pairs in length and is the 
first gene of a five-gene operon located at 55° on the B. subtilis 
chromosome. thiL deletion mutant was generated by inserting a 
chloramphenicol acetyltransferase cassette lacking (cat4) the 
endogenous rho-independent transcription termination site between 
nucleotide 267 and 272 of thiL. Removal of the terminator in cat4 
results in non-polar insertional mutations. To do this, PCR primer 
pair #1 - #2 (Table 2) was used to first generate DNA cassette cat4 
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gene. This fragment was then individually ligated to two DNA 
fragments containing either the 3’ or 5’ ends of thiL, which were also 
generated by PCR using primers #3 – #4 and #5 - #6 (Table 2). The 
PCR fragment containing the thiL::cat4 cassette was then inserted 
directly into the chromosomal thiL gene of strain PY79 by DNA 
transformation, selecting for colonies resistant to 5 μg/ml 
chloramphenicol. Strain TH12 containing thiL::cat4 was recovered.  
 
Table 2: List of PCR primers. 
Primer No. Sequence
1……………. 5’-GGGGGTACCGAAAATTGGATAAAGTGGG-3’ 
2……………. 5’-GGGACGCGTAAGTACAGTCGGCATTATCTCATA-3’ 
3……………. 5’-GGGGAATTCTACCAGTTGTTCTGCCAAGGGCAT-3’ 
4……………. 5’-GGGGGTACCGCAAGTGATACCAGATAAAACTTAGG-3’ 
5……………. 5’-GGGACGCGTCTTCAAAATGGACTGAATCTGAAA-3’ 
6……………. 5’-GGGGGATCCTTCAACGAGACAGACACCTTGTCCG-3’ 
7……………. 5’-ATGCGGATCCCGTCCGGACCGCC-3’ 
8……………. 5’-CGATCCCGGGGCCTCCCATCGCGGC-3’ 
9……………. 5’-ATGCCCCGGGATTTGCCTAAGCTTCATCCTAAC-3’ 
10…………... 5’-CGATGAATTCAGCCCTTCTGCAAAACCTT-3’ 
11…………... 5’-AGCTAAGCTTGGCAGCCGTTATTTTAGACATTG-3’ 
12…………... 5’-TGCAGGATCCATAAAAACTGCGCTGACCACTGA-3’ 
 
 
 
 
 
 
 
 
 
Plasmid pEpUC1 (S. Seror, personal communication) was 
used to construct in-frame, marker-less deletion mutation in B. 
subtilis. This E. coli vector contains a selectable erythromycin-
resistance (erm) cassette and the pE194 temperature-sensitive 
origin of replication that does not function over 51°C. To do this, a 
DNA fragment containing an in-frame gene deletion was prepared 
using standard PCR methods and inserted between the BamHI and 
EcoRI sites of the pEpUC1. Competent cells of the recipient strain 
were transformed at 51°C with the in-frame containing pEpUC1 
plasmid, selecting for erythromycin resistance at 5 μg/ml 
erythromycin. Emr colonies that are also Cmr were recovered and 
grown overnight at 28°C in the absence of antibiotic selection for 72 
hours. Bacteria were then plated onto TBAB agar plates and the 
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plates incubated overnight at 37°C. Approximately 25% of the 
colonies were found to be sensitive to both erythromycin and 
chloramphenicol. PCR analysis of chromosomal DNA from several 
EmS CmS colonies was used to confirm the presence of the in-frame 
mutation. 
 
Isolation of EMS-induced thiamin deregulated mutants.  
The strategy to isolate thiamin deregulated mutants of B. 
subtilis was to mutagenize bacteria that contained a thiC-lacZ fusion 
and then screen for colonies that were Lac+ in the presence of TPP 
or thiamin. A 732 bp-long DNA fragment containing 417 bp of the 5' 
promoter region of thiC was prepared by PCR using standard 
methods and cloned unidirectionally in front of the promoter-less 
lacZ gene of the pDG1728 vector [Guérout-Fleury et al., 1996], 
resulting in plasmid pTH12. This vector is designed to introduce 
ectopic transcriptional lacZ fusions into the non-essential amyE 
locus of B. subtilis. Plasmid pTH12 was linearized by restriction 
enzyme digestion and transformed into B. subtilis PY79, selecting 
for colonies that were resistant to 100 μg/ml spectinomycin (TH21). 
The same transcriptional fusion was also introduced into TH12 to 
generate TH22 (thiL::cat4, amyE::thiC-lacZ). Based on these 
results, thiC-lacZ reporter strain TH22 (thiL::cat4) was used to 
screen for deregulated mutants under repressing growth conditions. 
Two methods were used to isolate such mutants. In the first 
method, MM agar plates were prepared that contained 1 μM thiamin 
and 25 μg/ ml XGAL. After applying a uniform dilution of logarithmic 
growth phase TH22 cells, a paper disk containing 3 drops of 
ethylmethane sulfonate (EMS, d = 1.17 g/ml solution) was placed in 
the center of the plate. Lac+ colonies appeared over a period of 7 
days incubation at 37°C. In the second method, banks of EMS-
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mutagenized cells were prepared and screened. Accordingly, 
logarithmic stage TH22 cells were treated with 9.4 mM EMS for 90 
minutes and aliquots frozen in 10% glycerol at -90°C. Cells from the 
frozen stocks were diluted in VY medium, incubated at room 
temperature for 30 minutes and then plated onto MM medium 
containing 1 μM thiamin and 25 μg/ ml XGAL. Screening of Lac+ 
colonies led to mutants Tx11 and Tx26. 
 
Combination of mutations thiL, tx1 and tx26.  
As a first step, the mutations in Tx26 were transferred into 
TH12 (thiL::cat4) by DNA transformation followed by selection for 
resistance to 0.1 μM pyrithiamin (P-0256, Sigma, Saint-Louis, MO). 
One pyrithiamin-resistant (Pyrr) colony that was also Lac+ in the 
presence of TPP was recovered and designated TH48. Each strain 
was grown in minimal medium supplemented with micronutrients 
and 2.5% Difco nutrient broth (NB) for 18 hours at 37°C. The cat-
interrupted thiL gene was next replaced by an in-frame deletion 
using pEpUC1 (method described above). Using standard PCR 
methods, an in-frame deletion of thiL (removing amino acid residues 
Gly79 through Gly202) was first constructed using primers #7 – #8 
and #9 – #10 (Table 2) and inserted between the BamHI and EcoRI 
sites of pEpUC1 creating pTH30. This plasmid was then used to 
replace the thiL::cat4 mutation in TH48 with the in-frame thiL 
mutation (thiL), resulting in strain TH83. The tx1 (thiN) mutation 
was next introduced by transduction into TH83 by PBS1 
transduction by standard procedures using linkage to a silent Tn917 
insertion, yloA::Tn917 (strain 1A633 of the Bacillus Genetic Stock 
Center, also called CU4153 or zdi-82::Tn917). The resulting strain 
was called TH95. 
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Mapping experiments and constructions of mapping strains.  
Genetic mapping studies using PBS1 generalized 
transduction were performed under standard conditions [Cutting 
and Vander Horn, 1990] using donor strains from the collection of 
phenotypically-silent Tn917 mapping insertions [Vandeyar  and 
Zahler, 1986] and strains listed in Table 1. In order to inactivate the 
yuaJ gene, a 324 bp internal fragment of yuaJ starting at position 
353 was PCR-amplified and inserted between the BamHI and 
HindIII sites of pMUTIN2 using primers #14 and #15 (Table 2), 
creating plasmid pTH31. To determine if tx1 is allelic to thiN (yloS), 
a 448 bp deletion mutation, starting at base 124 of the thiN gene 
(thiN::cat4) was constructed using the cat4 gene and cloned into 
pBR322 [Bolivar et al;, 1977]. Long-flanking homology PCR was 
used to construct strains PY79 derivatives TH128 and TH138, 
which contains cat4-mediated deletions of the ispA and ykoD genes, 
respectively [Wach, 1996].  
 
Microarray profiling.  
TH22, Tx1, Tx26, and TH48 were grown in shake-flask 
cultures containing 50 ml Spizizen minimal medium with added 
thiamin pyrophosphate (0.34 μg/ml). Overnight cultures were diluted 
to Klett = 10 units into fresh medium and grown to exponential 
growth phase (Klett = 100 units). Cells from half of the culture were 
collected by centrifugation, and the total RNA was immediately 
extracted as previously described [Lee et al., 2001]. The remaining 
culture was grown to early stationary phase before RNA extraction. 
Early stationary phase was judged to be 30 min after glucose 
exhaustion; glucose content in the medium was measured by a 
glucose analyzer (Beckman, Fullerton, CA) using standard 
procedures. Preparation of RNA, labeled cDNA targets, microarray 
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hybridization and staining procedures, and data analysis are 
described in Lee et al., 2001. 
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Results 
 
Bacterial thiamin levels.  
As a first step in isolating B. subtilis thiamin deregulatory 
mutants, the intra- and extra-cellular levels of thiamin products from 
wild type and engineered B. subtilis strains were determined as 
described in Material and Methods. As a control, the thiamin 
deregulated E. coli PT-R1 mutant was similarly tested; this mutant 
is reported to produce only intracellular thiamin (no excretion of 
thiamin products into the medium) mostly in the form of TPP 
(>90%). Bioassay results indicated that thiamin products were 
readily detected from extracts of sonicated cells, but not from the 
culture medium (data not shown). The intracellular level of thiamin 
products in logarithmic or stationary phase wild-type B. subtilis was 
calculated to be approximately 100-200 μg/L (Table 3). This thiamin 
level was lower than for E. coli PTR1, which reached approximately 
1.6 mg/L in stationary phase cells. Determination of the individual 
thiamin forms using Thiochrome/HPLC showed only trace amounts 
of TMP and TPP in the supernatant of PY79 cultures (<0.05 μg/ml). 
However, intracellular thiamin products were 80% TPP and 20% 
TMP, in good agreement with the bioassay results. Intra- or 
extracellular levels of free thiamin were not observed. 
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Table 3: Thiamin production and expression of thiA-lacZ 
transcriptional fusions in wild-type and thiamin-deregulated mutants 
of B. subtilis. 
 
Accumulation (g/l) 
 
Regulation  
(-galactosidase specific activity [Miller units]c) 
 
Log Stationary 
 
 
Strain 
 
Genotype 
 
Extracellular a 
 
Intracellular b None HMP d TPP d None HMP TPP 
 
 
 
TH21 thiC
 
 
+ amyE::thiC-lacZ 
 
 
< 0.1 
 
190 
 
110 
 
6 
 
0.5 
 
31 
 
3 
 
1.2 
 
 
TH22 thiC
Tx1 thiC
Tx26 thiCthi
 
+ amyE::thiC-lacZ 
thiL::cat4 
 
0.9 530 140 26 1.3 75 9 1.8 
 
+ amyE::thiC-lacZ 
thiL::cat4  thiN 
 
5 500 NG 135 8 NG 177 5 
 
+ amyE::thiC-lacZ 
L::cat4  yuaJ  ykoD 
 
15 500 280 35 130 120 20 36 
 
 
 
 
 
 
  
 
a thiamin concentration in MM (30 ml) after 24 h of growth at 37°C. 
b thiamin concentration of 1-ml supernatant of sonicated cells collected 
from a 30-ml   MM culture after 24 h of growth at 37°C. 
c calculated according to Miller, 1972. NG, no growth. 
d final concentration of TPP and HMP were 1M. 
 
Construction and isolation of thiamin-deregulated mutants. 
  The strategy to isolate and characterize thiamin deregulated 
mutants was based on monitoring the activity of a thiC-lacZ 
transcriptional fusion in the presence of TPP or thiamin. As 
described in Material and Methods, TH21 (amyE::thiC-lacZ) is a 
derivative of PY79 in which a transcription thiC-lacZ fusion was 
integrated in single copy into the amyE gene. In control studies, 
TH21 displayed thiamin-regulated expression of the lacZ fusion. On 
minimal medium agar plates containing the indicator X-gal, colonies 
of TH21 were Lac+ (i.e. blue), but were Lac- if the medium was 
supplemented with thiamin or TPP (1μM). Moreover when grown to 
early logarithmic phase (OD600 = 0.8-0.9) in shake-flask cultures 
containing 1 μM TPP, β-galactosidase activity was repressed 
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approximately 200-fold compared to cells grown in minimal medium 
without TPP (Table 3). In stationary growth phase, the difference 
caused by TPP repression was less pronounced (30-fold 
repression). HMP (1 μM) also repressed expression of the fusion, 
but to a lesser extend. Both thiazole and adenosine (1 μM each) did 
not show any thiamin repressing activity (data not shown).  
The thiC-lacZ transcriptional reporter fusion was introduced 
into a thiL::cat4 mutant (TH22) to screen for Lac+ (i.e. blue) 
colonies under thiamin or TPP repressing growth conditions. 
In E. coli, inactivation of the thiL gene produces a thiamin 
deregulated strain which is a strict thiamin auxotroph. However, the 
B. subtilis thiL mutant was not a thiamin or TPP auxotroph, but 
instead it appeared to be a thiamin bradytroph (data not shown) and 
was slightly deregulated for thiamin gene expression (Table 3). We 
choose this strain to generate thiamin-deregulated mutants in order 
to exclude thiL mutants from our screen. Out of 50,000 EMS-
mutagenized colonies screened, twenty-six Lac+ mutants were 
recovered. Amongst these, two (Tx1 and Tx26) were selected for 
based on their unique phenotypes. Tx1 appeared to be a thiamin 
bradytroph based on its slow growth profile on minimal medium 
without TPP. Conversely, Tx26 was a prototroph but conveyed a 
much strong Lac+ phenotype than Tx1. In addition, Tx26 was found 
to be resistant to up to 10 μM pyrithiamin (Pyrr), a toxic thiamin 
analog. 
 
Thiamin-deregulated mutations are allelic to genes that are 
involved in thiamin salvage and transport.  
PBS1 generalized transduction and DNA transformation 
were used to determine the genetic map position of tx1 and tx26. In 
most cases, the Tn917 mapping strains were used as donors; since 
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these mapping strains carry the wild-type alleles we reasoned that 
replacement of the tx1 or tx26 mutation with the wild-type allele 
would result in a concomitant change in Lac phenotype (i.e. Lac+ to 
Lac-). In addition, conversion of Pyrr to Pyrs could also be used to 
map the lesion(s) in the Tx26 mutant.  
Initial mapping studies showed that the tx1 mutation was not 
linked to either the thiL::cat4 mutation or the amyE::thiC-lacZ 
fusion. However, the spoVM::Tn917 mutation (strain RL2066), 
showed the highest transduction (> 99 %) and transformation 
linkages (72 %) to tx1, indicating that this lesion was within or 
adjacent to spoVM. Inspection of this region located a possible 
candidate, thiN (yloS), a gene adjacent to spoVM which has been 
previously shown to have thiamin pyrophosphokinase activity 
(Thiamin-to-TPP activity; [Melnick et al., 2004]). To determine if tx1 
is allelic to thiN (yloS), the DNA sequence of thiN in the Tx1 mutant 
was determined. Results revealed a single base mutation that 
caused a leucine-to-phenylalanine substitution at amino acid 
residue 116 (Leu116 [CTT] >Phe116 [TTT]). 
Initial DNA transformation studies of Tx26 indicated that the 
transformation frequency of the pyrithiamin-resistance marker to 
sensitive bacteria was non-linear with respect to DNA concentration 
(data not shown). This result suggested that Pyrr in Tx26 was 
caused by more than one mutation. Transduction experiments 
confirmed that the Tx26 mutant contained two mutations located at 
different regions of the chromosome. One mutation, designated 
tx26-1, showed 70% linkage to yufR::Tn917, and the other 
mutation, designated tx26-2, showed 59% linkage to 
motA::Tn917. Further transformation mapping studies showed 
strong linkage of tx26-1 to yuaJ, a thiamin-regulated gene proposed 
to encode a thiamin permease [Rodinov et al., 2002]. To determine 
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if this lesion is allelic to yuaJ, a knock-out mutation of yuaJ was first 
constructed using pMUTIN. As expected, introduction of 
yuaJ::pMUTIN into wild type strains, (e.g. PY79) or thiC mutants 
were without phenotype. However introduction of yuaJ::pMUTIN 
into strain TH112 (tx26-1 + tx26-2 thiL) resulted in Emr colonies 
that were resistant to 0.1 μM pyrithiamin. Finally, DNA sequence 
analysis of yuaJ from Tx26 confirmed that tx26-1 was an allele of 
yuaJ. YuaJ is a predicted membrane-bound thiamin permease. 
Sequencing detected a single base mutation that resulted in the 
change of a glutamine residue at amino acid position to an ocher 
stop codon (Gln35 [CAA] > Stop [TAA]). Introduction of the tx26-1 
mutation is predicted to prematurely terminate translation resulting 
in an inactive, 35 amino acid truncated protein. In similar mapping 
studies, the tx26-2 allele showed strong linkage (65%) to the ispA 
locus (117°). This genetic map position corresponded to a cluster of 
genes, ykoFEDC, previously predicted to encode HMP transport 
proteins [Rodinov et al., 2002]. DNA sequencing of PCR fragments 
containing this operon and the promoter region detected a single 
missense mutation in the ykoD gene that resulted in an Asp180 
[GAC] to Asn180 [AAC] substitution.  
 
Mutant yloS (thiN) has decreased pyrophosphokinase activity.  
Growth of Tx1 was found to be slower on minimal medium 
lacking thiamin or TPP, taking more than three days to form 
colonies at 37°C. Addition of TPP or thiamin restored full growth 
within one day, suggesting than Tx1 was a strong thiamin 
bradytroph. In addition, Tx1 was strongly Lac+ on minimal medium 
containing thiamin, HMP, or TMP, but showed no Lac activity in 
presence of TPP. These phenotypes strongly suggested that the 
lesion in the pyrophosphokinase gene decreased the conversion of 
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thiamin to TPP whether thiamin is added externally or formed by 
dephosphorylation of TMP. Reconstruction of the Tx1 mutant 
confirmed this suspension. To do this, a double mutant (TH106) 
was constructed that consisted of a stable thiN deletion mutation 
(thiN::cat4) and a thiL disruption mutation (thiL::pMUTIN2). 
Growth on minimal or complex medium of this double mutant was 
similar to that displayed by the original Tx1 mutant: TH106 could 
only grow on minimal medium in presence of TPP, addition of 
thiamin or TMP failed to restore growth. The thiN::cat4 alone in 
PY79 (TH105) showed no discernible phenotype in terms of growth 
on MM. 
 
Simultaneous inactivation of both YkoD and YuaJ is required 
for thiamin deregulation.  
Unlike Tx1, Tx26 containing mutant ykoD and yuaJ genes 
was a thiamin prototroph and grew like the parental strain on both 
minimal and complex media. Reconstruction experiments confirmed 
that inactivation of both yuaJ and ykoD were required for resistance 
to pyrithimin. To do this, a double mutant (TH137) was constructed 
that consisted of a stable ykoD deletion mutation (ykoD::cat4) and 
a yuaJ disruption mutation (yuaJ::pMUTIN2). This mutant was 
found to be resistant to pyrithiamin (Figure 2). However, the yuaJ 
and ykoD single mutants were pyrithiamin sensitive. To investigate 
thiamin deregulation in Tx26 further, β-galactosidase levels of the 
thiC-lacZ reporter were measured when Tx26 was grown under 
thiamin repressing and derepressing conditions.  
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ykoD yuaJ ykoD 
PY79 
Tx26 
yuaJ 
cba
Figure 2: Reconstitution of the Tx26 pyrithiamin resistance 
phenotype. The strains with the indicated mutations were streaked for 
single colonies on MM (a) or MM containing 0.1M pyrithiamin and 
incubated for 3 days at 37°C (b). Panel (c) is a cartoon rendition of the 
results in panel b. 
 
As shown in Table 3, β-galactosidase activity was induced 
more that 200-fold relative to the wild-type control, when cells were 
grown to logarithmic stage in minimal medium containing TPP. The 
level of deregulation was reduced to about 30 fold in stationary 
phase. In addition, β-galactosidase levels were only two-fold higher 
in cells grown to logarithmic stage in minimal medium without TPP 
compared to cells grown with TPP (1 μM); this difference in β-
galactosidase levels was less pronounced in stationary growth 
phase. This variability in derepression of the thiC-lacZ fusion 
probably reflects fluctuation in TPP intracellular levels during 
growth. Interestingly, expression of the fusion was still partially 
repressed in the presence of HMP, which was likely caused by 
conversion of HMP to TPP via the salvage pathway.  
To determine if expression of other thiamin biosynthetic 
genes were deregulated in Tx26, transcription profiling was carried 
out using a custom Bacillus subtilis oligonucletotide microarray. A 
reconstructed, backcrossed thiamin deregulated mutant TH48 was 
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used in these first transcription profile experiments (see Material 
and Methods), because the mutation(s) causing thiamin 
deregulation (i.e. pyrithiamin-resistance) could be separated away 
from the thiC-lacZ fusion and any other unrelated EMS-induced 
mutation from the original Tx26 mutant (see below). Previous 
profiling results of wild-type B. subtilis PY79 observed a 30-90-fold 
thiamin-specific repression of the two major thiamin biosynthetic 
operons, thiC and tenAIthiOSGFD, but not of a third operon ywbI-
thiME [Lee et al., 2001]. As shown in Table 4, high-level, 
deregulated expression of both thiC and tenAI-thiOSGFD was 
observed in TH48. Transcript levels of thiC were increased 105-fold 
in TH48 compared to PY79 when both strains were grown in 
minimal medium containing repressing levels of TPP. Transcription 
levels of tenAI-thiOSGFD were increased 30 – 100 fold depending 
on the gene. Transcription of a third biosynthetic operon containing 
thiM and thiE, and other known thiamin biosynthetic or salvage 
genes, pdxK, dxs (yqiE), thiI (ytbJ), and thiN (yloS) remained 
unchanged. A similar result was obtained by comparing 
transcription profiles from the original Tx26 mutant vs. the parental 
TH21 strain (data not shown). The thiL::cat4 mutation in both TH48 
and Tx26 had little effect on the transcription profile of thiamin-
biosynthetic genes other that thiC (2-3 fold increase compared to 
PY79 when strains were grown to logarithmic stage in the presence 
of TPP; data not shown).  
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Table 4: Change in transcript levels of genes in B. subtilis in 
response to TPP. 
 
Ratio b 
Gene a thi-box element e Enzyme/Function 
a 
WT-/WT+ c Dereg+/WT+ d 
 
thiC + Biosynthesis of hydroxymethylpyrimidine phosphate 58 105 
 
ywbI
thiM 
thiE 
tenA
 - Similar to LysR family of transcriptional regulators NC NC 
- Hydroxyethylthiazole kinase NC NC 
- Thiamin phosphate synthase NC NC 
 + Thiaminase f 68 62 
+ Possible antagonist of TenA 25 27 
x
 
 
tenI 
thiO (go B) + Glycine oxidase 67 56 
S) + Sulfur carrier protein 87 86 
bT) + Thiazole synthase 82 61 
 
thiS (yjb
thiG (yj
thiF (yjbU) + ThiS adenylyltransferase 87 96 
bV) + Phosphomethylpyrimidine kinase 27 34 
iD) - Pyridoxal/pyridoxal/pyridoxamine kinase NC NC 
iA) - TMP kinase NC NC 
 
 
thiD (yj
pdxK (th
thiL (yd
thiN (yloS) - Thiamin pyrophosphorylase NC NC 
 
 
ytbJ 
dxs (yqi
- Possible thiI orthologs (sulfur transferase) NC NC 
E) - 1-deoxy-D-xylulose synthase NC NC 
 + Possible transmembrane component of thiamin-related 
ABC transporter 
10 15 
 + Possible ATPase component of thiamin-related ABC 
transporter 
11 16 
 + Possible transmembrane component of thiamin-related 
ABC transporter 
22 32 
 + Possible ligand-binding protein of thiamin-related ABC 
transporter 
17 23 
 
 ykoC
ykoD
ykoE
ykoF
yua
 
 
 
J + Possible thiamin permease 6.6 8.4 
 + Similar to acetylornithine deacetylase 15 11 ylmB
 
  
 
a Gene names and functions were described by Perkins and Pero, 2001, 
and in SubtiList (http://genolist.pasteur.fr/SubtiList). 
b Transcript ratios were calculated by dividing the average difference 
values (after normalization) from hybridization experiments of wild-type 
cells grown to exponential phase in MM without TPP treatment by those 
with TPP treatment (WT+/WT-) or from hybridization experiments of 
deregulated mutant cells grown to exponential phase in MM with TPP 
treatment by those of wild-type cells grown under the same condition 
(Dereg+/WT+). For some genes (in bold), average difference values were 
obtained from duplicate probe sets per hybridization experiment: NC, no 
change in average difference values. Some data were taken from Table 1 
in a report by Lee et al., 2001. 
c r value of 0.95 (TPP-treated versus untreated data sets). 
d r value of 0.85 (TPP-treated TH48 versus TPP-treated PY79 data sets). 
e Under thi box element control according to report by Rodionov et al., 
2002. 
f See Toms et al., 2005. 
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More interestingly, the transcript levels of genes recently 
shown to contain thi-box regulatory sequences [Rodinov et al., 
2002] also exhibited thiamin-specific derepression. For example, 
transcription of the ykoFEDC gene cluster was significantly 
increased in TH48 relative to PY79: ykoF, ykoD, and ykoC 
transcripts were increased 15- to 23-fold, whereas ykoE was 
increased 32-fold. Other examples include the yuaJ gene, and ylmB 
encoding a protein similar to acetylornithine deacetylase. The 
average difference levels of yuaJ and ylmB were 8- and 11-fold 
higher, respectively. A similar pattern of regulated gene expression 
of ykoFEDC, yuaJ, and ylmB, was also observed in microarray 
analyses of wild-type cells grown in the presence or absence of 
thiamin. Finally in HMP-grown TH48, only expression of thiC, 
thiOSGFD, and ykoFEDC, were repressed relative to cells grown in 
the absence of HMP (data not shown).  
 
Strains with mutant yloS, yuaJ, and ykoD genes overproduce 
and excrete thiamin products.  
As shown in Table 3, there appeared to be a direct 
correlation between the degree of thiamin deregulation (i.e. 
expression level of the thiC-lacZ fusion in the presence of TPP) and 
excretion of thiamin products. Strain TH22 with mutant thiL alone 
was only weakly thiamin deregulated and excreted the least amount 
of thiamin products relative to the TH21 wild-type control strain (9-
fold higher). Tx1 with mutant thiL and thiN genes, which showed 
partially thiamin deregulation, produced a 50-fold higher level of 
excreted thiamin products (5 μg/L). Lastly Tx26 containing mutant 
thiL, yuaJ and ykoK genes, which showed the highest level of 
thiamin deregulation, produced the highest level of excreted thiamin 
production (15 μg/L). This level of production was 100- to -150-
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times higher than that excreted by the control strain, of which 
slightly over 50% was in the form of TPP (data not shown). The 
level of intracellular thiamin production of all mutants was 
approximately 500 μg/L or about three fold higher than the wild-type 
strain.  
The four thiamin mutations, tx26-1, tx26-2, thiL and tx1, 
were next combined into a single strain (as described in Material 
and Methods) to determine if higher levels of thiamin overproduction 
and excretion could be obtained. Although Tx26 is a prototroph, the 
resulting strain (TH95) grew very poorly on minimal medium unless 
TPP or Nutrient Broth (reported as containing significant levels of 
thiamin precursors HMP and Thiazole; ref. 8) was added to the 
medium. In this respect TH95 was a stronger bradytroph than Tx1 
(i.e. TH95 colonies took longer to appear on minimal medium than 
Tx1 colonies). Despite this growth defect, TH95 produced 3-fold 
more excreted thiamin products in shake-flask cultures compared to 
Tx26 (Table 5). Moreover, a shift in the excretion profile was 
observed from predominantly TPP in Tx26 to a combination of 
thiamin and TMP in TH95. This shift in the thiamin product profile 
was confirmed by thiochrome/HPLC (data not shown). 
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Table 5: Thiamin production of TH95. 
 
 
Concentration produced (g/l) 
 
 
Extracellular 
 
Intracellular Straina OD600b 
 
Thiamin + 
TMP + TPP 
 
TPP Thiamin + TMP + TPP TPP 
 
Tx26 (thiL::cat4  yuaJ  ykoD amyE::thiC-lacZ) 
 
9.2 380 390 830 (25)c 370 
 
TH95 (thiL thiN  yuaJ  ykoD yloA::Tn917) 
 
10.4 1270 120 1150 (40)c 270 
 
 
 
 
 
 
 
 
 
 
 
a Bacteria were grown in MM supplemented with 2.5% nutrient broth for 18 
hours at 37°C. Culture media and cell-free extracts were measured for 
total thiamin products (thiamin + TMP + TPP) and TPP by a biological 
assay using S. enterica serovar Typhimurium indicators DM456 
(thiD906::MudJ) and DMI856 (thiL934::Tn10), respectively. 
b OD600, optical density at 600 nm. 
c Values in parentheses are the estimated extracellular concentrations of 
thiamin product if all are excreted into the culture medium in g/liter; see 
Table 1. 
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Discussion 
 
It is now well accepted that “thi box” genes are regulated by 
a mechanism referred as “Riboswitch”. Using mainly in vitro 
methods, Winkler et al., 2002 convincingly showed that TPP alone 
acts to regulate thiamin gene expression by directly interacting with 
the nascent RNA transcript at the thi-box sequence to either block 
transcription or translation. The work presented here describes 
mutagenesis studies that identified and characterized new thiamin-
deregulated mutations of Bacillus subtilis that are located within the 
coding regions of three genes: thiN, yuaJ, and ykoD. The encoded 
proteins have been lately suggested by in silico analysis to be 
involved in thiamin salvage and transport. We demonstrate here 
that indeed an important phenotype of these deregulatory mutants 
is the ability to excrete significant quantities of thiamin products and 
therefore that an important role of these proteins seems to be the 
control of TPP levels. It is important to note that the identification of 
deregulatory mutations within thiamin transport genes is strikingly 
similar to the recent results of Johansen et al., 2003 and Nygaard 
and Saxild, 2005, which showed that mutations that increase the 
activity of the pbuE encoded purine– specific pump deregulate 
expression of the G-box regulon by increasing the efflux of 
hypoxanthine, a metabolite that regulates purine gene expression 
by a Riboswitch mechanism.  
Melnick et al., 2004 first demonstrated that B. subtilis 
contained a thiamin pyrophosphoryation activity normally found in 
yeast. This activity was encoded by yloS, subsequently renamed 
thiN. We present here experimental evidences confirming the 
function of this enzyme in thiamin biosynthesis. Indirect genetic 
evidence for this gene came from mutagenesis studies of B. subtilis 
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thiL gene, which resulted in mutants that were thiamin bradytrophs 
rather than strict auxotrophs as shown for thiL mutants of S. 
typhimurium and E.coli. This shows that B. subtilis has two 
pathways to produce TPP. Direct evidence was obtained by 
showing that the tx1 mutation mapped to thiN and that 
reconstitution experiments indicated that inactivation of both thiN 
and thiL together resulted in a synthetic TPP auxotrophy in 
B.subtilis. In addition, the differential Lac activity displayed by Tx1 in 
the presence of thiamin (Lac+) and TPP (Lac-) is consistent with the 
presence of a direct thiamin-to-TPP route (Table 3). By blocking the 
ThiL reaction (TMP-to-TPP) and reducing the ThiN (YloS) reaction 
(THI-to-TPP) by the tx1 mutation, the expected intracellular TPP 
level would be too low to repress thi gene expression. What is not 
clear, however, is whether these two pathways are linked (Figure 
1). Preliminary genetic studies suggest that B. subtilis contains both 
thiamin kinase and TMP phosphatase activities (data not shown). 
However because the B. subtilis genome does not contain genes 
that display significant similarity to known thiamin kinase (e.g. E. 
coli thiK [ycfN]) or TMP phosphatase genes (yeast PHO3), it will be 
interesting to determine if these putative enzymes are specific to 
thiamin biosynthesis or represent activities from housekeeping or 
other biosynthetic pathways.  
The mutations in the Tx26 mutant were found to be allelic to 
two putative thiamin transport genes, yuaJ (tx26-1) and ykoD (tx26-
2). The yuaJ gene is predicted to encode a thiamin permease 
(passive transport) that contains six predicted trans-membrane 
domains [Rodinov et al., 2002]. The ykoD is predicted to encode an 
ATPase activity, which together with the ykoC and ykoE gene 
products, is predicted to form an ABC transporter [Rodinov et al., 
2002]. The tx26 mutations were found to generate three 
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phenotypes: deregulation of thiamin gene expression, an increase 
in pyrithiamin resistance, and an increase in extracellular levels of 
thiamin products. Moreover, the fact that inactivation of both yuaJ 
and ykoD was required to cause all three phenotypes suggested 
that these transporters control influx of TPP and other thiamin 
products into the cell (mutations that inactivate efflux transporters 
would not be consistent with our observation of higher extracellular 
levels of thiamin product with Tx26.). Based on these results we 
recommend that yuaJ be renamed thiT and the ykoFEDC operon, 
thiUVWX. Although in silico analysis does not indicate a function for 
ykoF, we have tentatively assigned it as a thi gene because it is co-
transcribed with the thiVWX genes and the crystal structure of its 
encoded protein indicates that it binds thiamin molecules [Devedjiev 
et al., 2004] 
Both lacZ reporter fusion (Table 3) and microarray 
experiments indicated that expression of all known thi-box-
containing genes (e.g. thiC, thiOSGFD, ykoFEDC, and yuaJ) was 
highly derepressed in the Tx26 mutant. Since a key phenotype of 
this mutant is efflux of thiamin products from the cell, gene 
deregulation is most likely caused by changes in TPP intracellular 
levels. Interestingly, addition of exogenous HMP appeared to 
partially regulate thiamin gene expression (Table 3) in Tx26. We do 
not believe HMP is functioning as a repressor (or co-repressor) 
independent of TPP because lacZ reporter fusion experiments 
showed that HMP did not repress thiC expression in the Tx1 
mutant. It seems more likely that HMP enters the cell by a different 
transport route and is converted to the TPP effector via the salvage 
pathway (HMP to HMP phosphate to TMP to TPP), which then 
interacts with thi box sequences of the nascent mRNA to repress thi 
gene expression via the Riboswitch mechanism.  
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Finally, an important application of our study was that these 
thiamin-deregulated mutants could be further manipulated to 
generate new strains that excreted more thiamin products. 
Combination of four mutations in thiL, thiN, thiT (yuaJ), and thiW 
(ykoD) has led to a strain that under 10-liter scale fermentation 
conditions excreted thiamin products in the mg/liter range (data not 
shown). Genetic engineering of the thiamin biosynthetic and 
precursor genes should lead to strains with a further increase in 
thiamin production. 
 
Acknowledgments 
We gratefully acknowledge Werner Bretzel for analytical 
support, Markus Goese for fermentation support, and Jian-ming Lee 
for microarray analysis of thiamin deregulated mutants. We thank 
Hans-Peter Hohmann for helpful discussion and critical reading of 
the manuscript. We also thank Tadhg Begley and Diana Downs for 
providing data before publication, and their expertise and support 
during the course of this work. 
 132
Chapter III               Thiamin-deregulated mutants of B. subtilis 
  
References 
 
Begley, T. P., D. M. Downs, S. E. Ealick, F. W. McLafferty, A. P. 
Van Loon, S. Taylor, N. Campobasso, H. J. Chiu, C. Kinsland, J. 
J. Reddick, and J. Xi. 1999. Thiamin biosynthesis in prokaryotes. 
Arch Microbiol. 171:293-300. 
 
Bolivar, F., R. L. Rodriguez, M. C. Betlach, and H. W. Boyer. 
1977. Construction and characterization of new cloning vehicles I. 
Amplicillin-resistant derivatives of the plasmid pMB9. Gene. 2:75-
91. 
 
Chiu, H.J., J. J. Reddick, T. P. Begley, and S. E. Ealick. 1999. 
Crystal structure of thiamin phosphate synthase from Bacillus 
subtilis at 1.25 Å resolution. Biochemistry.  38:6460-6470. 
 
Cutting, S. M., M. Anderson, E. Lysenko, A. Page, T. Tomoyasu, 
K. Tatematsu, T. Tatsuta, L. Kroos, and T. Ogura. 1997. SpoVM, 
a small protein essential to development in Bacillus subtilis, 
interacts with the ATP-dependent protease FtsH. J. Bacteriol. 
179:5534-5542. 
 
Cutting, S.M., and P. B. Vander Horn. 1990. Genetic analysis. 
p74. In C. R. Harwood and S. M. Cutting (ed.), Molecular biological 
methods for Bacillus. John Wiley and Sons, New York. 
 
Devedjiev, Y., Y. Surendranath, U. Derewenda, A. Gabrys, D. R. 
Cooper, R. Zhang, L. Lezondra, A. Joachimiak, and Z. S. 
Derewenda. 2004. The structure and ligand binding properties of 
 133
Chapter III               Thiamin-deregulated mutants of B. subtilis 
  
the B. subtilis YkoF gene product, a member of a novel family of 
thiamin/HMPbinding proteins. J Mol. Biol. 343:395-406. 
 
Difco. 1998. Manual, 11th ed. Difco Laboratories, Sparks. 
 
Downs, D. M., and L. A. Petersen. 1994. apbA, a new genetic 
locus involved in thiamin biosynthesis in Salmonella typhimurium. J. 
Bacteriol. 176:4858-4864. 
 
Guérout-Fleury, A. M., N. Frandsen, and P. Stragier. 1996. 
Plasmids for ecotopic integration in Bacillus subtilis. Gene. 180:57-
61. 
 
Harwood, C. R., and A. R. Archibald. 1990. Growth, maintenance 
and general techniques, p1-26. In C. R. Harwood and S. M. Cutting 
(ed.), Molecular Biological Methods for Bacillus. John Wiley & Sons, 
New York. 
 
Johansen, E. L. P., P. Naygarrd, C. Lassen, Y. Agersø, and H. H. 
Saxild. 2003. Definition of a second Bacillus subtilis pur regulon 
comprising the pur and xpt-pbuX operons plus pbuG, nupG (yxjA), 
and pbuE (ydhL). J. Bacteriol. 185:5200-5209. 
 
Kawasaki, T., and Y. Nose. 1969. Thiamine regulatory mutants in 
Escherichia coli. J Biochem. (Tokyo). 65:414-425. 
 
Lawhorna, B. G., S. Y. Gerdes, and T. P. Begley. 2004. A genetic 
screen for the identification of thiamin metabolic genes. J. Biol. 
Chem. 279:43555-43559. 
 
 134
Chapter III               Thiamin-deregulated mutants of B. subtilis 
  
Lawhornb, B. G., R. A. Mehl, and T. P. Begley. 2004. Biosynthesis 
of the thiamin pyrimidine: the reconstitution of a remarkable 
rearrangement reaction. Org Biomol Chem 2:2538-2546. 
 
Lee, J.-M., S. Zhang, S. Saha, S. Santa Anna, C. Jiang, and J. 
Perkins. 2001. RNA expression analysis using an antisense 
Bacillus subtilis genome array. J. Bacteriol. 183:7371-7380. 
 
Mandal, M., B. Boese, J. E. Barrik, W. C. Winkler, and R. R. 
Breaker. 2003. Riboswitches control fundamental biochemical 
pathways in Bacillus subtilis and other bacteria. Cell 113:577-586. 
 
Maniatis, T., E. Fritsch, and J. Sambrook. 1982. Molecular 
cloning. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 
NY. 
 
Melnick, J., E. Lis, J. H. Park, C. Kinsland, H. Mori, T. Baba, J. 
Perkins, G. Schyns, O. Vassieva, A. Osterman, and T. P. 
Begley. 2004. Identification of the two missing bacterial genes 
involved in thiamine salvage: thiamine pyrophosphokinase and 
thiamine kinase. J Bacteriol.186:3660-3662. 
 
Miller, J. H. 1972. Experiments in molecular genetics. Cold Spring 
Harbor Laboratory Press, Cold Spring Harbor, NY. 
 
Miranda-Rios, J., M. Navarro, and M. Soberson. 2001. A 
conserved RNA structure (thi box) is involved in regulation of 
thiamin biosynthesis gene expression in bacteria. Proc. Natl. Acad. 
Sci. USA. 98:9736-9741. 
 
 135
Chapter III               Thiamin-deregulated mutants of B. subtilis 
  
Mironov, A. S., I. Gusarov, R. Rafikov, L. E. Lopez, K. Shatalin, 
R. A. Kreneva, D. A. Perumov, and E. Nudler. 2002. Sensing 
small molecules by nascent RNA: a mechanism to control 
transcription in bacteria. Cell 111:747-756. 
 
Nosaka, K., Y. Kaneko, H. Nishimura, and A. Iwashima. 1993. 
Isolation and characterization of a thiamin pyrophohokinase gene, 
THI80, from Saccharomyces cerevisiae. J. Biol. Chem. 268:17440-
17447. 
 
Nygaard, P., and H. H. Saxild. 2005. The purine efflux pump PbuE 
in Bacillus subtilis modulates expression of the PurR and G-box 
(XptR) regulatons by adjusting the purine base pool size. J. 
Bacteriol. 187:791-794. 
 
Park, J. H., K. Burns, C. Kinsland, and T. P. Begley. 2004. 
Characterization of two kinases involved in thiamine pyrophosphate 
and pyridoxal phosphate biosynthesis in Bacillus subtilis: 4-amino-
5-hydroxymethyl-2-methylpyrimidine pyrophosphate kinase activity. 
J. Bacteriol. 186:1571-1573. 
 
Park, J. H., P. C. Dorrestein, H. Zhai, C. Kinsland, F. W. 
McLafferty, and T. P. Begley. 2003. Biosynthesis of the thiazole 
moiety of thiamin pyrophosphate (vitamin B1). Biochemistry. 
42:12430-12438. 
 
Perkins, J. B., and J. G. Pero. 2001. Vitamin biosynthesis, p279-
293. In A. L. Sonenshein, J.A. Hoch, and R. Losick (ed.), Bacillus 
subtilis and its relatives: from genes to cells. American Society for 
Microbiology, Washington, D.C. 
 136
Chapter III               Thiamin-deregulated mutants of B. subtilis 
  
 
Petersen, L. A., and D. M. Downs. 1997. Identification and 
characterization of an operon in Salmonella typhimurium involved in 
thiamine biosynthesis. J. Bacteriol. 179:4399-4402. 
 
Rodionov, D. A., A. G. Viteschak, A. A. Mironov, and M. S. 
Gelfand. 2002. Comparative genomics of thiamin biosynthesis in 
prokaryotes. J. Biol. Chem. 277:48949-48959. 
 
Schowen, R. 1998. Thiamin-dependent enzymes. In L. Sinnott 
(ed.), Comprehensive catalysis. Academic Press, San Diego. 
 
Toms, A. V., A. L. Haas, J. H. Park, T. P. Begley, and S. E. 
Ealick. 2005. Structural characterization of the regulatory proteins 
TenA and TenI from Bacillus subtilis and identification of TenA as a 
thiaminase II. Biochemistry 44:2319-2329. 
 
Vagner, V., E. Dervyn, and S. D. Erhlick. 1998. A vector for 
systematic gene inactivation in Bacillus subtilis. Microbiology 
144:3097-3104. 
 
Vandeyar, M. A., and S. A. Zahler. 1986. Chromosomal insertions 
of Tn917 in Bacillus subtilis. J. Bacteriol. 167:530-534. 
 
Wach, A. 1996. PCR-synthesis of marker cassettes with long 
flanking homology regions for gene disruptions in S. cerevisiae. 
Yeast. 12:259-265. 
 
Webb, E., K. Claas, and D. Downs. 1998. thiBPQ encodes an 
ABC transporter required for transport of thiamine and thiamine 
 137
Chapter III               Thiamin-deregulated mutants of B. subtilis 
  
 138
pyrophosphate in Salmonella typhimurium. J. Bacteriol. 273:8946-
8950. 
 
Webb, E., and D. M. Downs. 1997. Characterization of thiL, 
encoding thiamin-monophosphate kinase, in Salmonella 
typhimurium. J. Biol. Chem. 272:15702-15707. 
 
Webb, E. A., F. Ferbres, and D. M. Downs. 1996. Thiamin 
pyrophosphate (TPP) negatively regulates transcription of some thi 
genes in Salmonella typhimurium. J. Bacteriol. 178:2533-2538. 
 
Winkler, W. C., A. Nahvi, and R. R. Breaker. 2002. Thiamine 
derivatives bind messenger RNAs directly to regulate bacterial gene 
expression. Nature. 419:952-956. 
 
Zhang, Y., and T. P. Begley. 1997. Cloning, sequencing, and 
regulation of thiA, a thiamin biosynthesis gene from Bacillus subtilis. 
Gene. 198:73-82. 
 
Zhang, Y., H. J. Chiu, and T. P. Begley. 1997. Characterization of 
the Bacillus subtilis thiC operon involved in thiamine biosynthesis. 
J.Bacteriol. 179:3030-3035. 
Chapter IV                 Spore display using a coat-associated enzyme 
  
CHAPTER IV 
 
Bacillus subtilis spore display of recombinant 
proteins using a coat-associated enzyme 
as carrier 
 
Sébastien PototŦ, Claudia Serra¤,  
Adriano O. Henriques¤ and Ghislain SchynsŦ 
 
 
Applied and Environmental Microbiology. 2010. 76(17):5926-33. 
 
 
 
Ŧ DSM Nutritional Products, Biotechnology R&D, PO box 3255, 
Bldg 203/25, CH-4002 Basel, Switzerland. 
 
¤ Instituto de Tecnologia Química e Biológica, Universidade Nova 
de Lisboa, Apartado 127, 2781-901 Oeiras, Portugal. 
 
 
 
 
 
Contribution: 
Sébastien Potot conducted all the experiments described except the 
construction of E. coli strain SD58, B. subtilis strains AH7666, and 
AH2873, and the validation of the anti-phytase antibodies. 
 139  
Chapter IV                 Spore display using a coat-associated enzyme 
  
Abstract 
 
The display of proteins such as feed enzymes at the surface 
of bacterial spore systems has a great potential use for animal feed. 
Feed enzymes increase the digestibility of nutrients, leading to 
greater efficiency in the manufacturing of animal products and 
minimizing the environmental impact of increased animal 
production. To deliver their full potential in the gut, feed enzymes 
must survive the harsh conditions of the feed preparation and the 
gastrointestinal tract. The well documented resistance of spores to 
harsh environments, together with the ability to use proteins that 
compose the spore as carriers for the display of passenger proteins, 
suggests that spores could be used as innovative tools to improve 
the formulation of bioactive molecules. Although some successful 
examples have been reported, in which abundant structural proteins 
of the Bacillus subtilis spore outer-coat layer were used as carriers 
for the display of recombinant proteins, only one convincing 
example resulted in the display of functional enzymes. In addition, 
no examples are available about the use of an inner-coat protein for 
the display of an active passenger enzyme. In our study, we show 
that the inner-coat oxalate decarboxylase (OxdD) can expose an 
endogenous phytase, a commonly used feed enzyme for 
monogastric animals, in an active form at the spore surface. 
Importantly, despite the higher abundance of CotG outer-coat 
protein, an OxdD-Phy fusion was more represented at the spore 
surface. The potential of OxdD as a carrier protein is further 
documented through the spore display of a bioactive heterologous 
passenger, the tetrameric -glucuronidase enzyme from 
Escherichia coli. 
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Introduction 
 
Under extreme nutrient deprivation, Bacillus subtilis has the 
ability to enter a complex differentiation process that culminates 
with the formation of an extremely resistant spore. Spores consist of 
a central core compartment that contains a copy of the 
chromosome, and is surrounded by a thick layer of a modified form 
of peptidoglycan known as the cortex. The cortex is covered by a 
multilayered protein coat, formed by an inner layer apposed to the 
cortex, and an outer layer. In most characterized strains of B. 
subtilis, the outer-coat layer is the outermost spore structure. The 
spore coat is formed through synthesis in the mother cell of over 70 
polypeptides, which follow an ordered assembly program at the 
surface of the developing spore [Henriques et al., 2004]. Assembly 
is largely guided by a class of morphogenetic proteins that have 
important roles in the structural organization of the two main coat 
layers [Driks, 2002; Henriques and Moran, 2007; Imamura et al., 
2010]. SafA, for example, localizes at the interface between the 
cortex and inner coat, and has an important role in assembly of the 
inner-coat layer [Costa et al., 2006]. CotE, on the other hand, is 
found at the inner coat-outer coat interface, and is essential for 
assembly of the outer-coat structure. When conditions become 
conductive for growth, spores germinate to regenerate vegetative 
cells, which rapidly resume the normal cyclic pattern of growth and 
division. 
The B. subtilis spore coat has recently emerged as a 
nanostructure offering a novel and interesting surface for the display 
of biomolecules. Since B. subtilis presents a good safety record as 
an additive in human and animal preparations (GRAS; generally 
regarded as safe), one potentially valuable use of the spore coat 
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display system is in the area of probiotics. In animal nutrition, feed 
enzymes are commonly used to improve the nutrition value of feeds 
mainly by enhancing their digestibility and/or assimilation [Choct, 
2006]. Display of these enzymes at the spore surface could ensure 
in situ efficient enzymatic activity application at moderate cost. 
Examples of feed enzymes candidate for display are xylanase, 
hemicellulase, cellulase, protease, glycanase, or phytase. Phytase, 
in particular, is a commonly used feed enzyme for monogastric 
animals to improve nutritive value [Rao et al., 2009]. Most of the 
phosphorus (50-80%) contained in feedstuffs of plant origin exists 
as the storage form phytate and is indigestible for non-ruminant 
animals such as poultry and pigs, since they lack the enzyme to 
free phytate-bound phosphorus. Therefore, sufficient phytase needs 
to be added to the feed to decrease the supplementation of 
phosphorous to feedstuffs, thus reducing the environmental 
pollution in areas with intensive livestock production. However, 
despite successful spore display examples using the abundant 
structural coat proteins CotB [Duc et al., 2007; Hinc et al., 2010; 
Isticato et al., 2001], CotC [Hinc et al., 2010; Mauriello et al., 2004; 
Ricca and Cutting, 2003] and CotG [Hinc et al., 2010; Kim et al., 
2005] as an anchoring motif, a very limited number of studies is 
available regarding spore display of functional enzymes [Kim et al., 
2004; Kwon et al., 2007; Yim et al., 2009]. In all reported cases of 
spore display, the common denominator governing choice of the 
carrier protein seems to have been its abundance, and its ability to 
ensure the highest level of surface exposure. CotB, CotC and CotG, 
possibly the most represented proteins within the coat, are outer-
coat proteins, dependent on CotE for assembly (Fig. 1A). All three 
proteins also undergo extensive multimerization during their 
assembly at the spore surface [Isticato et al., 2004; Zilhão et al., 
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2004] (Fig. 1A). Thus far, the display of antigens, enzymes or other 
functional components on spores using inner-coat proteins as 
carriers, has not been reported.  
 
Figure 1: (A) Inner- and outer-coat 
carrier proteins. Morphogenetic proteins 
SafA (A) and CotE (E) have central roles 
in the assembly of the inner and outer-
coat layers respectively, and control the 
assembly of the indicated proteins. The 
location of SafA and CotE at the cortex-
inner coat and inner coat-outer coat 
interfaces respectively is indicated. The 
following coat carrier proteins, and their 
locations, are represented: B, CotB; C, 
CotC; D, OxdD; and G, CotG. D is 
presumed to be homohexameric; B forms 
covalently crosslinked dimers, whereas C 
and G undergo extensive multimerization 
(n) and crosslinking at the spore surface. 
The passenger proteins Phytase (P), and 
-glucuronidase (U) are shown as 
fusions to D or G.  
A  
 
Figure 1: (B) General strategy used to construct the various carrier-
passenger fusions. The indicated pDG364 derivatives, carrying the 
various gene fusions, were linearized and transferred to the non-
essential amyE locus through a marker replacement (double-crossover) 
recombination event. Promoters are represented by arrows and 
transcriptional terminators are represented by hairpin structures. L10, 
linker made of ten alanine residues; cat, gene encoding 
chloramphenicol acetyltransferase. The various genes, color-coded to 
match panel A, are not drawn to scale. 
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The 43.4-kDa product of the oxdD gene, OxdD, is a minor 
component of the spore coat [Costa et al., 2004]. OxdD is a 
component of the inner-coat layers, dependent on morphogenetic 
protein SafA for assembly [Costa et al., 2004; Ozin et al., 2001] 
(Fig. 1A). OxdD is highly similar to OxdC, a homohexameric 
enzyme (EC 4.1.1.2), which is specifically produced during growth 
of B. subtilis under acidic conditions [Tanner et al., 2001]. Both 
OxdD and OxdC show oxalate decarboxylase activity [Costa et al., 
2004; Tanner et al., 2001]. 
We show here that B. subtilis OxdD can be used as an 
original anchoring motif to display proteins of biological interest at 
the surface. Because of its relatively low abundance and internal 
localization, the use of the coat-associated OxdD enzyme as a 
carrier protein for spore display could afford a higher degree of 
protection to a passenger protein while minimizing any impact on 
the spore coat assembly process. First, as a step in the 
development of spore display for use in probiotics, OxdD was fused 
to B. subtilis phytase (Phy), a monomeric enzyme (EC 3.1.3.8) 
encoded by the phy gene with optimal activity at pH 7 to 7.5 
[Kerovuo et al., 1998]. We show that OxdD-Phy fusion protein is 
exposed at the spore surface and results in recombinant spores 
with phytase activity. We also show that the spore coat structural 
protein CotG can expose the endogenous phytase, but despite the 
higher abundance of this protein, the resulting recombinant spores 
show reduced levels of phytase compared to those of a strain 
expressing oxdD-phy. The potential use of OxdD as a carrier for the 
display of functional enzymes at the spore surface is further 
illustrated by the display of a fusion of OxdD to -glucuronidase 
(GusA) from Escherichia coli, a homotetrameric enzyme encoded 
by the uidA gene [Jefferson et al., 1986; Karow and Piggot, 1995]. 
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Materials and Methods 
 
Bacterial strains, media and general techniques. 
The B. subtilis strains used in the present study are listed in 
Table 1. They are derived from strain PY79 (1A747; Bacillus 
Genetic Stock Center). E. coli K-12 was used to PCR-amplify the 
uidA gene, encoding for -glucuronidase (GusA). The high-fidelity 
Herculase polymerase (Stratagene) was used to generate PCR 
products. Tryptone Blood Agar Broth (BD Difco) was used as the 
standard solid medium for routine propagation of all B. subtilis 
strains. Difco sporulation medium (DSM) was used to induce 
sporulation by nutrient exhaustion [Nicholson and Setlow, 1990].  
 
Table 1: Bacterial strains 
Strain Genotype / phenotype Origin or reference 
E. coli   
SD58 
pET16::phy / overproduction of His6-
Phy lacking its signal peptide, under the 
control of PT7lac 
This work 
B. subtilis   
PY79 B. subtilis wild type BGSC (b) 
SD48 PY79 amyE::cotG-phy / Cmr (a) This study 
SD50 PY79 amyE::oxdD-phy / Cmr (a) This study 
SD53 
(AH2873) 
oxdD::oxdD-gfp / Spr (a) Costa et al.., 2004 
SD60 PY79 amyE::oxdD-uidA / Cmr (a) This study 
AH7666 PY79 phy / Spr (a) This study 
 
 
 
 
 
 
 
  
 
 
 
 
a Cmr, chloramphenicol resistance; Spr, spectinomycin resistance 
b BGSC; Bacillus Genetic Stock Center (http://www.bgsc.org). 
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Construction of B. subtilis strains expressing CotG-Phy, OxdD-
Phy and OxdD-GusA fusion proteins. 
A schematic view of the cloning strategy used for the 
translational fusions is presented in Fig.1B. The original promoter of 
the spore-anchoring motif (300 bp of DNA upstream from oxdD start 
codon, or 465 bp of DNA upstream cotG start codon) was used to 
synchronize expression with the passenger protein during 
sporulation. Passenger proteins were fused in frame with the 
carboxyl terminus of the anchoring motif (either OxdD or CotG), 
deleted of its stop codon. B. subtilis native phytase Phy (GenBank 
accession number BG11198), was fused to either OxdD (BG13484) 
or CotG (BG11017) (numbering according to Genolist, Institut 
Pasteur, 1999-2001; Subtilist [http://genolist.pasteur.fr/SubtiList] 
and Colibri [http://genolist.pasteur.fr/Colibri]). The region encoding 
the signal peptide of Phy (encompassing the 26 first residues; 
Swiss-Prot P42094) was excluded. A linker made of 10 alanine 
residues was introduced between the carrier and passenger 
proteins. Gene fusions cotG-phy (2,173 bp long) and oxdD-phy 
(2,594 bp long) were synthesized as synthetic genes and 
sequenced by DNA2.0 Inc. (USA, CA). They were then cloned 
between the BamHI and HindIII sites of pDG364 suicide vector 
[Cutting and Vander Horn, 1990], resulting in plasmids pSD21 
(cotG-phy) and pSD22 (oxdD-phy). To construct a fusion of the E. 
coli uidA gene, coding for -glucuronidase (GusA; GenBank 
accession number EG11055) to the 3’-end of the oxdD gene, we 
first introduced a NheI restriction site into the 10-residue linker of 
pSD22, leading to the replacement of the sixth alanine residue by a 
serine. Then, the uidA gene of E. coli was cloned between NheI and 
HindIII sites of plasmid pSD22, to yield pSD27, carrying a 3,339-bp-
open reading frame coding for a OxdD-GusA fusion protein under 
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the control of the native oxdD promoter. After linearization with XhoI 
restriction endonuclease, pSD21, pSD22 and pSD27 were used to 
independently transform B. subtilis PY79 with selection for 
chloramphenicol (5 g/ml). Transformants that resulted from a 
marker replacement recombination event (double crossover) at the 
non essential amyE locus were identified and designated SD48 
(expressing the CotG-Phy fusion), SD50 (OxdD-Phy), and SD60 
(OxdD-GusA). 
 
Construction of SD58 (E. coli His6-Phy, N-term). 
A 1.1-kb PCR fragment containing the phy gene without its 
first 84 codons (corresponding to the signalling peptide) was 
amplified by using primers phy-for 5’-
GGAATTCCATATGGTGAATGAGGAACATCATTTCAAAG-3’ and phy-
rev 5’-ATCGCTCGAGGCCGTCAGAACGGTCTTTCAGCTTCCTC-3’, 
which generated NdeI and a XhoI restriction site ends, respectively. 
Chromosomal DNA of B. subtilis 168 was used for amplification. 
The PCR fragment was digested and inserted into pET16b 
(Novagen) to create pSD26. Selection of transformants was done 
on LB plates containing 100 g of ampicillin /ml. Plasmid pSD26 
carries an N-terminal fusion of B. subtilis phytase (without its 
signalling peptide) fused to a His tag. After purification, pSD26 was 
introduced into E. coli BL21 competent cells (Invitrogen) to allow 
efficient overexpression of the heterologous protein. Selection of 
transformants was done in LB plates containing 100 g of ampicillin 
/ml and 50 g of chloramphenicol /ml. The resulting strain was 
named SD58. 
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Overproduction and purification of B. subtilis phytase. 
A starter culture of strain SD58, grown overnight at 37°C 
with shaking, was used to inoculate 100 ml of fresh LB broth 
supplemented with ampicillin and chloramphenicol, which was 
incubated at 37°C and 150 rpm until reaching an optical density at 
600 nm of ~0.6. At this point, IPTG (isopropyl--D-
thiogalactopyranoside) was added to a final concentration of 1 mM 
and the culture was incubated for another 4 hours. The culture was 
then centrifuged 20 minutes at 8,000 x g and 4ºC, and the cell pellet 
was resuspended in 4 ml of ice cold lysis buffer (20 mM phosphate, 
300 mM NaCl, 1 mM CaCl2, 10 mM imidazole, 1 mM 
phenylmethylsulfonyl fluoride, 1X anti-protease EDTA free solution). 
The cell lysate was obtained by passage through a French Press 
cell at 19,000 lb/in2, and the supernatant fraction was used to purify 
the His6-tagged phytase on a Ni2+-nitrilotriacetic acid (NTA) column 
(Qiagen). The column was operated according to the 
manufacturer´s instructions. Bound phytase was eluted at an 
imidazole concentration of 300 mM. All purification steps were 
carried out at 4ºC. 
 
Isolation of B. subtilis extracellular proteins.  
The extracellular proteome was prepared essentially as 
described by Antelmann et al., 2007. Briefly, cultures (20 ml) of 
PY79 and its derivative bearing a Δphy mutation (AH7666), were 
grown in a synthetic medium containing 15 mM (NH4)2SO4, 8 mM 
MgSO4.7H2O, 27 mM KCl, 7 mM sodium citrate. 2H2O, 50 mM Tris-
HCl (pH8) supplemented with 0.16 mM KH2PO4, 2 mM CaCl2.2H2O, 
1 µM FeSO4.7H2O, 10 µM MnSO4.4H2O, 4.5 mM glutamic acid, 780 
µM tryptophan, 860 µM lysine, and 0.2% (wt/vol) glucose. Samples 
were collected 1 h after the end of the exponential phase of growth 
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by centrifugation for 30 minutes at 21,000 x g and 4ºC. Proteins 
present on the culture supernatant were then precipitated during 1 h 
at 4ºC with trichloroacetic acid (TCA) at a final concentration of 5% 
and recovered by centrifugation during 30 minutes at 21,000 x g 
and 4ºC. The protein pellet was once washed with 70% ice-cold 
ethanol and finally resuspended in 200 µl of a buffer containing 10 
mM Tris (pH 8), 10 mM MgCl2, 500 mM EDTA, 200 mM NaCl, 10% 
glycerol, 1mM PMSF, and 1X anti-protease EDTA free solution. 
 
Construction of AH7666 (B. subtilis wild-type with phy deleted). 
Long flanking homology PCR was used to delete the 
endogenous copy of phy in PY79 background [Walch, 1996]. The 
primers P1-phy 5’-ATATCTGCCTAAAAAAAGTGC-3’ and P2-phy-
spec 5’-
ACATGTATTCACGAACGAAAATCGAAATAGAAAGCAGCTTGTG
CAGC-3’ were used to amplify a fragment upstream of the phy 
gene, while the primers P3-phy-spec 5’-
ATTTTAGAAAACAATAAACCCTTGCACCTTCATTTGGTACCCTC
C-3’ and P4-phy 5’-CACCTGTTTAGGTGTAAGCAG-3’ were used 
to amplify a fragment downstream of phy. Both PCR products were 
bridged by a fragment containing the spectinomycin cassette 
[Guérout-Fleury et al., 1995]. The final PCR product was then used 
to replace the endogenous phy gene by the spectinomycin cassette 
via double crossover.  
 
Spore purification and analysis. 
Spores were harvested by centrifugation of DSM cultures 24 
h after the onset of sporulation. After washing, spores were purified 
with a 20 to 50% Gastrografin (Schering) step gradient, as 
previously described for Renocal-76 gradients [Henriques et al., 
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1995]. Purified spores were suspended in cold buffers (as specified 
below) supplemented with protease inhibitors (Complete EDTA-
free; Roche). Samples of the purified spore suspension were used 
to analyze the coat polypeptide composition as described before 
[Henriques et al., 1995]. The total cell count, as well as the titer of 
heat or lysozyme-resistant spores was determined in samples of 
DSM cultures 24 h after the onset of sporulation [Henriques et al., 
1995]. 
 
Detection of -glucuronidase (GusA) activity by fluorescence 
microscopy. 
In situ detection of -glucuronidase activity was performed 
using the fluorogenic substrate C12FDGlcU, a lipophilic analog of 
fluorescein di--D-glucuronic acid containing a 12-carbon aliphatic 
chain supplied with the ImaGene Green C12FDGlcU GUS gene 
expression kit from Molecular Probes. Cleavage by -glucuronidase 
releases the yellow-colored, green-fluorescent compound 5-
dodecanoylaminofluorescein (Exmax= 495 nm, Emmax= 518 nm). This 
substrate was used on purified spores of PY79 and SD60, 
according to the indications of the manufacturer. Before adding the 
substrate, part of the spore suspension was washed with water and 
incubated for 1 h at 37°C in a 0.1% trypsin solution (Amimed), as a 
control. Spores were washed three times with phosphate-buffered 
saline (PBS) at pH 7.4 (Roche). The spores were then examined by 
fluorescence microscopy (Eclipse E600; Nikon) using phase-
contrast optics and a standard filter for the visualization of green 
fluorescence emission (Ex = 490 nm, Em = 520 nm), reflecting 
GusA activity at the spore surface. Images were acquired with a 
digital camera (CoolSnap EZ; Visitron Systems) and processed with 
ImageJ (W.S Rasband, ImageJ, 1997-2008. 
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[http://rsb.info.nih.gov/ij/]; National Institutes of Health, Bethesda, 
MD, USA) for quantification of the fluorescence signal. Background 
was measured for each picture and subtracted from the 
fluorescence intensity of the samples. The quantification was made 
on 150 spores per strain.  
Assay of B. subtilis phytase activity.  
Whole-cell extracts were prepared from 24-h DSM cultures 
of strains SD48, SD50 and PY79. Cells and mature spores were 
harvested by centrifugation (20 min, 8,000 x g), and suspended in a 
buffer containing 100 mM Tris-HCl pH 7.4 (Fluka), a cocktail of 
protease inhibitors (Complete EDTA-free) and 2 mM CaCl2 (Sigma), 
required to maintain active conformation of B. subtilis phytase 
[Kerovuo et al., 2000; Shimizu, 1992]. The mixture was passed 
twice in French cell press (Sim-Aminco) at 900 lb/in2 to release both 
forespores and the cytoplasm content of the mother cells. Spores 
were purified from whole-cell extracts as described previously 
[Zilhão et al., 2004]. Phytase activity was measured by incubating 
either 10 l of whole-cell extracts or 10 l of pure spores 
suspensions with 40 l of 2 mM sodium phytate (Sigma) in the 
above-mentioned buffer. After 30 min of incubation at 55°C, the 
reaction was stopped by adding 50 l of 5% TCA (Merck) [Shimizu, 
1992]. After centrifugation (4 min, 8,000 x g), 50 l of the 
supernatant was diluted in 500 l of water. The released 
orthophosphate (Pi) was photometrically measured at 700 nm by 
monitoring the production of phosphomolybdate for 15 min at 50°C 
after the addition of 500 l of the color reagent.  The color reagent 
was prepared freshly by mixing one volume of 2.5% ammonium 
molybdate (Fluka), one volume of 10% sodium ascorbate  (Fluka), 
and three volumes of 1 M H2SO4 (Fluka) [Kim and Lei, 2005]. One 
unit of phytase was defined as the amount of enzyme required to 
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release one micromole of Pi from sodium phytate in one minute. 
The total amount of protein was assayed with the bicinchoninic acid 
method (Pierce), in order to calculate specific activity. The dry 
weight was measured after drying spores suspensions for 24 h at 
80°C.  
   
Immunodetection of spore displayed phytase. 
An anti-phytase rabbit polyclonal antibody was produced by 
immunizing rabbits with a mix of 2 synthetic phytase-specific 
peptides (NH2-CAEPGGGSKGQVVDRA-COOH and NH2-
CHKQVNPRKLKDRSDG-COOH) (Eurogentec). Before 
immunolabelling, part of the spores was incubated at 37°C for 1h in 
a 0.1% trypsin solution (Amimed), as a control. They were washed 
three times with PBS (pH 7.4) supplemented with 2% bovine serum 
albumin (Sigma) and then probed with primary and secondary 
antibodies. Immunostained spores were mounted on agarose-
coated microscope slides and observed by fluorescence as 
described above. Fluorescence signal was quantified on 150 spores 
per strain.  
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Results and Discussion 
 
Amongst spore-associated enzymes, OxdD resides in the 
inner-coat layers of B. subtilis spores [Costa et al., 2004] (Fig. 1A). 
A passenger protein fused to this enzyme could in theory be more 
protected than when fused to a carrier located in the outer coat. 
Here, we investigated the behavior of the inner-coat protein OxdD 
by comparison to the outer-coat protein CotG, as a carrier for the 
display of monomeric B. subtilis phytase. We also assessed the 
ability of OxdD to display the heterologous multimeric E. coli -
glucuronidase. 
 
Spore display of B. subtilis phytase. 
Although green fluorescence protein (GFP) fused to OxdD 
has been successfully exposed at the surface of B. subtilis spores 
[Costa et al., 2004], spore display of a functional enzyme has not 
been reported. The B. subtilis Phy passenger enzyme, truncated for 
its 26-residues signal peptide, was translationally fused to the C 
terminus of the anchoring motif OxdD. A linker, made of ten 
aliphatic amino acids, was introduced between the carrier and 
passenger proteins to minimize any potential steric effect that could 
disturb the correct folding of either protein (Fig.1B). Since CotG had 
been previously described as the carrier for the spore display of 
recombinant proteins [Hinc et al., 2010; Kim et al., 2004; Kwon et 
al., 2007], a control fusion CotG-Phy was also designed (Fig. 1B). 
The translational oxdD-phy and cotG-phy fusions are carried by 
strains SD50 and SD48, respectively (Table 1). 
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Table 2: Heat resistance and Lysozyme resistance to various B. 
subtilis strains 
 
 
Sporulation (CFU/ml)a 
 
Strain Relevant genotype 
Viable cells Heat-resistant cells 
 
Lysozyme-
resistant cells 
 
 
PY79 
 
 
Wild-type 
 
4.2 x 108 
 
3.2 x 108 
 
2.5 x 108 
 
SD48 
 
 
amyE::cotG-phy 
 
4.2 x 108 
 
4.8 x 108 
 
4.0 x 108 
 
SD50 
 
 
amyE::oxdD-phy 
 
4.5 x 108 
 
4.3 x 108 
 
3.2 x 108 
 
SD60 
 
 
amyE::oxdD-uidA 
 
4.8 x 108 
 
2.6 x 108 
 
2.9 x 108 
 
 
 
 
 
 
 
 
 
 
 
 
 
a The total viable, heat-resistant, or lysozyme-resistant cell enumeration 
was determined 24 hours after the onset of sporulation in liquid medium 
(DSM), as described in Materials and Methods. CFU: colony forming unit. 
 
Since in spores of cotG insertional mutants the normal 
structural organization of the outer coat is severely disturbed 
[Henriques et al., 1998], we have chosen to allow expression of the 
wild-type cotG allele in strains expressing passenger-carrier fusions 
(strain SD48). A similar approach was used with OxdD as a carrier 
(strain SD50), since the function of OxdD in spore assembly is not 
yet fully elucidated [Costa et al., 2004]. Both integrations at the 
amyE locus of the wild-type strain PY79 had no detectable effect on 
spore viability and resistance to heat and to lysozyme (Table 2). 
Moreover, examination of the collection of coat polypeptides 
extracted from spores of strains SD48 or SD50 resulted in a pattern 
that did not differ from that obtained for the wild-type PY79 spores 
(data not shown). We concluded that expression of the wild-type 
 154
Chapter IV                 Spore display using a coat-associated enzyme 
  
 155
and engineered carrier proteins did not interfere in any detectable 
way on the assembly and function of the spore coat lattice. 
A B
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(kDa) M 1 2 3 4 5 6 
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*
To test whether the fusion proteins were presented at the 
spore surface, we conducted immunofluorescence microscopy 
experiments. For these studies, we used a rabbit polyclonal anti-
Phy antibody (see Material and Methods). This antibody specifically 
recognized the purified His6-Phy protein (Fig. 2A). In addition, it 
recognized the native Phy protein in extracts prepared from culture 
supernatants of the wild-type strain PY79, grown under conditions 
where Phy is known to accumulate [Antelmann et al., 2007], and did 
not react with any protein in extracts prepared in parallel from a 
phy-deletion mutant (AH7666) (Fig. 2B). Spores were collected 24 h 
after the onset of sporulation, purified on density gradients (see 
Material and Methods) and either directly analyzed or treated with 
trypsin as a control.  
A 
 
B 
 
 
 
 
 
 
 
Figure 2. Purification of B. subtilis phytase (Phy) and specificity of an 
anti-Phy antibody. (A) SDS-PAGE analysis (lanes 1 to 3) and 
immunoblot analysis (lanes 4 to 6) of extracts of E. coli strain SD58 
noninduced (lanes 1 and 4), induced with 1 mM IPTG (lanes 2 and 5) and 
of the His6-Phy protein (lanes 3 and 6), partially purified by Ni2+ affinity 
chromatography. The asterisk refers to a cross-reactive species or to a 
degradation product of the His6-phytase (B) SDS-PAGE (lanes 1 and 2) 
and immunoblot analysis (lanes 3 and 4) of the cell culture supernatants of 
the PY79 wild-type strain of B. subtilis (lanes 1 and 3) and of strain 
AH7666, bearing a phy mutation (lanes 2 and 4). 
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Significant fluorescence was observed on purifed spores 
harbouring the CotG-Phy or OxdD-Phy fusions (Fig. 3A). As 
expected, no significant fluorescence was observed at the surface 
of spores of the wild-type strain PY79. Importantly, treatment with 
trypsin resulted in loss of the fluorescence signal. Treatment with 
trypsin also resulted in the complete loss of fluorescence from 
spores of a strain (AH2873; Table 1) expressing an oxdD-gfp fusion 
(data not shown). As an additional control, the primary antibody was 
omitted, to test for specific binding of the secondary antibody 
coupled with the fluorophore. No fluorescence was observed under 
these conditions. We then quantified the fluorescence signal for 
spores of strains SD48 and SD50, in comparison to wild-type PY79 
spores. The results show that the average signal on SD48 (85 AU) 
and SD50 (91 AU) were ~3-fold higher compared to the baseline 
signal observed for PY79 spores (29 AU) (Fig. 3B, 4A). In spite of a 
similar average intensity for SD48 and SD50, 75% of SD48 spores 
displayed at least 2-fold more fluorescence than the baseline (> 60 
AU), whereas 100% did so for SD50. Together, these results 
suggest that the OxdD-Phy fusion was more efficiently displayed at 
the spore surface. 
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Figure 3. Immunofluorescence detection of CotG-Phy and OxdD-Phy 
protein fusions at the surface of purified spores. FITC, Fluorescein 
isothiocyanate (A) Phase-contrast microscopy (PC) and fluorescence 
microscopy (FITC). Scale bars, 2 m. (B) Fluorescence intensity was 
quantified on 150 spores. AU, arbitrary units. Purified spores were 
submitted or not to trypsin proteolysis. noAb , control without primary 
antibody. Spores were purified from cultures of the following strains: PY79, 
wild-type; SD48, CotG-Phy; and SD50, OxdD-Phy. 
 
Phytase activity at the surface of B. subtilis spores. 
Having determined that both CotG and OxdD served as 
carriers for the display of Phy at the surface of B. subtilis spores, we 
then wanted to determine whether the passenger protein was 
presented in an active form. For this purpose, we conducted 
measurements of Phy specific activity. We first measured Phy 
activity in whole-cell extracts prepared from samples directly 
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collected from DSM cultures of strains SD48, SD50, and PY79, 24 
hours after the onset of sporulation (Fig. 4B). Although a specific 
activity of 3.1 U/mg of protein was obtained for PY79, reflecting the 
endogenous B. subtilis phytase activity, values of 11.4 U/mg and 
6.9 U/mg were obtained for SD48 and SD50, respectively (Fig. 4B). 
For reference, a partially purified His6-tagged version of the B. 
subtilis phytase missing its signal peptide (Fig. 2A) gave a specific 
activity of 23 U/mg of protein when produced in E. coli (data not 
shown). The phytase activity detected for SD48 and SD50 extracts 
over the activity obtained for PY79 cultures clearly demonstrated 
expression of a functional phytase during sporulation, from the 
sporulation specific promoters that drive expression of either cotG 
or oxdD. Next, we thought to determine whether phytase activity 
could be detected on density gradient-purified spores - in other 
words, whether the CotG-Phy or OxdD-Phy fusion detected at the 
spore surface (see above) represented active enzyme (Fig. 4C). 
Since not all proteins are extractable from the spore coat, units of 
phytase activity in purified spores were normalized with respect to 
spore dry weight. Activities of 5.7 x 103 U/g (dry weight) and of 2.7 x 
103 U/g (dry weight) were obtained for SD48 and SD50, 
respectively. No activity could be detected for PY79 spores or for 
spores of strains SD48 and SD50 that were treated with trypsin 
prior to the assay (data not shown). These results indicate that both 
the CotG or OxdD carriers resulted in the display of active phytase 
at the spore surface.  
Although the OxdD-Phy fusion protein appeared more 
abundant than CotG-Phy at the spore surface, as assessed by 
immunofluorescence (see above), spores of SD50 (OxdD-Phy) 
showed a 2-fold-decreased specific activity compared to those of 
SD48 (CotG as the carrier). One possibility is that the OxdD-Phy 
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fusion protein, presumed to be mostly associated with the inner-
coat layers, is less accessible to the substrate than is CotG-Phy, 
thought to be mainly located in the outer coat. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Abundance of the displayed phytase at the spore surface 
and specific activity of B. subtilis phytase. (A) Immunofluorescence 
detection of CotG-Phy and OxdD-Phy protein fusions at the surface of 
purified spores (average signal). (B) Assay of whole-cell extracts prepared 
from B. subtilis cultures in sporulating medium, 24 h after the onset of 
sporulation. (C) Assay of purified spores from the same cultures. DW, dry 
weight. Spores were purified from cultures of the following strains: PY79, 
wild-type; SD48, CotG-Phy; and SD50, OxdD-Phy. One unit (U) of phytase 
was defined as the amount of enzyme required to release one mole of 
inorganic phosphate from sodium phytate in one minute. 
 
Spore display of active E. coli -glucuronidase. 
The results presented above show that the inner-coat 
protein, OxdD, can be used as a carrier for the display of active, 
monomeric phytase at the spore surface. We then wanted to test 
whether OxdD could be used for spore display of a larger, 
oligomeric enzyme. We tested whether E. coli -glucuronidase, 
encoded by the uidA gene, could be presented in active form at the 
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spore surface as a fusion to OxdD. The crystal structure of human 
GusA has been determined, and suggests that the enzyme is likely 
to function as a 273-kDa homotetramer [Cervera, 2005] with the 
catalytic site formed from a large cleft at the interface of two 
monomers [Jain et al., 1996]. Presumably, the E. coli enzyme, 
which shares 50% amino acid identity with the human version, is 
also a homotetramer [Flores and Ellington, 2002]. To attempt the 
functional display of E. coli GusA at the surface of B. subtilis spores, 
the uidA gene was fused to the 3´-end of the oxdD gene with, as for 
the oxdD-phy fusion (see above), an interspacing ten amino acid-
linker (Fig. 1B). Ectopic integration of the gene fusion at amyE 
resulted in strain SD60 (Table 1). Expression of the OxdD-GusA 
fusion at the amyE locus of PY79 did not measurably interfere with 
spore function or assembly (Table 2 and data not shown). 
Spores of strain SD60 were collected 24 h after the onset of 
sporulation in DSM, purified, and assayed for in situ detection of -
glucuronidase activity using the fluorogenic substrate C12FDGlcU, 
(see Material and Methods). In parallel, activity assays were 
conducted in trypsin-treated SD60 spores, and in spores of the wild-
type strain PY79. Cleavage of the colorless C12FDGlcU substrate 
into 5-dodecanoylaminofluorescein results in the production of a 
stable green-fluorescent product, allowing -glucuronidase activity 
to be monitored by fluorescence microscopy. Fluorescence was 
emitted by SD60 spores (Fig. 5A). In contrast, no fluorescence was 
detected for PY79 spores, as well as for SD60 or PY79 spores 
treated with trypsin prior to the assay (Fig. 5A). Quantification of the 
fluorescence signal (Fig. 5B, 5C) showed that 40% of SD60 spores 
emitted at least 2-fold more fluorescence than the baseline (>60 
AU). Possible explanations for the occurrence of non-fluorescent 
spores might be that the fluoregenic product of cleavage diffuses 
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away from spores or that the high molecular weight (882 g/mol) and 
lipophilic nature (12-carbon aliphatic chain) of the fluorogenic 
substrate limits its penetration into the inner coat, where OxdD-
GusA presumably resides. It can also be speculated that OxdD-
GusA fusion has not assembled into an active form in non 
fluorescent spores. In any event, our results show that active GusA 
can be displayed at the spore surface as a fusion to the inner-coat 
protein OxdD. 
Further works will address the optimization of strain 
engineering to increase activity of the passenger enzyme fused to 
OxdD. For instance, improvement might result from increased multi-
copy driven expression, from expression in protease-deficient B. 
subtilis strains or through the selection of passenger enzymes with 
higher specific activity (e.g. phytase from Citrobacter braakii). 
Nevertheless, based on the current activity measured at the surface 
of spores displaying B. subtilis OxdD-Phy (2.7 x 103 U/g dry weight), 
about 0.4 g of spores (dry weight) would represent 1,000 U of 
phytase. This amount of enzyme, added to 1 kg of feed in a daily 
swine diet, would replace 1 g of inorganic phosphorus 
supplementation, and therefore could reduce total phosphorus 
excretion by 30 to 50% [Lei and Porres, 2003]. 
Based on the results presented here, spore-associated 
enzymes, such as OxdD, seem to be valuable carriers for spore 
display of passenger proteins. One question raised by our study is 
whether exposure of the spores to acid or proteases in the upper 
parts of the gastro-intestinal tract would result in the inactivation of 
the displayed carrier-enzyme fusion protein. This may indeed 
happen to some extent. However, B. subtilis spores were recently 
shown to have the ability to germinate and re-sporulate upon exiting 
the stomach, leading to persistence of B. subtilis strain in the gut 
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[Cartman et al., 2008; Nguyen et al., 2006] and to constant surface 
display of freshly synthesized and fully active enzymes. Spore 
surface display thus provides the basis for novel means of 
formulation for proteins of interest such as feed enzymes (phytases, 
lipases, hemicellulases and others). 
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Figure 5.  Assay for the activity of GusA at the spore surface, through 
conversion of the colorless substrate C12FDGlcU (see Materials and 
Methods) into a yellow fluorescent product. (A) Detection of a 
functional OxdD-GusA fusion by phase-contrast microscopy (PC) and 
fluorescence (FITC) microscopy. Bars, 2 µm. (B) The fluorescence 
intensity was quantified on 150 spores. Purified spores submitted or not to 
trypsin proteolysis. Spores were purified from cultures of the following 
strains: PY79, wild-type; and SD60, OxdD-GusA. (C) Average 
fluorescence intensity quantified on 150 spores. AU: arbitrary units. 
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During the last decades, industrial microbial processes, 
known as “white biotechnology”, have been developed and have 
become economically competitive compared to the chemical 
processes they have replaced. White biotechnology refers to the 
production of biochemicals (food/feed ingredients, fine chemicals, 
pharmaceuticals), biomaterials and biofuels of commercial interest 
from renewable resources (generally agricultural by-products). 
White biotechnology relies on enzymes derived from 
microorganisms (biocatalysis) and on living cells as factories 
(fermentation technology). In the area of industrial microbiology, 
microorganisms used (bacteria, yeast, or fungi) may be natural 
isolates, selected mutants or genetically engineered organisms. 
Microbial production processes are of an ecological interest 
compared to traditional chemical processes, as they consume less 
raw materials, water and energy, enabling economies to become 
less dependent on fossil fuels. Finally, use of expensive substrates 
and optically resolved racemic intermediates, which are required for 
chemical processes, can be avoided. 
Bacillus subtilis is a key player among the favorite 
microorganisms for industrial biotechnology. In the soil, its principal 
environment, B. subtilis is able to secrete degradative enzymes that 
release nutrients from macromolecules which are too large to be 
directly taken up. This innate capacity to secrete proteins makes of 
this organism an efficient microbial factory for high-yield production 
of commercial enzymes or metabolites such as vitamins. Moreover, 
the safety of B. subtilis and its ability to form resistant endospores 
constitute major advantages to use this species for probiotic 
applications. Overproduction of the desired metabolites/enzymes, 
and the development of innovative products to improve the daily life 
of consumers by ensuring sustainable profits, involve important 
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efforts in applied microbiology research of private companies. More 
specifically, elucidating the molecular basis of microbial physiology 
is crucial to either modulate the control of metabolic pathways or 
divert natural physiological features of the microorganisms toward 
new commercial applications. The results discussed in this chapter 
illustrate both of these aspects.  
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1. Toward a B. subtilis industrial workhorse for the  
production of vitamin B1 
 
Microbial processes using B. subtilis have been developed 
and implemented for the industrial production of vitamin B2 
(riboflavin). A commercially relevant production yield of riboflavin 
results from the intensive metabolic engineering of a wild-type 
strain, otherwise secreting negligible amount of this product 
(collaboration between Omnigene Bioproducts Inc., USA and Roche 
Vitamins Ltd., Switzerland). This successful example of biotech-
based industrial production opened the way toward the 
development of B. subtilis strains able to secrete high amounts of 
other water-soluble vitamins. The market for chemically produced 
thiamin currently consists of several tons per year, for feed (40%), 
pharma (40%) and food (20%) applications [Perkins et al., 2009]. 
Vitamin B1 (thiamin) is a nutritional requirement for 
mammals, being a cofactor for several enzymes in the metabolism 
of carbohydrates and aminoacids (e.g. pyruvate dehydrogenase, 
pyruvate oxidase and transketolase). Thiamin is synthesized by 
many microorganisms, plants, and fungi, but is not produced by 
vertebrates. No complete “glucose to thiamin” microbial process has 
been described so far. The biologically active form of thiamin is 
thiamin pyrophosphate (TPP), which represents 98% of the 
intracellular thiamin content. Biosynthesis of thiamin in B. subtilis 
appears to use the same enzymes and intermediates as in E. coli 
[Perkins and Pero, 2001].  
Thiamin biosynthesis results from the assembly of a 
pyrimidine moiety (HMP-PP: hydroxymethylpyrimidine 
pyrophosphate), derived from the purine biosynthetic pathway 
(synthesis of HMP involves the product of thiC gene), and a thiazole 
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moiety (HET-P: hydroxyethylthiazole phosphate pyrimidine), derived 
from the condensation of aminoacid residues (glycine, cysteine) 
with an intermediate of the isoprenoid biosynthesis pathway (DXP: 
1-deoxy-d-xylulose phosphate). The coupling of HMP-PP and HET-
P results in thiamin monophosphate (TMP), which is then 
phosphorylated into TPP. This reaction is catalyzed by a thiamin 
pyrophosphokinase encoded by thiL gene. 
TPP biosynthesis follows a complex multistep pathway with 
numerous enzymatic reactions and involvement of cofactors, and is 
associated with large energy expenditure. Therefore, as an 
alternative to the de novo biosynthesis, bacteria have developed 
ways to salvage residues of thiamin degradation in the environment, 
released from the decay of various organisms in the soil. These 
residues uptaken by the bacteria, converted to new building blocks, 
and are recycled in the thiamin biosynthetic pathway. Figure V-1 
summarizes the key genes of the thiamin biosynthesis and the 
salvage pathways previously known or discovered in our studies.  
Salvage pathways described in the past occur either at the 
level of the pyrimidine moiety with ThiD kinase [Park et al., 2004], of 
the thiazole moiety with ThiM kinase [Melnick et al., 2004], or of 
thiamin. During thiamin salvage, thiamin kinase catalyzes the 
formation of TMP, subsequently converted into TPP by ThiL.  
Alternatively to this two-step pathway, the product of yloS (thiamin 
pyrophosphokinase) catalyzes the direct conversion of thiamin to 
TPP [Melnick et al., 2004].  
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FIGURE V-1: Simplified thiamin biosynthesis and salvage pathways 
in B. subtilis. G-3P (glyceraldehyde-3-phosphate); DXP (1-deoxy-d-
xylulose phosphate); AIR (aminoimidazole ribotide); (1) gene organized in 
thiB operon (tenAI-thiOSGFD); (2) thiA synonym was used in chapter II, 
referring to thiC; black arrows (biosynthetic pathways); blue arrows 
(salvage pathways) 
 
Chapter II illustrates how the discovery of new metabolic 
intermediates at the crossroad of thiamin degradation and 
biosynthesis constitutes the first step in the identification of 
unknown salvage pathways. The previously reported role of TenA 
(thiaminase II) in thiamin degradation into HMP and HET [Toms et 
al., 2005] was difficult to rationalize, since tenA clusters with genes 
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of the thiamin biosynthetic pathway (thiB operon) in B. subtilis. The 
gene organization in Bacillus halodurans reveals an association of 
tenA with the uncharacterized ylmB locus and with thiXYZ, which 
was shown, by comparative genomics of thiamin biosynthesis within 
prokaryotes, to encode an ABC transporter involved in the transport 
of HMP analogs [Rodinov et al., 2002]. These elements led to 
reconsidering the role of TenA, and to propose a new model in 
which TenA could be involved, together with YlmB and ThiXYZ, in a 
salvage pathway from thiamin-degraded products of the soil. 
In order to validate this hypothesis, environmental chemistry 
experiments based on HPLC analyses of soil solutions containing 
degradation products resulted in the identification of a pyrimidine 
analog (formylaminopyrimidine) which was shown to bind to ThiY. 
Formylaminopyrimidine appeared to be converted into HMP when 
the soil solution was supplemented with recombinant purified YlmB 
and TenA proteins. More specifically, our data suggested that a 
residue of thiamin degradation in the soil, released by the decay of 
various organisms in the environment, could be salvaged when 
taken up by bacteria through its interaction with the ThiXYZ ABC 
transporter. YlmB catalyzes then its deformylation into 
aminopyrimidine, which is then hydrolyzed by TenA into 
hydroxypyrimidine. A detailed mechanism for the TenA-catalyzed 
amino-pyrimidine hydrolysis was recently proposed [Jenkins et al., 
2008]. Further phosphorylation of hydroxypyrimidine by ThiD results 
in HMP, supplied to thiamin biosynthetic pathway.  
TenA is not essential for thiamin biosynthesis, as tenA 
mutants are able to grow in minimal medium. On the contrary, thiC 
mutants display thiamin auxotrophy in minimal medium. 
Complementation analyses (with either thiamin, HMP, 
aminopyrimidine, formylaminopyrimidine, or based-degraded 
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thiamin) on B. subtilis thiC and/or tenA mutants led to the 
observation that TenA enables growth of thiC mutant in presence of 
thiamin degradation products. These results confirm the hypothesis 
of a thiamin salvage pathway from thiamin-degraded residues which 
involves TenA and results in supplying HMP to the biosynthetic 
pathway, independently from de novo HMP synthesis catalyzed by 
ThiC activity.  
In light of the results presented in chapter II, one can 
speculate that similar salvage pathways do exist for other vitamins 
of the B group, or even for other metabolites of commercial interest. 
This surely opens new research directions for the identification of 
unknown salvage pathways in B. subtilis, broadening the 
possibilities of optimization by metabolic engineering to bring 
vitamins production levels up to industrial relevance. 
Work toward the generation of a B. subtilis strain for relevant 
vitamin B1 industrial production is described in chapter III. 
Mutagenesis studies allowed identifying and characterizing new 
thiamin-deregulated mutations in B. subtilis. Regulation of thiamin 
biosynthetic genes has been reported to be based on the direct and 
specific binding of TPP to the 5’-untranslated regions of messenger 
RNAs (thi box). This binding promotes conformational changes that 
affect the expression of downstream genes [Winkler et al., 2002]. 
This riboswitch mechanism is highly conserved within thiamin 
producing microorganisms. Aiming to provide data for the 
reconstruction of the thiamin metabolic pathway and its regulation, 
comparative genomic analyses of the thi box sequence in all 
available bacterial genomes resulted in the identification of new 
putative thiamin-related loci, including the hypothetical transporters 
YuaJ and YkoEDC. yuaJ, predicted to encode a passive thiamin-
permease, is the only thiamin-regulated gene in several organisms 
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known to miss the thiamin biosynthesis pathway [Rodionov et al., 
2002], suggesting that it is involved in thiamin uptake. ykoD, 
predicted to encode a part of an ATP-dependant ABC transporter, 
was linked to the thiamin salvage system based on the positional 
clustering of the ykoEDC genes with other thiamin salvage genes 
[Rodionov et al., 2002]. Until the work described in this manifest, no 
genetic experiments had confirmed the role of these genes in 
thiamin transport.  
Ethyl methanesulfonate-induced mutants of B. subtilis 
deregulated for thiamin production were selected on the basis of the 
activity of a lacZ transcriptional fusion with the thiC biosynthetic 
gene in the presence of TPP. Screening was performed in a thiL 
mutant in order to exclude thiL mutants from the pool of LacZ+ 
thiamin-deregulated clones, and focus on mutations related to 
exogenous thiamin uptake (i.e. salvage pathway). Interestingly, 
thiL mutants are not strictly auxotroph unlike in E. coli or 
Salmonella enterica. This supports the hypothesis of an alternative 
way to produce TPP in B. subtilis, distinct from the biosynthetic 
pathway. Based on their unique phenotype, two mutants were 
selected for further characterization. Clone Tx1 has a bradytroph 
growth (slow on minimal medium without supplementation in 
thiamin or its derivatives), and harbored one mutation in the yloS 
locus (L116F). The mutation leads to a reduced pyrophosphokinase 
activity, since the addition of external TPP or thiamin can restore a 
normal prototroph phenotype. This result supports the direct thiamin 
to TPP route. Clone Tx26 grows like the parental strain, is resistant 
to a toxic analog of thiamin (pyrithiamin) and has two remarkable 
mutations respectively in yuaJ (Q35*; predicted to result in a 
truncated inactive protein) and ykoD genes (D180N). 
Transcriptomics profiling of mutant Tx26 (yuaJ, ykoD) showed a 
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deregulated expression of all genes known to contain a thi-box (i.e. 
thiC, thiOSGFD, ykoFEDC, yuaJ). This deregulation was confirmed 
to be independent from thiL. Resistance to pyrithiamin and to 
higher levels of external thiamin suggested that the two Tx26 
mutations control together the uptake of thiamin and of its 
precursors rather than act as efflux transporters. Combination of the 
four mutations (yloS, yuaJ, ykoD and thiL) in the same B. subtilis 
host resulted in a strain (TH95) able to excrete thiamin in 
fermentation (ten-liter scale) in the mg per liter range.  
Although the expected fermentation yield could not be 
reached so far to develop a commercially relevant biotechnological 
process for vitamin B1 production (range of gram per liter being 
required), results presented in chapter III constitute a significant 
step forward through the isolation and characterization of four 
mutations in thiamin biosynthetic and salvage genes. Improvement 
of the basic knowledge of the biosynthetic pathway of thiamin is 
crucial to move forward to a commercially relevant strain.  
A possible way of improvement could consist in increasing 
the pool of thiamin precursors in the biosynthetic pathway. To test 
this hypothesis, fermentation experiments of strain TH95 were 
performed by co-feeding both HMP and HET precursors (0.54 g/l 
each), leading to a 27-fold increase in thiamin production. A putative 
bottleneck in the thiamin pathway could also be the coupling 
reactions between both HMP and HET moieties. In a new TH95-
based strain, expression of thiE was driven by a strong constitutive 
promoter derived from Bacillus bacteriophage SP01 (SP01-26). Co-
feeding HMP and HET in fermentation led to about 40-times more 
thiamin than TH95. These results suggested that our deregulated 
strain has a large capacity to synthesize TPP by coupling the 
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exogenous-added moieties, to dephosphorylate TPP to thiamin, and 
to excrete thiamin in the growth medium.    
Intracellular supply of either HET or HMP precursors was 
then addressed. Two mutants were generated using SP01-26 
promoter, in order to respectively increase the pool of HET (thiB 
operon; i.e tenAI-thiOSGFD) or HMP (thiC) in the biosynthetic 
pathway. Fermentation, with either HMP or HET supplementation 
was performed. Both mutants resulted in a significantly increased 
thiamin production compared to TH95. However, the thiC mutant 
(HMP supply) produced significantly less thiamin than the thiB 
operon mutant (HET supply). This result suggests a limitation in the 
formation of HMP in the pathway, possibly due to a low level of 
ThiC substrate (AIR: aminoimidazole ribotide) or an insufficient 
additional activity. To confirm this hypothesis, the pool of AIR 
available for ThiC was increased in TH95 (the purine operon was 
deregulated through a mutation in purO, and the conversion to the 
carboxy-aminoimidazole ribotide side product was blocked through 
a mutation in the purE locus). Fermentation of the resulting strain 
with HET supplementation led to more thiamin than TH95 SP01-26 
thiC. This result supports the hypothesis that HMP formation is a 
rate-limiting factor. Possibly, another unknown gene (not located in 
the thiB operon) may be involved in HMP biosynthesis and would 
need to be overexpressed to improve the precursor supply. In any 
event, our data suggest that increasing the pool of precursors in the 
biosynthetic pathway successfully improves the production of 
thiamin in B. subtilis strain TH95, even though it does in a limited 
manner (< 10-fold). 
Increase of the HMP pool in the cell could for instance 
involve genetic engineering of the new salvage pathway described 
in chapter II, or the previously described ThiD kinase pathway 
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[Park et al., 2004]. The current emergence of metagenomics could 
also help circumventing the limitation of HMP in the thiamin 
biosynthetic pathway by finding new biological chemistry to 
generate HMP. 
 181
Chapter V                                Summary and Perspectives 
   
2. B. subtilis for innovative probiotic applications 
 
Probiotics can display growth-promoting, prophylactic or 
therapeutic attributes. As they also improve weight gain in modern 
farming, they represent an alternative to antimicrobial drugs 
commonly employed as growth-promoter to broilers, avoiding drug 
residues to accumulate in the animal, and therefore in the food 
meat. When ingested in sufficient amount, probiotics are believed to 
play an important role in the control of host intestinal microbiota. 
However, understanding the molecular processes underlying the 
host-microbe interactions constitute a special challenge, mostly 
because of the complexity and diversity of the microbial community 
inhabiting the gastrointestinal tract.  
Although their mechanism of action remains poorly 
understood, spores from several Bacillus species are currently used 
as human and animal probiotic. Criteria to screen strains targeting 
probiotic application include functional criteria such as the ability to 
resist environmental conditions found in the digestive tract (low 
gastric pH and bile salts), to antagonize or competitively exclude 
pathogens by secretion of antimicrobial compounds or to compete 
with pathogenic organisms for nutrients and adhesion sites. The 
use of B. subtilis as probiotic relies on its capability to sporulate, 
because spores can survive to the harsh conditions of gastric juices 
before reaching the intestine where they can reactivate their 
germination/sporulation cycle pattern. Proficient use of selected 
strains isolated from intestinal microbial ecosystems has led to a 
variety of microbiological products. Therefore, the screening of 
undomesticated gut-associated bacterial strains that evolved to 
survive and proliferate in the intestine environment constitutes a 
source of potential new probiotic candidates. Such a screening was 
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for instance performed for Bacillus isolates in the broiler 
gastrointestinal tract of poultry raised in organic farms. Interesting 
isolates exhibited high sporulation ability and antimicrobial activity 
against food spoilage and pathogenic organisms such as 
Clostridium perfringens, Staphylococcus aureus and Listeria 
monocytogenes [Barbosa et al., 2005]. Assuming that these B. 
subtilis strains are deprived of any toxicity and that proof of their 
safety toward their host can be made, they could be considered to 
be part of a probiotic product to be used in animal farming. 
Furthermore, such isolates have not been engineered, which would 
give them a non-GMO status, in agreement with current regulation. 
Social acceptance of GM foods or ingredients is not uniform 
in developed countries, and is especially difficult in Europe. The 
introduction of new probiotics based on GM strains would surely 
raise safety concern. The main issues with GMOs, and above all 
those of human origin, is the evaluation of the risk for human health 
of uncontrolled product expression following horizontal transfer of 
recombinant genes into commensal bacteria. A strain genetically 
engineered to introduce foreign DNA or even create a punctual 
mutation is considered as a GMO. The paradox is that a similar 
mutant occurring naturally (e.g. replication errors, plasmid loop-out, 
transposons, or phage-elements) or generated by classical strain 
improvement methods (e.g. chemical mutagenesis) might not be 
classified as GMO, even though it is less characterized.  
Even if GM probiotics are not yet authorised on the market, 
research on these potential products for the future should go 
forward. These new strains would have a great potential when used 
to maintain health, prevent or treat disease, or be of nutritional 
value. Because of their intrinsic properties, probiotic spores could 
be of interest to offer long-shelf stability, avoiding costly formulation 
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process (e.g encapsulation in a polymer matrix, such as alginate or 
chitosan) to keep beneficial microorganisms alive until they reach 
the intestine. In this scope, spore display of bioactive molecules 
with a commercial interest (e.g. feed enzymes) could constitute a 
major advance for their in situ delivery in the host intestine. Chapter 
IV provides preliminary data for the development of innovative 
recombinant probiotics using B. subtilis spore display.   
The spore display concept was introduced for the first time 
almost a decade ago [Isticato et al., 2001]. So far, research on 
spore display was turned toward pharmaceutical applications 
(vaccinology), as most of the reported studies addressed the 
presentation of antigenic molecules at the surface of B. subtilis 
endospores in order to promote an immune response after being 
inhaled or orally administrated. All the successful published 
examples use anchoring motifs which are abundant structural 
proteins of the outermost layer of the spore coat (CotB, CotC, 
CotG). Among the 80 polypeptides of the coat, about 20 show an 
enzymatic activity or have a sequence highly similar to known 
enzymes [Henriques and Moran, 2007]. The work presented in 
chapter IV explores the use of one of these coat-associated 
enzymes, OxdD, as carrier protein.  
Although its association with the spore coat still remains 
unclear, the product of the yoaN gene was characterized as an 
oxalate decarboxylase, targeted in a SafA-dependant manner to the 
inner coat [Costa et al., 2004]. In order to demonstrate that this 
original anchoring motif can be used to display bioactive passenger 
molecules, we first analyzed spores from a culture of a recombinant 
strain harbouring a fusion of OxdD carrier with B. subtilis phytase 
(Phy) which functions as a monomer. As a positive control, and for 
comparison, a similar fusion was also made with CotG carrier, 
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successfully used in several published examples. Results of our 
immunofluorescence experiments (anti-Phy antibody) indicated that 
OxdD is a potential anchoring motif for the display of passenger 
phytase at the spore surface. Importantly, spore-exposed phytase, 
with one or the other fusion, displays activity (in the range of 103 U/g 
of gradient-purified spores). To further challenge our innovative 
system, spore display of a fusion between the OxdD carrier and a 
large oligomeric enzyme was performed.  The -glucuronidase 
(GusA) of E. coli encoded by the uidA locus was selected as 
passenger.  Fluorescence microscopy observations on gradient-
purified spores harbouring the OxdD-GusA fusion enabled the 
detection of a green fluorescent compound resulting from the 
specific hydrolysis of a colourless substrate by GusA. In situ activity 
of the displayed GusA enzyme was therefore clearly confirmed. 
These successful spore display examples of both a bioactive 
endogenous monomeric phytase and a heterologous oligomeric -
glucuronidase demonstrate the potential of coat associated oxalate 
decarboxylase located in the inner coat to be used as anchoring 
motif [Schyns et al., 2008].  
Proof-of-concept described in chapter IV open a new way in 
the design of recombinant spores. Spore display using OxdD 
requires however to be better characterized and optimized. 
Interestingly, not all the spores displaying OxdD-GusA were 
fluorescent. In addition, a 2-fold lower specific phytase activity was 
observed with OxdD-Phy compared to CotG-Phy. These 
discrepancies are thought to be due to the position of the OxdD 
fusion in the inner layer of the coat, being therefore less accessible 
to either of the substrates. Another explanation could be that OxdD 
is a less abundant protein than CotG (present in the range of 103 
copies per spore). This hypothesis is however not consistent with 
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our immonufluorescence results, where the OxdD-Phy fusion is 
more abundant than the CotG-Phy. This could be explained by the 
relatively lower importance of OxdD in the coat structure compared 
to CotG, a key player of the coat protein assembly. In a cotG 
mutant, the coat structure was shown to be affected, whereas the 
disruption of the oxdD locus had no detectable effect on spore 
resistance to lysozyme, reflecting a well structured coat [Costa et 
al., 2004; Henriques and Moran, 2007]. The OxdD-Phy fusion may 
preferentially be assembled in the coat during spore formation 
compared to CotG-Phy, because wild-type (non-fused) CotG, that is 
required in the coat network formation, could compete with the 
assembly of CotG-Phy. Using a non-structural protein as anchoring 
motif for spore display, rather than a protein involved in the coat 
formation, could thus be seen as an advantage. To address this 
question, more experiments are required, such as for instance the 
analysis of spores produced from strains with cotG deletion or 
bearing multicopies of oxdD-phy fusions in their genome, or in a 
replicative plasmid (e.g. pMK3 shuttle vector, GenBank EU549779).  
OxdD is presumed to be a homohexameric enzyme, as 
suggested by its high similarity to the OxdC molecule crystal whose 
structure was resolved [Anand et al., 2002]. To improve the 
efficiency of spore display of a bioactive passenger, it can be 
hypothesized that the degree of polymerization of OxdD in the 
fusion is an important determinant of the steric conditions leading to 
the optimal folding of the displayed enzyme. A possible approach to 
figure out the degree of multimerization would consist in the 
expression of the fusion protein in the cytoplasm of B. subtilis, 
preventing its assembly in the spore coat (for instance by driving 
expression with the promoter of a gene specific of the vegetative 
state). SDS-PAGE under reducing and non-reducing conditions or 
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gel filtration analysis could then be carried-out. Information obtained 
from such experiments could support the selection of a less 
oligomerized carrier protein of the coat for spore display purpose. 
Recent identification of small open-reading frames in 
intergenic regions of the B. subtilis genome could also provide new 
insights in the development of innovative spore display systems 
[Schmalish et al., 2010]. Using high-density microarrays covering all 
intergenic regions larger than 50 nucleotides, the study focused on 
unknown genes, transcriptionally active during sporulation. The 
authors reported that two predicted products show a high similarity 
to the respective products of ydgB and ydzH genes. Analysis of 
specific mutants revealed that these genes might be expressed 
under the control of the late-appearing, mother cell specific sigma K 
factor. Fluorescence microscopy experiments with GFP fusions 
gave evidence that YdgB and YdzH localize around the forespore, 
suggesting that they could be components of the spore coat. These 
results provide two unexplored spore-associated proteins to be 
tested in the future as original anchoring motifs for spore display 
applications. They could be of particular interest due to their low 
molecular weight (< 10 kDa), which could prevent possible 
interferences in the folding of the fused passenger protein. 
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3. Conclusion and future directions on B. subtilis research  
for the biotechnology industry 
 
The studies in this thesis illustrate how exploration of the 
metabolic pathways involved in the biosynthesis of vitamin B1 
contributes to the development of an industrially relevant B. subtilis 
overproducer (chapters II and III). The other application of B. 
subtilis genetic engineering (chapter IV) gives new input toward the 
design of an innovative spore-display system, using for the first time 
a coat-associated enzyme (oxalate decarboxylase) of the inner-coat 
as anchor. This work also constitutes a successful example of 
display for enzymes exhibiting activity on spores, which could in 
particular open perspectives for future feed additives and probiotics.  
Progresses in the use of the spore as display system for useful 
enzymes will strongly depend on a better understanding of the 
molecular mechanisms involved in the assembly pathway of 
particular carrier proteins. Another topic to explore is the influence 
of the peptide linker between carrier and passenger proteins (i.e. 
length, flexible versus helical structure) on the assembly and activity 
of the fusion proteins at the spore surface. 
Being one of the preferred organisms for the industrial 
production of secreted enzymes and fine chemicals, and a very 
popular Gram-positive model for fundamental research, B. subtilis 
has been extensively engineered with a set of diverse and efficient 
genetic tools which have been developed in the course of the last 
fifty years. Future developments of B. subtilis biotechnological 
applications involve obviously the combination of classical genetic 
engineering with recent powerful technologies that allow ultra fast 
generation and/or identification of genetic diversity.  
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FIGURE V-2: Future perspectives in biotechnology research with B. 
subtilis. “Classical genetic engineering” gathers the strategies and 
techniques developed in the course of the last fifty years for B. subtilis 
strain improvement (as described in chapter I, 3). This current knowledge 
is supplied (broken arrows) in emerging research areas (green bullets). 
Further information from the complex metabolisms, synthetic biology and 
the selection of well-adapted strains for the biotechnology industry 
resulting from the exploration of the natural and artificial diversities, may 
constitute a new input (solid arrows) for further genetic engineering. 
 
Random and directed mutageneses currently stay the most 
efficient concepts available in number of cases for metabolic 
engineering. Chapters II and III of this thesis demonstrate once 
again that engineering the metabolic pathways needs a massive 
and specific knowledge to successfully rechannel metabolic fluxes. 
The growing recognition of a higher degree of complexity in B. 
subtilis metabolism is a step toward solving this well-defined 
problematic, which is a prerequisite to overrun the metabolic 
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limitations. Several examples demonstrate this high level of 
complexity. For instance, little is understood about the regulatory 
networks (e.g. non-transcriptional mechanisms such as metabolite-
protein interaction, protein phosphorylation etc.) enabling the 
metabolism to take control of itself [Heinemann and Sauer, 2010]. 
Another poorly explored area of metabolic pathways was lately 
pointed out. For the first time, the critical interactions between the 
glycolytic enzymes (6-phosphofructokinase, enolase and 
phosphoglycerate kinase) and essential protein partners were 
introduced. In addition, some of the glycolytic enzymes (6-
phosphofructokinase and enolase) might interact with proteins 
involved in RNA metabolism, resulting in a complex equivalent to 
the E. coli degradosome [Commichau et al., 2009]. These examples 
highlight the requirement for a multi-dimensional view toward a 
successful genetic engineering of metabolic pathways. Although 
mathematical modelling tools constantly progress, difficulties to 
integrate the large data-sets produced by “omics” technologies 
(transcriptomics, proteomics, metabolomics, fluxomics), and to align 
them with the global regulation of gene transcription also remain.  
New research work streams recently emerged to solve these 
issues. The development of high-throughput genomics tools and 
new computational methodologies for the quantitative interpretation 
of the data is the topic of the BaSysBio (Bacillus Systems Biology) 
project, launched in 2006 (www.basysbio.eu). The elaboration of B. 
subtilis strains fitting industrial conditions is directly related to 
industrial research. The current program of genome minimalization 
in the scope of the Basynthec (Bacterial Synthetic Minimal 
Genomes for Biotechnology) project, aims at reducing the bacterial 
chromosome to generate a set of strains with industrially relevant 
phenotypes (i.e. good growth rate on various nutrients sources, 
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genetic stability and low waste of energy). In practice, the expected 
outcome is a simpler cell in which synthetic functional modules or 
regulators can be plugged in and their effects can be well 
monitored.  
Another exciting approach for future strain improvement or 
innovative applications is the naturally occurring diversity of B. 
subtilis strains. Because of the great adaptation skills of B. subtilis, 
and its ability to survive in extreme conditions (e.g. extreme pH, 
temperatures or salt concentrations, high radiation), it is likely that 
exploring the natural diversity of microbes in unusual or specific 
environments would lead to the discovery of strains with new 
abilities fitting with industrial applications. Less than a third of the B. 
subtilis genes (paleome) is conserved across other Bacilli. This 
suggests that the large part of its genome is present in response to 
environmental cues (cenome), meaning that B. subtilis has 
genetically evolved for the occupation of diverse habitats and 
niches [Alcaraz et al., 2010].  
As an example, genes putatively encoding enzymes related 
to the degradation of complex polysaccharides, as well as possible 
collagen-binding adhesins, have been identified in the genome of a 
gut-associated strain [Schyns et al., manuscript in preparation; C. 
Serra and A.O. Henriques, personal communication]. This 
undomesticated B. subtilis has been isolated from faecal material of 
organically reared broilers. The presence of these genes, absent 
from laboratory strains, together with the enhanced sporulation 
phenotype of the strain, may represent a considerable advantage in 
terms of adaptation to the gut environment, and might be of interest 
for the putative use of this strain in probiotic applications.  
Exploration of the mutations occurring in the course of strain 
engineering (i.e. artificial diversity of B. subtilis) can also be of 
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interest for industrial biotechnology. Dramatic decrease in the cost 
of accurate whole-genome re-sequencing during the five past years 
(about 1,500 € during the writing of this thesis) drew attention to the 
large amount of untargeted mutations resulting from random and 
directed mutagenesis campaigns in the multiple-step construction of 
industrial production strains. To limit the amount of untargeted 
mutations, a better characterization of the dose-response of 
mutagenic agents (e.g. nitrosoguanidine, ethylmethane sulphonate 
etc.) in B. subtilis would probably be relevant. Nevertheless, part of 
these mutations greatly contributes to the predisposition of B. 
subtilis to become a high metabolite producer. Hence, identification 
of the relevant ones is of interest, the beneficial mutations providing 
new strain improvement leads. To support prediction of relevant 
untargeted mutations, computational tools such as SNAP 
(Screening of Non-Acceptable Polymorphisms) appeared, based on 
integration of several databases [Bromberg et al., 2008]. It can also 
be speculated that a minor part of untargeted mutations has an 
adverse effect on the expected phenotype. Correction of these 
mutations, back to the wild-type situation, can therefore directly 
result in improvement of products yield. The artificial diversity in B. 
subtilis could also be generated in a closely-controlled way, using 
recent technologies that can speed up the introduction of specific 
SNPs (Single Nucleotide Polymorphisms). For instance, the 
RTDS™ (Rapid Trait Development System) developed by Cibus 
Global (San Diego, USA), is an oligo-based technique designed to 
alter a targeted gene by utilizing the cell’s own gene repair system, 
without insertion of foreign DNA [Breyer et al., 2009]. This 
technology has been successfully used in eukaryotes, and should 
demonstrate its possible applications in B. subtilis. Due to the 
complex interactions of metabolic pathways, the profile of an ideal 
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candidate for high metabolites production likely depends on multiple 
genes broadly distributed throughout the genome. Consequently, 
direct application of targeted genetic engineering for strain 
improvement has a relatively low chance of success. Genome 
mixing of a small number of strains obtained by classical strain 
improvement methods constitutes a valuable method to promote 
artificial diversity in B. subtilis strains. Resulting in subtle progresses 
in the expected phenotype, this concept could be beneficial in 
biotechnology research. Successful examples of genome shuffling 
by performing few rounds of protoplast fusion with Streptomyces 
[Zhang et al., 2002] and Lactobacillus genera [Patnaik et al., 2002] 
have already been reported. A similar approach with B. subtilis 
would therefore surely be of interest.  
The greater knowledge and the well-selected strains gained 
from the above-described emerging axes (synthetic biology, 
exploration of both natural and artificial genomic diversities), will 
support further strain improvement, and reinforce the central role of 
B. subtilis in research for biotechnology industries.  
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